Genome-Wide DNA Methylation and Gene Expression Profiling of Cancer-Associated Myofibroblasts by Najgebauer, H
i 
 
 
 
Genome-Wide DNA Methylation and  
Gene Expression Profiling of               
Cancer-Associated Myofibroblasts 
 
 
Thesis submitted in accordance with the requirements of the University of Liverpool 
for the degree of Doctor in Philosophy by 
 
 
Hanna Najgebauer 
 
 
January 2016 
 
 
i 
 
Acknowledgements 
First and foremost I would like to thank my primary supervisor Professor Chris 
Sanderson for giving me the opportunity to embark on this adventure and learn 
about cancer biology, epigenetics and bioinformatics. I am thankful for all the help 
and scientific guidance throughout this PhD project. I would also like to thank my 
secondary supervisor Professor Andrea Varro for providing the cells for this study 
and for helping set up the myofibroblast cultures and proliferation and migration 
assays. 
 
Special thanks to Dr Lakis Liloglou for his expert advice and time spent helping me 
set up pyrosequencing and qPCR assays. Also to Dr Jithesh Puthen for his initial help 
and advice regarding the bioinformatics analysis workflow, and to Dr Andy 
Jarnuczak for helping with proteomic data processing and analysis.  
 
I would like to thank all who have helped me in different ways during the last           
4 years: Dave, Emily, Jo, Amy, Jen, Bron, Olivier, Ben, Amelia, Israa, Bubaraye and 
Ahmed. Thank you for your help in the lab, it was much appreciated. You have all 
made this experience memorable and made day-to-day lab life enjoyable. 
 
A huge thank you to the Cancer Research UK for funding this work. 
 
Most importantly, I would like to thank my family and Andy for their continuous 
support.  
 
ii 
 
Contents  
 
Acknowledgements ..................................................................................................... i 
Contents  ................................................................................................................... ii 
List of Figures ............................................................................................................ ix 
List of Tables ............................................................................................................ xv 
Appendices ............................................................................................................xviii 
Abbreviations ......................................................................................................... xix 
Abstract  ............................................................................................................... xxii 
 
Introduction ............................................................................................................. 1 
1.1  Overview ........................................................................................................... 2 
1.2  Cancer ............................................................................................................... 3 
1.2.1  Molecular basis of cancer .......................................................................... 3 
1.2.2  Hallmarks of cancer ................................................................................... 4 
1.2.3  Gastric cancer ............................................................................................ 4 
1.2.3.1  Risk factors ................................................................................................... 5 
1.2.3.2  Classification ................................................................................................ 5 
1.2.3.3  Clinical outcomes ......................................................................................... 7 
1.2.3.4  Molecular biomarkers .................................................................................. 8 
1.3  Tumour microenvironment .............................................................................. 9 
1.3.1  Components of tumour microenvironment .............................................. 9 
1.3.2  Stromal-epithelial interactions ................................................................ 10 
1.3.3  Myofibroblasts ......................................................................................... 12 
1.3.3.1  Myofibroblasts in wound healing .............................................................. 12 
1.3.3.2  Myofibroblasts in cancer ............................................................................ 13 
1.3.4  Hypoxia .................................................................................................... 17 
1.3.4.1  Cellular responses to hypoxia .................................................................... 17 
1.3.4.2  Hypoxia-associated epigenetic changes .................................................... 18 
1.3.4.3  Hypoxia in gastric cancer ........................................................................... 19 
 iii 
 
1.3.5  Targeting the tumour microenvironment ............................................... 20 
1.3.5.1  Prognostication and diagnosis ................................................................... 20 
1.3.5.2  Stroma targeted therapy ........................................................................... 20 
1.4  Epigenetics ...................................................................................................... 22 
1.4.1   Mechanisms of gene regulation ............................................................. 22 
1.4.2  DNA methylation ..................................................................................... 24 
1.4.2.1  Genomic distribution of CpG methylation ................................................. 25 
1.4.2.2  DNA methyltransferases ............................................................................ 27 
1.4.2.3  Dynamics of DNA methylation ................................................................... 27 
1.4.3  DNA methylation in cancer ...................................................................... 28 
1.4.4  DNA methylation in gastric cancer .......................................................... 29 
1.4.5  Epigenetic cancer therapy ....................................................................... 29 
1.4.5.1  DNA methyltransferase inhibitors ............................................................. 30 
1.4.5.2  Histone deacetylase inhibitors ................................................................... 30 
1.5  Personalized cancer therapy .......................................................................... 31 
1.5.1  Gene expression profiling ........................................................................ 31 
1.5.2  DNA methylation profiling ....................................................................... 32 
1.6  Objectives and Aims ....................................................................................... 34 
 
Materials and Methods ...................................................................................... 35 
2.1  Materials ......................................................................................................... 36 
2.2  Tissue Culture ................................................................................................. 37 
2.2.1 Generation of human primary gastric myofibroblasts ............................ 37 
2.2.2  Gastric myofibroblast cell culture ............................................................ 37 
2.2.3  Gastric cancer cell culture ....................................................................... 39 
2.3  Integrated multi-omics experiments ............................................................. 39 
2.3.1  Patient information ................................................................................. 39 
2.3.2  Myofibroblast cell culture ........................................................................ 40 
2.3.3 Conditioned media preparation for secretome profiling ........................ 41 
2.3.4  DNA extraction for Illumina Infinium HumanMethylation450k array ..... 42 
 iv 
 
2.3.5  RNA extraction for Illumina Human HT-12 v4 array ................................ 43 
2.4  Myofibroblast conditioned media preparation ............................................ 44 
2.4.1  Standard conditioned media ................................................................... 44 
2.4.2  Hypoxic conditioned media ..................................................................... 44 
2.5  Cancer cell based assays ................................................................................ 45 
2.5.1  Cancer cell migration assay ..................................................................... 45 
2.5.2  Cancer cell proliferation assay ................................................................. 46 
2.6  Omics data processing and analysis .............................................................. 47 
2.6.1  Illumina Infinium 450k data processing ................................................... 47 
2.6.2  Differential methylation analysis ............................................................. 48 
2.6.3  Illumina HT-12 Expression data processing ............................................. 48 
2.6.4  Differential gene expression analysis ...................................................... 49 
2.6.5  Integration of DNA methylation and gene expression data .................... 50 
2.6.6  Secretome data processing ..................................................................... 50 
2.6.7  Integration of gene expression and secretome data .............................. 52 
2.6.8  R/Bioconductor ........................................................................................ 52 
2.6.9  Ingenuity Pathway Analysis ..................................................................... 52 
2.6.10  ConsensusPathDB .................................................................................... 54 
2.7  DNA methylation data analysis ..................................................................... 54 
2.7.1  Gene ontology enrichment analysis ........................................................ 54 
2.7.2  Associating differentially methylated CpG loci with genes ..................... 55 
2.7.3  Pathway Analysis for common differentially methylated genes in gastric 
and oesophageal CAMs .......................................................................................... 55 
2.8  Gene expression data analysis ....................................................................... 56 
2.8.1  Gene ontology enrichment analysis ........................................................ 56 
2.8.2  Gene set enrichment analysis .................................................................. 56 
2.9  Comparative transcriptome and secretome analysis ................................... 57 
2.9.1  Gene ontology enrichment analysis ........................................................ 57 
2.9.2  Gene set enrichment analysis .................................................................. 57 
2.9.3  Ingenuity Pathway Analysis ..................................................................... 58 
 
 v 
 
2.10  Pyrosequencing DNA methylation analysis ................................................... 59 
2.10.1  DNA extraction ......................................................................................... 59 
2.10.2  Pyrosequencing analysis .......................................................................... 59 
2.11  TaqMan gene expression analysis ................................................................. 62 
2.11.1  RNA extraction ......................................................................................... 62 
2.11.2  TaqMan qPCR analysis ............................................................................. 62 
 
Identification of Genome-Wide DNA Methylation Signatures in Gastric 
and Oesophageal Cancer-Associated Myofibroblasts ............................... 65 
3.1  Introduction .................................................................................................... 66 
3.2  Aims ................................................................................................................ 67 
3.3  Results ............................................................................................................. 68 
3.3.1  Comparison of global DNA methylation between CAMs and ATMs from 
gastric and oesophageal cancers ........................................................................... 68 
3.3.2  Identification of differentially methylated loci in gastric CAMs, ATMs and 
NTMs  ................................................................................................................. 68 
3.3.2.1  Characterization of differentially methylated loci in gastric CAMs 
compared to patient-matched ATMs ............................................................................ 71 
3.3.2.2  Technical validation of identified differentially methylated CpG loci ....... 73 
3.3.2.3  Gene ontology enrichment analysis of differentially methylated loci 
identified in gastric CAMs compared to ATMs .............................................................. 75 
3.3.2.4  Identification of CpG loci that might serve as proxies for gastric CAM 
identification ................................................................................................................. 77 
3.3.3  Identification of differentially methylated loci in oesophageal CAMs and 
ATMs  ................................................................................................................. 80 
3.3.3.1  Characterization of identified differentially methylated loci in oesophageal 
CAMs compared to ATMs .............................................................................................. 81 
3.3.3.2  Gene ontology enrichment analysis for differentially methylated loci in 
oesophageal CAMs compared to ATMs ........................................................................ 83 
3.3.4  Identification of conserved DNA methylation patterns in gastric and 
oesophageal CAMs ................................................................................................. 84 
3.3.4.1  Conserved methylation pattern at the individual CpG loci in gastric and 
oesophageal CAMs ........................................................................................................ 85 
 vi 
 
3.3.4.2 Identification of common differentially methylated genes in gastric and 
oesophageal CAMs ........................................................................................................ 89 
3.4  Discussion ....................................................................................................... 95 
 
Identification of Genes that Exhibit Correlated Changes in Gene 
Expression and DNA Methylation in Gastric Myofibroblasts .................. 99 
4.1  Introduction .................................................................................................. 100 
4.2  Aims .............................................................................................................. 101 
4.3  Results ........................................................................................................... 102 
4.3.1  Identification of differential gene expression profiles in gastric CAMs, 
ATMs and NTMs ................................................................................................... 102 
4.3.2  Technical validation of identified differentially expressed genes ......... 104 
4.3.3  Potential biological significance of the identified changes in gene 
expression profiles ............................................................................................... 107 
4.3.3.1  Gene ontology enrichment analysis......................................................... 107 
4.3.3.2  Gene set enrichment analysis .................................................................. 111 
4.3.3.3  Pathway analysis ...................................................................................... 114 
4.3.4  Integration of differentially methylated loci with differential gene 
expression profiles in gastric CAMs compared to ATMs ..................................... 117 
4.3.4.1  Analysis of the relationship between DNA methylation and gene 
expression in gastric CAMs .......................................................................................... 119 
4.3.4.2  Identification of genes exhibiting correlated changes in promoter 
methylation and gene expression ............................................................................... 121 
4.3.4.3  Identification of genes exhibiting correlated changes in gene-body 
methylation and gene expression ............................................................................... 127 
4.4  Discussion ..................................................................................................... 133 
 
Validation of DNA Methylation Patterns that Correlate with          
CAM-specific Gene Expression Profiles ........................................................ 137 
5.1  Introduction .................................................................................................. 138 
5.2  Aims .............................................................................................................. 139 
 vii 
 
5.3  Results ........................................................................................................... 140 
5.3.1  Validation of CAM differentially methylated CpG loci by targeted 
pyrosequencing analysis ...................................................................................... 140 
5.3.2  Pyrosequencing analysis identifies concordant DNA methylation changes 
within interrogated regions of gastric CAMs ....................................................... 142 
5.3.3  Locus specific changes in CAM DNA methylation also affect expression of 
neighbouring genes .............................................................................................. 145 
5.3.3.1  Selection of target regions ....................................................................... 145 
5.3.3.2  Promoter hypermethylation may repress SMAD3 expression in gastric 
CAMs .................................................................................................................. 145 
5.3.3.3  Promoter hypomethylation may induce SPON2 expression in gastric CAMs 
 .................................................................................................................. 148 
5.3.3.4  Promoter hypermethylation may repress ZNF536 expression in gastric 
CAMs .................................................................................................................. 151 
5.3.3.5  DNA hypermethylation may repress the expression of FOXF1 and   
FENDRR in gastric CAMs .............................................................................................. 154 
5.4  Discussion ..................................................................................................... 157 
 
Effects of Hypoxia on Gene Expression and Secretion of                     
Pro-tumorigenic Factors in Gastric Stromal Myofibroblasts ................. 163 
6.1  Introduction .................................................................................................. 164 
6.2  Aims .............................................................................................................. 166 
6.3  Results ........................................................................................................... 167 
6.3.1  Hypoxia enhances CAM-induced cancer cell migration and promotes 
CAM-like properties in NTMs ............................................................................... 167 
6.3.1.1  Gastric cancer cell migration assays ........................................................ 167 
6.3.1.2  Gastric cancer cell proliferation assays .................................................... 167 
6.3.2  Identification of hypoxia-induced gene expression signatures in gastric 
CAMs, ATMs and NTMs ........................................................................................ 168 
6.3.2.1  Differential hypoxia-induced myofibroblast phenotypes are not due to 
induced changes in DNA methylation profiles ............................................................ 171 
6.3.3 Potential biological significance of hypoxia-induced gene expression 
signatures in CAMs, ATMs and NTMs .................................................................. 172 
 viii 
 
6.3.3.1  Universal hypoxia-induced gene expression signatures in CAMs, ATMs and 
NTMs .................................................................................................................. 173 
6.3.3.2  Unique CAM, ATM and NTM hypoxia-induced gene expression signatures . 
 .................................................................................................................. 176 
6.3.3.3  Predicted biological effects of hypoxia on CAMs, ATMs and NTMs ........ 183 
6.3.3.4  Prediction of factors that may be secreted by hypoxic CAMs and NTMs ...... 
 .................................................................................................................. 183 
6.3.4  Secretome analysis of CAM and NTM hypoxic conditioned media ....... 186 
6.3.4.1  Identification and quantification of CAM and NTM secreted proteins ... 186 
6.3.4.2  Hypoxia–induced secretome signatures in gastric CAMs and NTMs ....... 188 
6.3.4.3  Potential biological effects of the hypoxia-induced CAM and NTM 
secretomes .................................................................................................................. 191 
6.3.4.4  Integration of hypoxia-induced CAM and NTM secretomes with CAM and 
NTM hypoxia-induced gene expression signatures .................................................... 194 
6.4  Discussion ..................................................................................................... 196 
 
Final Discussion ................................................................................................... 203 
7.1  Summary and Conclusions ..................................................................... 204 
7.2  DNA methylation profiling of CAMs ...................................................... 206 
7.3  Global hypomethylation in CAMs .......................................................... 207 
7.4  DNA methylation in CAMs from different tissues ................................. 209 
7.5  Stromal DNA methylation signatures .................................................... 211 
7.6  Limitations of the study ......................................................................... 212 
7.7  Concluding remarks ............................................................................... 213 
 
Supplementary Data .......................................................................................... 214 
Chapter II .............................................................................................................. 215 
Chapter III ............................................................................................................. 219 
Chapter IV ............................................................................................................. 223 
Chapter V .............................................................................................................. 225 
Chapter VI ............................................................................................................. 236 
S6.1  Gene Set Enrichment Analysis (GSEA) ..................................................... 237 
 ix 
 
S6.2  Leading Edge Analysis .............................................................................. 238 
References ............................................................................................................ 242 
 
 
 
ix 
 
List of Figures  
Figure 1.1 Parts of the stomach. .................................................................................. 7 
Figure 1.2 Components of the tumour microenvironment. ...................................... 10 
Figure 1.3 Stromal-epithelial interactions in normal tissue and during malignant 
transformation ........................................................................................................... 11 
Figure 1.4 Tumour promoting properties of cancer associated myofibroblasts ....... 15 
Figure 1.5 Interplay between different aspects of epigenetic regulation of gene 
expression. ................................................................................................................. 24 
Figure 1.6 Distribution of CpG sites in genomic regions. .......................................... 26 
Figure 1.7 Schematic representations of DNA methylation patterns in normal and 
cancer cells ................................................................................................................. 28 
Figure 2.1 Bioinformatics analysis workflow–integration of DNA methylation and 
gene expression data ................................................................................................. 51 
Figure 2.2 Bioinformatics analysis workflow–integration of gene expression and 
secretome data .......................................................................................................... 53 
Figure 3.1 Global DNA methylation of gastric and oesophageal patient-matched 
CAMs and ATMs ......................................................................................................... 69 
Figure 3.2 Differentially methylated CpG loci in gastric myofibroblasts purified from 
different tissue microenvironments .......................................................................... 70 
Figure 3.3 Distribution of differentially methylated CpG loci identified in gastric 
CAMs vs ATMs. ........................................................................................................... 72 
Figure 3.4 Genomic region and gene associations of differentially methylated         
CpG loci in gastric CAMs vs ATMs .............................................................................. 73 
Figure 3.5 Correlations between Illumina 450k array data and pyrosequencing 
analysis in gastric myofibroblasts .............................................................................. 74 
Figure 3.6 Heatmap representations of CpG loci that may serve as proxies for 
gastric CAM, ATM and NTM identification ................................................................ 78 
Figure 3.7 Genomic region and gene associations of CpG proxies that might be used 
to distinguish gastric CAMs from ATMs and NTMs ................................................... 80 
 x 
 
Figure 3.8 Differentially methylated CpG loci identified in oesophageal CAM vs ATM 
comparison ................................................................................................................. 82 
Figure 3.9 Genomic region and gene associations of differentially methylated         
CpG loci in oesophageal CAMs vs ATMs. ................................................................... 82 
Figure 3.10 Overlap of differentially methylated CpG sites identified in gastric and 
oesophageal CAMs vs ATMs ...................................................................................... 86 
Figure 3.11 Representative conserved DNA methylation patterns in gastric and 
oesophageal patient-matched CAM and ATM samples ............................................ 87 
Figure 3.12 Genome-wide overview of DNA methylation changes in stromal 
myofibroblasts ........................................................................................................... 88 
Figure 3.13 Differentially methylated genes in gastric and oesophageal CAMs. ...... 89 
Figure 3.14 Comparison of gene ontology (GO) biological process (BP) terms                    
identified for gastric and oesophageal differentially methylated CpG loci ............... 92 
Figure 4.1 Differential gene expression signatures in gastric myofibroblasts purified 
from different tissue microenvironments. .............................................................. 103 
Figure 4.2 Quantitative PCR validations of genes identified as differentially 
expressed in CAM vs ATM and CAM vs NTM comparisons ..................................... 106 
Figure 4.3 Gene ontology (GO) cellular component (CC) enrichment for differentially 
expressed genes identified in gastric CAM vs ATM comparison. ............................ 109 
Figure 4.4 GSEA enrichment plots for gene sets enriched in CAM and ATM 
phenotypes, which gene members are reported to be epigenetically regulated. .. 113 
Figure 4.5 Unfolded protein response pathway ...................................................... 115 
Figure 4.6 Reactome and KEGG pathways overrepresented in CAM vs ATM 
comparison. .............................................................................................................. 116 
Figure 4.7 Identification of a subset of genes, which expression may be regulated by 
DNA methylation changes in gastric CAMs. ............................................................. 118 
Figure 4.8 Simultaneous negative correlation between gene expression and        
DNA methylation in promoter region and positive correlation in gene body              
of TGFBR2 in patient-matched CAM and ATM samples. ......................................... 120 
Figure 4.9 Negative correlations identified between gene expression and promoter 
methylation in patient-matched CAM and ATM samples. ...................................... 122 
 xi 
 
Figure 4.10 Positive correlations identified between gene expression and gene-body 
methylation in patient-matched CAM and ATM samples. ...................................... 128 
Figure 5.1 Representative pyrograms from comparative pyrosequencing                  
DNA methylation assays. ......................................................................................... 141 
Figure 5.2 Methylation changes at CpG loci identified in gastric CAMs and ATMs by 
Illumina 450k array are concordant within a broader local genomic region. ......... 143 
Figure 5.3 DNA methylation in the SMAD3 promoter region regulates SMAD3 
expression in gastric CAMs and ATMs. .................................................................... 147 
Figure 5.4 DNA methylation in the SPON2 promoter region correlates with SPON2 
gene expression profiles in gastric CAMs and ATMs. .............................................. 150 
Figure 5.5 DNA methylation levels within the ZNF536 promoter region correlate 
with ZNF536 gene expression profiles in gastric CAMs and ATMs. ......................... 153 
Figure 5.6 DNA methylation pattern in the genomic region associated with 
regulation of FOXF1 and FENDRR expression in gastric CAMs and ATMs. .............. 156 
Figure 6.1 Differential effects of CAM/NTM hypoxic conditioned media on            
AGS gastric cancer cell migration or proliferation. .................................................. 169 
Figure 6.2 Hypoxia-induced gene expression signatures in gastric myofibroblasts 
purified from different tissue microenvironments .................................................. 170 
Figure 6.3 Comparative global DNA methylation profiles of primary gastric 
myofibroblasts following exposure to hypoxic or normoxic conditions. ................ 172 
Figure 6.4 Comparison of hypoxia-induced gene expression signatures identified in 
gastric CAMs, ATMs and NTMs ................................................................................ 173 
Figure 6.5 Universal changes induced by hypoxia in gastric CAMs, ATMs and NTMs
 .................................................................................................................................. 174 
Figure 6.6 GSEA enrichment plots for most significantly enriched hallmark gene set 
and canonical pathway gene set .............................................................................. 175 
Figure 6.7 GSEA enrichment plots for the most significantly enriched hallmark gene 
sets ........................................................................................................................... 180 
Figure 6.8 IPA canonical pathways significantly enriched in unique CAM, ATM and 
NTM hypoxia-induced gene expression profiles ...................................................... 182 
Figure 6.9 Predicted biological effects of hypoxia on gastric CAMs, ATMs and NTMs
 .................................................................................................................................. 184 
 xii 
 
Figure 6.10 Predicted pro-migratory and pro-proliferative factors secreted by 
hypoxic CAMs and hypoxic NTMs. ........................................................................... 185 
Figure 6.11 Venn diagram representation of database searches used to classify 
proteins identified in CAM and NTM conditioned media obtained from normoxia 
and hypoxia. ............................................................................................................. 187 
Figure 6.12 Volcano plots of differentially secreted proteins ................................. 189 
Figure 6.13 Comparison of differentially secreted proteins identified in               
CAM-hypoxic-CM and NTM-hypoxic-CM compared to their respective         
normoxic-control-CM ............................................................................................... 190 
Figure 6.14 Predicted biological effects of the hypoxia-induced CAM and NTM 
secretomes ............................................................................................................... 193 
Figure 6.15 Predicted activation of HIF-1α regulates expression of proteins secreted 
by hypoxic NTMs. ..................................................................................................... 194 
Figure 6.16 Integration of secretome and gene expression data............................ 195 
Figure 7.1 Novel insights into molecular mechanisms underlying the                  
tumour-promoting phenotype of gastric CAMs that have emerged from this study
 .................................................................................................................................. 206 
 
Figure S2.1 Quality of DNA samples used for Illumina Infinium 
HumanMethylation450k array ................................................................................. 215 
Figure S3.1 Increased migration of gastric cancer cells in response to CAM 
conditioned media (CM) compared to ATM-CM and NTM-CM ............................... 219 
Figure S3.2 Increased proliferation of gastric cancer cells in response to CAM 
conditioned media (CM) compared to ATM-CM and NTM-CM ............................... 220 
Figure S3.3 Heatmap representation of differentially methylated regions (DMRs) 
identified in gastric CAMs compared to their patient-matched ATMs. .................. 221 
Figure S3.4 Heatmap representation of differentially methylated regions (DMRs) 
identified in oesophageal CAMs compared to their patient-matched ATMs. ......... 222 
Figure S4.1 Representative examples of genes showing consistent changes in gene 
expression profiles in two independent studies of gastric CAM vs ATM gene 
expression profiles. .................................................................................................. 223 
 xiii 
 
Figure S4.2 PCP pathway ......................................................................................... 224 
Figure S5.1 SMAD3 expression in gastric and oesophageal CAMs compared to their 
parent-matched ATMs ............................................................................................. 226 
Figure S5.2 Negative correlations between gene expression (qPCR data) and 
promoter methylation (pyrosequencing data) in patient-matched CAMs and ATMs
 .................................................................................................................................. 227 
Figure S5.3 Differentially methylated SPON2 promoter-region identified by Illumina 
450k array in oesophageal patient-matched CAM and ATM samples .................... 228 
Figure S5.4 Simultaneous negative correlation between promoter methylation and 
SPON2 gene expression and positive correlation between gene-body methylation 
and SPON2 gene expression levels in patient-matched CAM and ATM samples .... 229 
Figure S5.5 Negative correlation between SPON2 gene expression and promoter 
methylation in patient-matched CAMs and ATMs and NTMs ................................. 230 
Figure S5.6 Simultaneous negative correlation between promoter methylation and 
ZNF536 gene expression and positive correlation between gene-body methylation 
and ZNF536 gene expression levels in patient-matched CAM and ATM samples. . 231 
Figure S5.7 Simultaneous negative correlation between promoter methylation and 
ZNF536 gene expression and positive correlation between gene-body methylation 
and ZNF536 gene expression levels in patient-matched CAMs and ATMs in 
comparison to NTMs ................................................................................................ 232 
Figure S5.8 Comparative DNA methylation profiles within a genomic region on  
chromosome 16 spanning 526,340bp identified by Illumina 450k array in gastric 
stromal myofibroblasts. ........................................................................................... 233 
Figure S5.9 Comparative DNA methylation profiles within a genomic region on  
chromosome 16 spanning 9,673bp identified by Illumina 450k array in oesophageal 
patient-matched CAM and ATM samples ................................................................ 234 
Figure S5.10 Pyrosequencing analysis of the FOXF1 promoter region in gastric 
cancer cell lines ........................................................................................................ 234 
Figure S5.11 Differential DNA methylation data for stomach adenocarcinoma from 
the Cancer Genome Atlas (TCGA) ............................................................................ 235 
Figure S6.1 Universal gene expression changes induced under hypoxia in gastric 
CAMs, ATMs and NTMs ............................................................................................ 236 
 xiv 
 
Figure S6.2 Comparison of enriched MSigDB gene sets identified for unique CAM, 
ATM and NTM hypoxia-induced gene expression profiles ...................................... 237 
Figure S6.3 Volcano plots of differentially secreted proteins ................................. 239 
Figure S6.4 Differential expression and secretion of gelsolin, vascular endothelial 
growth factor A and glucose-6-phosphate isomerase in hypoxic CAMs and hypoxic 
NTMs compared to respective control-normoxic myofibroblasts........................... 240 
Figure S6.5 Differential expression and secretion of angiopoietin-related protein 4, 
insulin-like growth factor-binding protein 3, insulin-like growth factor-binding 
protein 6 and thrombospondin-2 in gastric CAMs and NTMs under hypoxia and 
normoxia .................................................................................................................. 240 
Figure S6.6 Differential expression and secretion of enzyme lysyl oxidase in gastric 
CAMs and NTMs under hypoxia and normoxia. ...................................................... 241 
Figure S6.7 Global DNA methylation after long-term hypoxia treatment assessed by 
LINE-1 pyrosequencing assays ................................................................................. 241 
 
 
xv 
 
List of Tables  
Table 2.1 List of materials used in this study. ............................................................ 36 
Table 2.2 Patient information relating to age, gender, tumour location and tumour 
clinical assessment for gastric cancer patients who provided CAM and ATM cells 
used in this study. ...................................................................................................... 38 
Table 2.3 Information relating to age, gender and cell origin for post-mortem organ 
donors who provided NTM cells used in this study. .................................................. 39 
Table 2.4 List of samples used for integrated multi-omic experiments. ................... 41 
Table 2.5 Nucleotide sequences of PCR primer sets and sequencing primers used 
for pyrosequencing DNA methylation assays ............................................................ 61 
Table 2.6 List of TaqMan assays and nucleotide sequences used in this study. ....... 64 
Table 3.1 Gene ontology (GO) enrichment analysis for differentially methylated CpG 
loci identified in gastric CAMs compared to ATMs. ................................................... 76 
Table 3.2 Gene ontology (GO) enrichment analysis for differentially methylated CpG 
loci identified in oesophageal CAMs compared to ATMs. ......................................... 84 
Table 3.3 KEGG and Reactome pathways affected by DNA methylation changes in 
gastric and oesophageal CAMs. ................................................................................. 90 
Table 3.4 Common gene ontology (GO) biological process (BP) terms associated 
with gastric and oesophageal differentially methylated loci in CAMs compared to 
patient–matched ATMs.............................................................................................. 93 
Table 4.1 List of Illumina HT-12 probes identified as differentially expressed in   
CAM vs ATM and CAM vs NTM comparisons that were validated by                 
TaqMan qPCR assays ................................................................................................ 105 
Table 4.2 Gene ontology (GO) biological process (BP) enrichment for differentially 
expressed genes identified in gastric CAM vs ATM comparison ............................. 108 
Table 4.3 GSEA results showing a list of significantly enriched hallmark gene sets in 
CAM and ATM phenotypes. ..................................................................................... 112 
Table 4.4 Genes that are hypomethylated and transcriptionally induced in CAMs 
compared to ATMs. .................................................................................................. 124 
 xvi 
 
Table 4.5 Genes that are hypermethylated and transcriptionally repressed in CAMs 
compared to ATMs. .................................................................................................. 126 
Table 4.6 Top 10 genes that are hypomethylated in gene-body and transcriptionally 
repressed in CAMs compared to ATMs. .................................................................. 130 
Table 4.7 Top 10 genes that are hypermethylated in gene-body and 
transcriptionally induced in CAMs compared to ATMs. .......................................... 132 
Table 6.1 GSEA result summary. Significantly enriched hallmark gene sets and 
canonical pathways for universal CAM, ATM and NTM gene expression profiles    
 .................................................................................................................................. 175 
Table 6.2 Gene ontology (GO) biological process (BP) enrichment for unique   
hypoxia-induced gene expression signatures identified in CAMs, ATMs                      
or NTMs. ................................................................................................................... 177 
Table 6.3 GSEA result summary. Significantly enriched hallmark gene sets for CAM, 
ATM and NTM unique hypoxia-induced gene expression profiles. ......................... 181 
Table 6.4 Gene ontology (GO) biological process (BP) enrichment for differentially 
secreted proteins by hypoxic NTMs ......................................................................... 192 
 
Table S2.1 Quality control information for RNA and DNA samples used for Ilumina 
HumanHT-12 v4 Expression and Illumina Infinium HumanMethylation450k arrays
 .................................................................................................................................. 216 
Table S2.2 Patient information relating to the scoring details. ............................... 217 
Table S2.3 Patient information relating to age, gender, tumour location and tumour 
clinical assessment for oesophageal cancer patients who provided CAM and ATM 
cells used in this study. ............................................................................................ 218 
Table S5.1 Reproducibility of pyrosequencing assays. Correlation R2 between 
methylation levels for biological replicates. ............................................................ 225 
Table S6.1 Summary of leading edge analysis (LEA) of enriched MSigDB gene sets 
identified for unique CAM, ATM and NTM hypoxia-induced gene expression 
profiles. .................................................................................................................... 238 
 
 
xviii 
 
Appendices 
 
List of supplementary files provided on CD: 
 
 
 
Appendix I Quality control reports for the ‘gastric’ and ‘oesophageal’ Illumina 
Infinium HumanMethylation450 BeadChip arrays 
 
Appendix II Lists of differentially methylated CpG sites and genomic regions, 
including promoter, gene, island and tilling identified in gastric 
(CAM vs ATM, CAM vs NTM, ATM vs NTM) and oesophageal   
(CAM vs ATM) comparisons 
 
Appendix III Quality control report for the Illumina HumanHT-12v4 Expression 
BeadChip array 
 
Appendix IV Lists of differentially expressed genes identified in the following 
comparisons: CAM vs ATM, CAM vs NTM, ATM vs NTM,             
CAM hypoxia vs CAM normoxia, ATM hypoxia vs ATM normoxia 
and NTM hypoxia vs NTM normoxia 
 
Appendix V Table of identified and quantified proteins 
 
Appendix VI File 1 – Superpathway of Cholesterol Biosynthesis 
 File 2 – Integrin Signalling  
xix 
 
Abbreviations  
5-mC 5-methylcytosine 
α-SMA alpha-smooth muscle actin 
ASPH aspartate beta-hydroxylase 
ATM Adjacent Tissue Myofibroblasts 
AURKA aurora kinase A 
B4GALT6 beta-1,4-galactosyltransferase 
bp base pair 
CAF Cancer Associated Fibroblast 
CAM Cancer Associated Myofibroblast 
CM Conditioned Media 
CPDB ConsensusPathDB 
CpG Cytosine-phosphate-Guanine 
DACOR1 DNMT1-associated colon cancer repressed lncRNA 1 
DAG directed acyclic graph 
DEPTOR DEP domain containing MTOR-interacting protein 
DMEM Dulbecco’s Modified Eagle’s Medium 
DMR Differentially Methylated Region 
DNA deoxyribonucleic acid  
DNMT DNA methyltransferase 
dNTP deoxynucleoside triphosphate 
ECM extracellular matrix 
EdU 5-ethynyl-2’-deoxyuridine 
ER endoplasmic reticulum 
FBS fetal bovine serum 
FDR false discovery rate 
FENDRR FOXF1 adjacent non-coding developmental regulatory RNA 
FGF fibroblast growth factor 
FOXC1 forkhead box C1 
FOXF1 forkhead box F1 
 xx 
 
GO Gene Ontology 
GO_BP Gene Ontology Biological Process 
GO_CC Gene Ontology Cellular Component 
GO_MF Gene Ontology Molecular Function 
GOrilla Gene Ontology enRIchment anaLysis and visuaLizAtion tool 
GREAT Genomic Regions Enrichment of Annotations Tool 
GSEA Gene Set Enrichment Analysis 
H. pylori Helicobacter pylori 
HGF hepatocyte growth factor 
HIF hypoxia-inducible factor 
HOXA5 homeobox A5 
HSPA5 heat shock protein family A (Hsp70) member 5 
IKB Ingenuity Knowledge Base 
IPA Ingenuity Pathway Analysis 
kb kilobase 
KEGG Kyoto Encyclopedia of Genes and Genomes 
LC-MS/MS liquid chromatography–mass spectrometry 
LEA Leading Edge Analyses 
LFQ label free quantification 
lncRNA long non-coding RNA 
MetazSecKB Metazoa Secretome and Subcellular Proteome Knowledge Base 
miR microRNA 
MSigDB Molecular Signatures Database 
MUC2 mucin 2 
NTM Normal Tissue Myofibroblasts 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PDGF platelet-derived growth factor 
PDGF-R PDGF receptor 
PFA paraformaldehyde 
RNA ribonucleic acid 
 xxi 
 
ROS reactive oxygen species 
SAM S-adenosylmethionine 
SEM standard error of the mean 
SMAD3 SMAD family member 3 
SNP single nucleotide polymorphisms 
SPON2 spondin 2 
SULF sulfatase 
TCGA The Cancer Genome Atlas 
TGF-β transforming growth factor β 
TGFBR2 TGF-β receptor type II 
TSS transcription start site 
UPR unfolded protein response 
VEGF vascular endothelial growth factor 
VPS28 vacuolar protein sorting 28 homolog 
ZNF536 zinc finger protein 536 
 
 
Abstract 
 
 
xxii 
 
Abstract 
In recent years it has become increasingly apparent that tumour development and 
metastasis are not simply driven by mutations within cancer cells. Factors produced 
by stromal myofibroblasts play a key role in the development and metastasis of 
many forms of cancer. However, our knowledge of the range of molecular 
mechanisms that drive paracrine communication between cancer and stromal cells 
remains incomplete. Evidence from previous studies show that myofibroblasts 
derived from gastric tumours (CAMs) not only retain their ability to enhance the 
proliferation and migration of cancer cells in vitro but also have inherently different 
gene expression profiles compared to patient-matched adjacent tissue 
myofibroblasts (ATMs), or normal tissue myofibroblasts (NTMs). In addition, it was 
shown that CAMs are characterized by global loss of DNA methylation when 
compared to patient-matched ATMs. Taken together, these observations indicate 
that epigenetic programming of myofibroblasts within the tumour 
microenvironment may contribute to their tumour-promoting properties.  
 
In this study, genome-wide DNA methylation and gene expression profiling was 
performed on a collection of primary patient-matched gastric CAM and ATM 
samples and normal NTM samples in order to identify CAM-specific                      
DNA methylation signatures and to assess the extent to which these genome-wide 
DNA methylation changes may regulate CAM-specific gene expression profile.     
The differential methylation analysis identified widespread alterations of DNA 
methylation in gastric CAMs compared to ATMs and NTMs. In addition, the 
integrated analysis of DNA methylation and gene expression showed that            
DNA methylation is involved in epigenetic regulation of biological pathways and 
processes involved in the tumour–promoting function of gastric CAMs. In particular, 
promoter DNA hypomethylation emerged as regulatory mechanism for 
transcriptional activation of genes involved in secretion and transport of molecules 
while promoter DNA hypermethylation emerged as regulatory mechanism for 
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transcriptional repression of genes involved in pathology of gastrointestinal cancers 
and regulation of developmental processes.  
 
Additionally, given that hypoxic conditions may be common within the tumour 
microenvironment, we were interested to know what role hypoxia may play in 
regulating paracrine communication between CAMs and gastric cancer cells. Using 
cell based assays and a combination of genomic, transcriptomic and proteomic 
approaches we provided a novel insight into the profile of changes in gene 
expression and protein secretion that result from exposure of normal (NTMs) or 
cancer-associated myofibroblasts (CAMs) to hypoxic conditions and identified 
hypoxia-induced factors that may drive CAM-, ATM- and NTM-specific hypoxic 
responses, which have differential effects on cancer cell migration and 
proliferation. Importantly, data from this study show that gastric myofibroblasts 
purified from different tissue microenvironments (CAMs, ATMs, NTMs) have 
distinct responses to hypoxia, which most probably stem from differential 
epigenetic profiles providing, once again, strong evidence that epigenetic 
programming of CAMs is in part mediated by interactions with cancer cells. 
However, hypoxia is unlikely to be a driving factor in conferring cancer related 
changes in DNA methylation profiles of gastric myofibroblasts. 
 
Taken together, this study is the first to perform a comparative genome-wide 
analysis of DNA methylation and gene expression patterns in gastric cancer-
associated myofibroblasts. Significantly, widespread epigenomic and transcriptomic 
alterations were observed in CAMs compared to their patient-matched ATMs, 
providing potential clues as to the molecular mechanism of cancer mediated 
stromal cell programming. Finally, CAM-specific DNA methylation patterns 
identified in this study may prove useful in future clinical practice as biomarkers for 
improved diagnosis and prognosis of gastric cancer. 
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1.1  Overview 
Recent technological advancements in high-throughput ‘omics’ techniques have 
transformed the field of cancer research. Scientists can now routinely use these 
techniques to profile the genome, epigenome, transcriptome, proteome and 
metabolome of cancer cells. As such, data generated using these technologies have 
provided a valuable insight into the broader mechanisms of cancer biology.      
Multi-institutional collaborative projects, such as The Cancer Genome Atlas (TCGA), 
the Cancer Genome Project, and the International Cancer Genome Consortium, 
were established to generate and integrate those data and comprehensively 
characterise common types of human cancers with the aim to provide a resource to 
guide and improve current clinical practice.  
 
Gastric cancer is one of the most common cancers worldwide. Despite its declining 
incidence the mortality rate for gastric cancer remains high, mainly due to late 
diagnosis and lack of precise prognostic biomarkers. In recent years,                    
high-throughput large-scale gene expression profiling technology has significantly 
improved our understanding of gastric cancer biology. The analysis of gastric cancer 
gene expression data has identified gene expression signature that can be used to 
determine, differentiate and categorize gastric cancer subtypes, thereby 
complementing traditional morphological and clinical assessment and providing 
real potential for improving patient prognosis and enhancing our ability to 
rationally design more appropriate tailored therapies (Brettingham-Moore, Duong 
et al. 2011, Lin, Zhao et al. 2015)  
 
Significantly, it is now evident that tumour growth and metastasis are not simply 
driven by cancer cells alone. The tumour microenvironment plays a profound role in 
these processes. In particular, cancer associated myofibroblasts have been shown 
to promote the migration and proliferation of gastric cancer cells, through                
a complex mechanism of reciprocal communication with the developing tumour.  
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As such, the tumour stroma offers a better potential for the identification of 
consistent stage specific markers and novel approaches to therapeutic intervention 
(Zhi, Shen et al. 2010, Holmberg, Quante et al. 2012). Although a number of studies 
have demonstrated the importance of CAMs in gastric cancer progression (Yan, 
Wang et al. 2015) the detailed mechanisms underlying tumour-promoting 
phenotype of gastric CAMs remain elusive. 
 
1.2  Cancer 
With an ever-aging population cancer remains a major human health problem     
and a leading cause of death worldwide. We now understand that cancer is              
a multistep and multifactorial disease that results from a combination of genetic 
and epigenetic changes that affect key regulatory pathways in the cell. Although 
cancer can develop in almost any tissue and each type of cancer has unique 
features, there are common processes involved in the progression of many forms of 
cancer. For all forms of cancer there is a direct link between stage of detection and 
patient prognosis. Therefore, there is a pressing need to develop a better 
understanding of the sequential processes that contribute to each stage of tumour 
development, in order to facilitate the development of improved diagnostic and 
therapeutic strategies. 
 
1.2.1  Molecular basis of cancer 
Cancer arises from a single cell which accumulates multiple genetic and epigenetic 
changes in the expression or regulation of oncogenes and/or tumour suppressor 
genes. These alterations provide the transformed cell with important growth 
advantages that allow cell clones to form a malignant mass, which ultimately 
dominates and outcompetes neighbouring cells (Jones and Baylin 2002, Vogelstein 
and Kinzler 2004). The progression of cancer involves a pre-invasive phase, followed 
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by invasion of the surrounding stroma, entry to blood and lymphatic vessels and 
metastasis to secondary sites (Chaffer and Weinberg 2011). The intratumour 
heterogeneity that arises during carcinogenesis introduces significant challenges 
contributing to resistance to radio- and chemotherapy (Bedard, Hansen et al. 2013). 
 
1.2.2  Hallmarks of cancer 
The hallmarks of cancer, as defined by Hanahan and Weinberg, include sustaining 
proliferative signalling, evading growth suppressors, resisting cell death, enabling 
replicative immortality, inducing angiogenesis, activating invasion and metastasis, 
genome instability and mutation, tumour promoting inflammation, reprogramming 
energy metabolism and evading immune destruction (Hanahan and Weinberg 
2011).  
 
1.2.3  Gastric cancer 
Gastric cancer is one of the most common cancers worldwide. Despite its declining 
incidence (Bertuccio, Chatenoud et al. 2009), it remains the third leading cause of 
cancer death worldwide (Ferlay, Soerjomataram et al. 2015) and the tenth most 
common cause of cancer death in the United Kingdom (Cancer Research UK 2012).            
Also, the prevalence of gastric cancer continues to be much higher in Asia and 
South America (Brenner, Rothenbacher et al. 2009) and treatment options for 
gastric cancer remain limited. The typical treatment strategy for the non-metastatic 
disease includes endoscopic treatment, surgical resection and chemotherapy. 
However, the disease is usually diagnosed at advanced stages, which explains its 
elevated mortality rate (American Cancer Society 2015), with a median survival for 
patients with advanced stage gastric cancer of 8–10 months (Lorenzen and Lordick 
2011). Cancer Research UK reported in 2010-2011 that only 15% of gastric cancer 
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patients in England and Wales are expected to survive their disease for more than 
ten years (Cancer Research UK).   
 
1.2.3.1  Risk factors 
Gastric cancer is a very complex and a highly heterogeneous disease, which tends 
to develop slowly over many years, therefore emergency presentation are the most 
common mechanism of diagnosis. The risk of gastric cancer is strongly linked with 
age and sex. Around 95% of gastric cancer cases are diagnosed in people aged 55 or 
older. It is more common in men than women. In United Kingdom, it is the seventh 
most common cause of cancer death in men and the twelfth most common cause 
of cancer death in women (Cancer Research UK 2012). An estimated 75% of gastric 
cancer cases in the United Kingdom are linked to lifestyle factors, including 
Helicobacter pylori (H. pylori) infection, high salt intake, and tobacco/smoking. 
Other risk factors include ionising radiation, certain occupational exposures, low 
fruit and vegetables intake, alcohol, overweight and obesity as well as certain 
medical conditions (Cancer Research UK 2012). Also, people with first-degree 
relatives who have had gastric cancer are more likely to develop the disease 
(American Cancer Society 2015). 
 
1.2.3.2  Classification 
Adenocarcinoma, which originating from the glandular epithelium of the stomach 
lining, is the most common histological type of gastric cancer, accounting for 95% of 
all gastric malignancies (Cancer Research UK). Gastric adenocarcinomas can be 
further divided into two forms based on Lauren classification, diffuse and intestinal, 
which have different clinicopathological and prognostic features (Lauren 1965).  
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The intestinal type of gastric cancer is often found in the corpus and antrum of the 
stomach (Figure 1.1) (Wagner and Moehler 2009) and is associated with H. pylori 
infection, obesity, and certain dietary factors, such as high salt intake, preserved 
food and smoked meats. It is believed to arise through a long-term multistep 
progression from chronic gastritis to chronic atrophy to intestinal metaplasia to 
dysplasia and finally to gastric tumour (Correa, Haenszel et al. 1975). This form of 
gastric cancer is well differentiated and occurs more frequently in older patients 
(Crew and Neugut 2006).  
 
In contrast, the diffuse type of gastric cancer is usually located in the proximal 
stomach (cardia, fundus, corpus) and gastroesophageal junction (Figure 1.1) 
(Wagner and Moehler 2009). This form of gastric cancer is poorly differentiated and 
confers a comparatively worse prognosis. It is more prevalent in the obese, young 
male population suffering from chronic reflux disease (Crew and Neugut 2006). 
However, studies showed that H. pylori infection also plays a role in the 
development of diffuse gastric cancer as a consequence of chronic inflammation, 
but is not associated with the occurrence of intermediate steps, such as gastric 
atrophy and intestinal metaplasia (Milne, Carneiro et al. 2009). 
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Figure 1.1 Parts of the stomach. 
 
 
1.2.3.3  Clinical outcomes 
Gastric cancer patients from different parts of the world show different clinical 
outcomes. Traditionally, these differences have been attributed to differences in 
clinical management and disease stage. However, recent meta-analysis of >1600 
gastric cancers revealed that Asian and non-Asian gastric cancers exhibit distinct 
molecular signatures related to T-cell function (Lin, Gagnon-Bartsch et al. 2015). 
These findings might impact the design of future gastric cancer trials as they may 
well have an effect on treatment responses and clinical outcomes. Also, cancers 
starting in different parts of the stomach can cause different symptoms and tend to 
have different clinical outcomes. The location of the tumour can also affect the 
treatment options (American Cancer Society 2015). Gastric cancers can grow 
through the stomach wall and invade adjacent organs, or metastasize to lymph 
vessels and nearby lymph nodes, which form a very rich network in the stomach.   
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In advanced stages cancer cells can invade the bloodstream and spread to the liver, 
lungs and bone (American Cancer Society 2015).  
 
1.2.3.4  Molecular biomarkers 
The high mortality rate of gastric cancer is mostly attributed to the lack of early 
detection and effective medical treatment of advanced stages of the disease. At 
present serum carcinoembryonic antigen, carbohydrate antigen (CA) 19-9 and 
CA72-4 are the most widely used gastric cancer biomarkers (Duraes, Almeida et al. 
2014), however they have a relatively low sensitivity and specificity in gastric cancer 
diagnosis and prognosis (Emoto, Ishigami et al. 2012, Kanda, Fujii et al. 2014). 
Therefore, a lot of efforts have been put into identification of more effective 
biomarkers which could be used to detect early gastric cancer and predict both 
recurrence and chemosensitivity. Recent progress in molecular techniques have 
provided new insight into the aberrant expression of gastric cancer-related 
molecules, including oncogenes and tumour suppressor genes, microRNAs, long 
non-coding RNAs, and aberrant DNA methylation, as potential novel molecular 
biomarkers that may have clinical value and therefore may be used for gastric 
cancer screening, diagnosis, tumour classification, prognosis and the prediction of 
therapeutic responses (Pinheiro, Silva Ferreira et al. 2014, Kanda and Kodera 2015). 
However, despite these extensive efforts, there are only a few defined gastric 
cancer biomarkers that are currently used in clinical practice. For that reason, it was 
proposed that several different biomarkers (genetic, epigenetic and proteomic) 
should be used in combination for each patient, in order to offer a much more 
reliable option for improved patient stratification (Pinheiro, Silva Ferreira et al. 
2014).  
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1.3  Tumour microenvironment  
It is now widely recognised that solid tumours are highly complex tissues  
composed of multiple distinct cell types that participate in dynamic and conditional 
heterotypic interactions. These changing interactions contribute to most aspects of 
tumour development, including initiation, progression, metastasis and 
chemoresistance (Hanahan and Weinberg 2011).  
 
1.3.1  Components of tumour microenvironment  
The tumour microenvironment consists of a dynamic system of various                
non-transformed cells, including fibroblasts, myofibroblasts, endothelial cells, 
immune cells and bone marrow-derived cells, as well as a specialised extracellular 
matrix (ECM) and various soluble paracrine factors, such as growth factors, 
cytokines, chemokines, enzymes and metabolites (Figure 1.2) (Bhowmick, Neilson 
et al. 2004, Allen and Jones 2011). Tumour progression is directly linked to special 
and temporal changes in hypoxia and acidosis, which have a significant impact on 
the bidirectional interactions between cancer cells and stromal components 
(Casazza, Di Conza et al. 2014, Kharaishvili, Simkova et al. 2014). Therefore, better 
understanding of the specific interactions between cancer cells and the surrounding 
microenvironment is needed to identify the mechanisms underlying tumour 
development and progression as well as driving the development of novel 
prognostic and therapeutic targets. 
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Figure 1.2 Components of the tumour microenvironment.  
Elevated levels of cancer cell-derived growth factors and cytokines recruit diverse      
tumour-associated cells, which secrete additional growth factors, forming a positive 
feedback loop that promotes tumour cell progression and metastasis. 
 
1.3.2  Stromal-epithelial interactions  
The development of the tumour and progression towards advanced stages of the 
disease involves the co-evolution of both cancer cells and stromal cells (Shimoda, 
Mellody et al. 2010). In normal tissues paracrine communication between epithelial 
and stromal cells is required for the maintenance of normal tissue function     
(Figure 1.3A). During malignant transformation epithelial cells acquire mutations 
that dysregulate normal cell-cell communication. These mutations not only alter 
intrinsic cellular signalling pathways but also change the way cells respond to 
signals emerging from the neighbouring stromal cells. Ultimately, the altered 
paracrine signalling leads to tissue remodelling and changes within the surrounding 
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stroma, which then drive tumour progression (Figure 1.3B) (Wiseman and Werb 
2002).  
 
 
 
Figure 1.3 Stromal-epithelial interactions in A. normal tissue and B. during malignant 
transformation. 
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1.3.3  Myofibroblasts 
Myofibroblasts, also known as activated fibroblasts, are stromal spindle-shaped 
cells that are relatively rare in most normal healthy tissues (Eyden 2008). They are 
characterised by the expression of α-smooth muscle actin (α-SMA) that distinguish 
them from ‘normal’ tissue fibroblasts (Skalli, Schurch et al. 1989). Myofibroblasts 
secrete ECM components, cytokines, chemokines, growth factors, proteases and 
their inhibitors (Tomasek, Gabbiani et al. 2002, Hinz 2007). They were first 
discovered in wound granulation tissue of healing skin wounds, where it was 
hypothesized that they were responsible for the wound contraction (Gabbiani, Ryan 
et al. 1971). Since then, myofibroblasts have been described in a number of 
different pathologies, including cancer. Although myofibroblasts have similar 
morphology, function and biochemical repertoire regardless of their tissue of 
residence, they may express some phenotypic and functional heterogeneity 
depending on the initial cause or process of their activation, such as tissue 
inflammation or proximity to a developing tumour. Notably, in contrast to other 
tissues, the gastrointestinal tract was reported to have a consistent but potentially 
dynamic population of activated myofibroblasts, which help to maintain normal 
epithelial function (Powell, Mifflin et al. 1999). 
 
1.3.3.1  Myofibroblasts in wound healing  
Myofibroblasts are activated as part of a normal wound healing response (Hinz 
2007). When tissue is repaired myofibroblasts are either cleared by apoptosis 
(Desmouliere, Redard et al. 1995), or may become deactivated (Hecker, Jagirdar et 
al. 2011). Dysregulation of this normal process of repair can lead to persistent 
myofibroblast activation, for instance by chronic inflammation or mechanical stress 
in the tissue, which is associated with many fibrotic and scarring disorders (Noble, 
Barkauskas et al. 2012, Weber, Sun et al. 2013), and cancer (Cox and Erler 2011).  
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1.3.3.2  Myofibroblasts in cancer 
Myofibroblasts are the most abundant cell type in tumour stroma and can be 
isolated from various cancer types, including breast cancer, prostate cancer, 
pancreatic cancer, cholangiocarcinoma, lung cancer, gastric cancer, and colorectal 
cancer. However, myofibroblasts are relatively rare in brain, renal and ovarian 
cancers (Shiga, Hara et al. 2015). The presence of myofibroblasts in large numbers 
is often correlated with poor prognosis (Yamashita, Ogawa et al. 2012, Ha, Yeo et al. 
2014) and may be involved in cancer cell resistance to therapy (Li, Hu et al. 2015).  
 
Cancer associated myofibroblasts (CAMs), also sometimes referred to as cancer 
associated fibroblasts (CAFs), are functionally distinct and exhibit an altered 
phenotype when compared to non-cancerous tissue-derived myofibroblasts at least 
in part due to epigenetic changes (Jiang, Gonda et al. 2008). This includes changes 
in CAM transcriptome (Peng, Zhao et al. 2013) and microRNA expression profile 
(Zhao, Sun et al. 2012) as well as a characteristic changes in CAM metabolome 
(Martinez-Outschoorn, Lisanti et al. 2014) and secretome (Holmberg, Quante et al. 
2012). Human tumour xenograft models have shown that co-injection of CAMs with 
cancer cells enhances tumour growth compared to injection of non-cancer 
associated or non-activated fibroblasts (Orimo, Gupta et al. 2005). 
 
It is now well established that tumour-promoting attributes of CAMs are not a 
consequence of genetic alterations analogous to these observed in cancer cells 
(Campbell, Polyak et al. 2009). As CAMs are more genetically stable then cancer 
cells, they represent high priority targets for biomarker discovery and development 
of novel therapeutic strategies (De Vlieghere, Verset et al. 2015) as discussed in 
section 1.3.5.  
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1.3.3.2.1  Origin of CAMs 
Cancer associated myofibroblasts form a heterogeneous population of cells, which 
can be derived from several cell types, including resident tissue fibroblasts 
(Ronnovjessen and Petersen 1993, Mitra, Zillhardt et al. 2012), adipocytes (Kidd, 
Spaeth et al. 2012), epithelial cells (Petersen, Nielsen et al. 2003), endothelial cells 
(Zeisberg, Potenta et al. 2007), and bone marrow derived mesenchymal stem cells 
(Mishra, Mishra et al. 2008). The recruitment and activation of CAMs is mainly 
driven by cancer-derived growth factors and cytokines, such as transforming 
growth factor β (TGF-β), platelet-derived growth factor (PDGF) and interleukin 6  
(IL-6) (Ronnovjessen and Petersen 1993, Shao, Nguyen et al. 2000, Giannoni, 
Bianchini et al. 2010). However, recently other mechanisms have also been 
reported such as hypoxia and reactive oxygen species (ROS). ROS have been 
demonstrated to promote conversion of fibroblast into myofibroblasts through the 
accumulation of the hypoxia-inducible factor HIF1-α, while treatment with 
antioxidants have been found to reduce HIF1-α levels and supress numerous 
myofibroblasts features (Toullec, Gerald et al. 2010). In addition, cancer-derived 
exosomes have also been shown to contribute to the recruitment and 
differentiation of fibroblasts and mesenchymal stem cells to CAMs (Webber, 
Steadman et al. 2010, Gu, Qian et al. 2012). 
 
1.3.3.2.2  Tumour-promoting properties of CAMs 
Numerous studies have reported that primary stromal myofibroblasts derived from 
various types of tumours, exhibit tumour-promoting properties and actively 
contribute to tumour progression and metastasis compared to non-cancerous 
tissue-derived myofibroblasts. As such, CAMs have been shown to influence several 
emerging hallmarks of cancer (Figure 1.4). It was demonstrated that multiple   
CAM-derived factors sustain pro-proliferative signalling in cancer cells, support the 
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resistance of cancer cells to cell death and growth suppressors and promote cancer 
cell invasion and metastasis. In addition, CAMs have been strongly implicated in 
tumour angiogenesis, immunosuppression, inflammation and ECM remodelling 
(Pietras and Ostman 2010, Polanska and Orimo 2013, Ohlund, Elyada et al. 2014). 
Significantly, CAMs have also been reported to play a role in deregulating cellular 
energetics and to contribute to genome instability and the accumulation of 
mutations in cancer cells (Martinez-Outschoorn, Balliet et al. 2010, Martinez-
Outschoorn, Lisanti et al. 2014). In this study the effects of CAM-derived secretory 
factors on gastric cancer cell migration and proliferation are being investigated as 
highlighted in Figure 1.4. 
 
 
 
 
Figure 1.4 Tumour promoting properties of cancer associated myofibroblasts (CAMs) 
reported in numerous studies. Properties highlighted in boxes are being investigated in 
this study. 
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1.3.3.2.3  Myofibroblasts in gastric cancer  
Myofibroblasts are well represented in normal gastric tissue, where they are closely 
allied to the epithelium. However in gastric cancers, myofibroblasts exhibit 
disordered architecture, morphology and function (Balabanova, Holmberg et al. 
2014). Studies conducted in Professor Varro’s group (University of Liverpool) 
showed that gastric cancer associated myofibroblasts (CAMs) secrete factors that 
increase the migration and proliferation of gastric cancer cells when compared to 
adjacent tissue myofibroblasts (ATMs), or normal tissue myofibroblasts (NTMs) 
(Holmberg, Quante et al. 2012). In addition, a comparative secretome analysis of 
myofibroblast conditioned media shows that gastric CAMs have differential protein 
secretion compared to ATMs. This study identified a decreased level of the 
extracellular matrix ECM adaptor protein like transforming growth factor β-induced 
gene-h3 (TGFβig-h3) in the CAM secretome, which also correlated with lymph node 
metastasis, worse prognosis and shorter patient survival (Holmberg, Quante et al. 
2012).  
 
Significantly, a number of other factors that distinguish gastric CAMs from their 
normal non-cancerous counterparts have also been reported. One such factor is 
galectin-1 which shows strong expression in CAMs and was shown to enhance 
gastric cancer cell migration and invasion by upregulating integrin-β1 expression 
(Xu‐Jun, Hou‐Quan et al. 2014). In addition, CAM-derived galectin-1 was shown to 
promote angiogenesis in gastric cancer (Tang, Gao et al. 2015). Other examples 
include miR-106b and fibroblast growth factor 9 (FGF-9) which are upregulated in 
gastric CAMs (Ting-Song, Xiao-Hu et al. 2014, Sun, Fukui et al. 2015). FGF-9 was 
shown to promote the anti-apoptosis and invasive capability of gastric cancer cells 
(Sun, Fukui et al. 2015) whereas upregulated miR-106b was associated with poor 
patient prognosis as it was shown to enhance gastric cancer cell migration and 
invasion (Ting-Song, Xiao-Hu et al. 2014). Immunohistochemistry and real-time PCR 
experiments showed that CAMs are frequently accumulated in gastric cancer tissue, 
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and the prevalence of CAMs is positively correlated with tumour size, depth and 
metastasis (Zhi, Shen et al. 2010). Also, studies in scirrhous gastric cancer, which 
has the worst prognosis among types of gastric cancer, revealed that CAMs might 
regulate the stemness of cancer stem cells (CSCs) (Tsuyoshi, Masakazu et al. 2014) 
and identified Asporin as an unique CAM-derived secretory protein that promotes 
coordinated invasion of CAMs and cancer cells (Satoyoshi, Kuriyama et al. 2014).  
 
Taken together, these findings demonstrate that CAMs play a vital role in various 
aspects of gastric cancer pathogenesis. It is therefore critical to further elucidate 
the role of gastric CAMs in tumour progression and patient prognosis.  
 
1.3.4  Hypoxia 
Hypoxia is a condition in which a region of the body is deprived of oxygen and is 
rare in normal tissue. In solid tumours, however regions of hypoxia are common 
due to high rate of tumour growth that cannot be sustained by a limited oxygen 
supply and abnormal tumour vasculature (Harris 2002). Hypoxic tumours exhibit 
increased aggressiveness and metastasis, and are often associated with poor 
patient prognosis and resistance to therapy (Subarsky and Hill 2003, Vaupel and 
Mayer 2007).  
 
1.3.4.1  Cellular responses to hypoxia 
Hypoxia activates the hypoxia-inducible factor (HIF) family of transcription factors, 
which plays a central role in the adaptation of tumour cells to hypoxic condition by 
regulating diverse cellular processes, including metabolism, angiogenesis, cell 
proliferation, apoptosis, tissue remodelling and metastasis (Carmeliet, Dor et al. 
1998, Bertout, Patel et al. 2008, Gilkes, Semenza et al. 2014). Under hypoxic 
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conditions, HIF-1α is stabilized and forms a heterodimer with the oxygen-
independent subunit HIF-β, translocates to the nucleus, and directly activates the 
expression of hundreds of target genes (Semenza 2003). Significantly, hypoxia was 
reported to induce the expression of a number of microRNAs in cancer cells 
(Kulshreshtha, Ferracin et al. 2007) and promote the release of cancer-derived 
exosomes (King, Michael et al. 2012). In addition, exosomes secreted under hypoxic 
condition were found to enhance cancer cell invasiveness, stemness, and induce 
microenvironment changes in contrast to exosomes secreted under normal oxygen 
condition (Ramteke, Ting et al. 2015).  
 
1.3.4.2  Hypoxia-associated epigenetic changes 
It is increasingly evident that hypoxic tumour cells display a distinct epigenetic 
profile. A number of genes have been reported to be transcriptionally repressed   
by promoter hypermethylation and various histone modifications in cancer cells   
under hypoxic conditions (Ramachandran, Ient et al. 2015). Interestingly, chromatin 
immunoprecipitation (ChIP) analyses identified a hypoxia-induced signature of 
chromatin modifications which may play a role in gene regulation in proliferating 
tumour cells undergoing cyclic periods of hypoxia and reoxygenation (Johnson, 
Denko et al. 2008). The authors found that low oxygen level causes widespread 
repression of transcription and globally induces a mixture of histone modifications 
commonly associated with either transcriptional activation or repression. In 
general, the performed ChIP analyses of core promoters of hypoxia-repressed and 
hypoxia-activated genes showed that gene-specific profiles of repressed or 
activated chromatin structure correlate with hypoxia-regulated, decreased or 
increased gene expression. However, at each hypoxic-responsive promoters tested, 
whether activated or repressed, the authors found increased trimethylation of 
histone 3 lysine 4 (H3K4me3) and decreased trimethylation of histone3 lysine 27 
(H3K27me3) induced by hypoxia. These specific exceptions to commonly accepted 
principles of ‘histone code’, which associate H3K4me3 with transcriptional 
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activation and H3K27me3 with transcriptional repression, reveal a hypoxia-induced 
histone signatures that may be characteristic for the often transient state of 
tumour hypoxia (Johnson, Denko et al. 2008). In addition, low oxygen concentration 
has also been linked to an increase in global DNA hypomethylation in hypoxic 
cancer cells (Shahrzad, Bertrand et al. 2007, Liu, Liu et al. 2011). 
 
1.3.4.3  Hypoxia in gastric cancer 
Hypoxia is an important factor in gastric cancer pathogenesis. 
Immunohistochemical study of gastric biopsies show that HIF-1α expression is an 
early event in gastric carcinogenesis as its expression increases with progression 
from normal mucosa to gastric cancer (Griffiths, Pritchard et al. 2007). Inhibition of 
HIF-1α activity was shown to impair gastric tumour growth, angiogenesis and vessel 
maturation (Stoeltzing, McCarty et al. 2004). It was also suggested that HIF-1α 
expression and H. pylori infection may play a synergistic role as both are closely 
related with gastric cancer occurrence, the depth of cancer cell invasion and lymph 
node metastasis (Wu, Zheng et al. 2013). In addition, hypoxic microenvironment 
was reported to induce epithelial–mesenchymal transition (EMT), enhance       
stem-like properties of gastric cancer cells and promote gastric cancer cell invasion 
and metastasis (Matsuoka, Yashiro et al. 2013, Guo, Wang et al. 2015).  
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1.3.5  Targeting the tumour microenvironment 
Targeting of the tumour microenvironment is an area of the considerable interest 
for both patient stratification and the identification of new targets for 
pharmacological inhibition.  
 
1.3.5.1  Prognostication and diagnosis 
It is now well documented that higher amounts of stroma components within the 
tumour bulk have negative prognostic impact on patient survival (Labiche, Heutte 
et al. 2010, Wang, Ma et al. 2012). In addition, numerous single biomarkers, either 
CAM-specific of CAM-derived, which demonstrated independent association with 
patient survival have been identified in immunohistochemical studies (Hale, Hayden 
et al. 2013, Paulsson and Micke 2014, De Vlieghere, Verset et al. 2015). 
Significantly, gene expression profiling of CAMs derived from breast cancer tumours 
have been reported to identify stroma signatures that are correlated with clinical 
outcome (Finak, Bertos et al. 2008) and can predict therapy response (Farmer, 
Bonnefoi et al. 2009). Also, it was shown recently that a population of circulating 
CAMs (cCAM) could be identified in the peripheral blood of patients with metastatic 
breast cancer. Therefore, cCAMs together with circulating tumour cells (CTC) might 
be used as a clinically relevant biomarker for the detection of cancer metastasis 
(Ao, Shah et al. 2015). 
 
1.3.5.2  Stroma targeted therapy 
The reactive tumour stroma is increasingly being viewed as a potential therapeutic 
target, and strategies are being developed to disrupt tumour-stroma interactions 
(Gonda, Varro et al. 2010). Stroma targeted therapy might be a valid complement 
to conventional cancer cell–directed treatments and might have broad clinical 
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implications as a therapeutic strategy. For example, in gastric cancer tissue, it was 
shown that cancer cells express platelet-derived growth factor (PDGF), whereas 
stromal cells, including CAMs, pericytes and lymphatic endothelial cells express 
PDGF receptor (PDGF-R) (Sumida, Kitadai et al. 2011). Using an orthotopic nude 
mouse model of human gastric cancer, it was demonstrated that oral 
administration of PDGF-R tyrosine kinase inhibitor in combination with 
intraperitoneal injection of cytotoxic chemotherapeutic agent not only significantly 
inhibited the growth of tumours but also the incidences of lymph node and 
peritoneal metastasis (Sumida, Kitadai et al. 2011). In addition to disrupting the 
crosstalk between tumour cells and stroma components, other treatment strategies 
include: i) inhibiting or sequestering stroma-derived factors that stimulate 
neoplastic cell behaviour and drug resistance, such as vascular endothelial growth 
factor (VEGF), which is one of the most potent factors contributing to angiogenesis 
(Hurwitz, Fehrenbacher et al. 2004, Crawford, Kasman et al. 2009); ii) targeting the 
hypoxic milieu by targeting HIF-1α (Semenza 2003), and iii) targeting the stromal 
barrier to increase drug delivery (Provenzano, Cuevas et al. 2012).  
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1.4  Epigenetics 
In the past few decades, epigenetics has emerged as an exciting new field in 
development and disease. Epigenetics is usually defined as the study of heritable 
changes in gene expression that are not due to direct changes in the primary DNA 
sequence (Bird 2007).  
 
It is now well recognized that the genetic information itself is not sufficient to 
explain many complex phenotypes and causes of human diseases. Epigenetic 
mechanisms, including DNA and histone modifications, must also be considered as 
they play an important role in regulating distinct gene expression profiles and 
therefore control diverse normal cellular phenotypes and functions. As such, 
alterations of epigenetic code are central to many common human diseases, 
including cancer (Robertson 2005, Esteller 2007, Feinberg 2007). Better 
understanding of the interplay between epigenetic changes, gene expression and 
cancer hold promise for the development of new approaches to improve molecular 
diagnosis and targeted therapies (Egger, Liang et al. 2004, Feinberg 2007, Gal-Yam, 
Saito et al. 2008).  
 
1.4.1   Mechanisms of gene regulation 
Epigenetic mechanisms that control gene expression include DNA methylation, 
histone modifications, chromatin remodelling and regulation by small and long  
non-coding RNAs (Han, Witmer et al. 2007, Jones and Baylin 2007). 
 
DNA methylation was the first recognized and one of the most studied epigenetic 
modifications. It regulates the expression of both protein-coding and non-protein 
coding RNAs, such as microRNAs ((Han, Witmer et al. 2007). Conversely, microRNAs 
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can also regulate histone modifications and the expression of                                 
DNA methyltransferases, which regulate DNA methylation (Benetti, Gonzalo et al. 
2008, Sinkkonen, Hugenschmidt et al. 2008). Long noncoding RNAs may modulate 
the activity of DNA methyltransferases and interact with the histone machinery 
(Rinn and Chang 2012, Merry, Forrest et al. 2015). Furthermore, specific histone 
modifications such as acetylation, methylation and phosphorylation contribute to 
the remodelling of chromatin structure, thus regulate its accessibility and 
compactness (Kouzarides 2007). In turn, the state of chromatin can control the 
expression of non-protein coding RNAs (Chen, Fu et al. 2014). Histone modifications 
can also attract DNA methyltransferases to initiate cytosine methylation, which in 
turn can reinforce histone modification patterns conducive to silencing (Cedar and 
Bergman 2009). This complex interplay between the different types of epigenetic 
mechanisms and modifications creates an ‘epigenetic landscape’, which ultimately 
results in the regulation of phenotype-specific gene expression profiles (Figure 1.5), 
which are important for a given phenotype, or play an important role in response to 
internal or external stimuli.  
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Figure 1.5 Interplay between different aspects of epigenetic regulation of gene 
expression. 
 
 
1.4.2  DNA methylation 
DNA methylation is a stable epigenetic mark which results from addition of the 
methyl group (-CH3) at the 5-carbon ring of the cytosine nucleotides (Ehrlich and 
Wang 1981). This conversion of cytosine to 5-methylcytosine (5-mC) is catalysed by 
DNA methyltransferases (DNMTs) and is associated with gene silencing (Herman 
and Baylin 2003). DNA methylation is essential for normal development and plays 
important role in a number of key cellular processes, including genomic imprinting, 
X-chromosome inactivation, suppression of repetitive elements and preservation of 
chromosome stability (Robertson 2005, Smith and Meissner 2013). It regulates 
gene expression either by recruiting repressive methyl-binding proteins or by 
impairing the binding of transcription factors to their regulatory sequences (Klose 
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and Bird 2006). More recently, it has also been found to play a role in alternative 
splicing (Maor, Yearim et al. 2015). 
 
1.4.2.1  Genomic distribution of CpG methylation 
In somatic cells, 5-mC occurs primarily in CpG contexts, where a cytosine residue is 
followed by guanine base. The genomic distribution of CpG methylation is highly 
non-random as evidence suggests that the function of DNA methylation may vary 
with genomic context.  
 
Early studies focused on CpG islands, stretches of DNA that have high CpG density 
in an otherwise CpG-sparse genome (Figure 1.6). CpG islands often co-localize with 
gene promoters and are typically unmethylated allowing gene transcription. 
Aberrant hypermethylation of these regions results in transcriptional gene 
repression (Figure 1.7) (Bird 1986, Jones and Baylin 2002). The same methylation 
pattern is observed for CpG island ‘shores’, which are defined as the 2kb regions 
flanking a CpG island (Figure 1.6). These regions have been reported to be more 
dynamic then the CpG islands. In addition, most of the tissue-specific DNA 
methylation seems to occur in CpG island shores (Doi, Park et al. 2009, Irizarry, 
Ladd-Acosta et al. 2009). Beyond shores are ‘shelves’, which are defined as the 2 kb 
regions flanking CpG island ‘shores’ (Figure 1.6) (Bibikova, Barnes et al. 2011). 
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Figure 1.6 Distribution of CpG sites in genomic regions. 
 
 
Contrary to promoter region, methylation at the gene body facilitates transcription 
and is common in ubiquitously expressed genes (Hellman and Chess 2007). It has 
been proposed that gene body methylation might be related to elongation 
efficiency and prevention spurious initiations of transcription (Zilberman, Gehring 
et al. 2007). In disease, the gene body tends to lose methylation (Figure 1.7), 
allowing transcription to be initiated at several incorrect sites.  
 
Finally, DNA methylation is not only associated with gene regulation. Heavily 
methylated CpGs fraction is found in repetitive sequences. The hypermethylation at 
these regions is needed to protect chromosomal integrity which is achieved by 
preventing reactivation of endoparasitic sequences that cause chromosomal 
instability, translocations and gene disruptions (Esteller 2007). This methylation 
pattern is commonly altered in cancer (Figure 1.7)  
 
 
 
Methylated 
Unmethylated
N Shelf 
2kb
S Shelf 
2kb
N Shore 
2kb
S Shore 
2kb
CpG Island
Introduction 
 
 
27 
 
1.4.2.2  DNA methyltransferases 
Different members of the DNA methyltransferase (DNMT) family of enzymes are 
required either for maintenance or de novo establishment of DNA methylation 
patterns. DNMT1 is responsible for the maintenance of established DNA 
methylation patterns. It functions during DNA replication to copy the DNA 
methylation pattern from the existing DNA strand onto the newly synthesized 
daughter strand (Szyf, Bozovic et al. 1991). DNMT3a and DNMT3b are highly 
expressed in developing embryos as they mediate establishment of de novo DNA 
methylation patterns, putting the initial pattern of methyl group in place on a 
unmodified DNA sequence (Okano, Bell et al. 1999). 
 
1.4.2.3  Dynamics of DNA methylation 
In spite of being relatively stable, DNA methylation can also be quite dynamic, 
changing in response to cell environmental stimuli. One such example might be 
regular endurance training. A study in humans showed that regular exercise over a 
period of 3-months induces genome-wide DNA methylation changes in human 
skeletal muscles which are correlated with gene expression changes          
(Lindholm, Marabita et al. 2014). A similar study has been done in mice   
(Kanzleiter, Jaehnert et al. 2015). In fact, it was suggested that an analysis of 
specific genomic regions, which were identified as ‘highly dynamic differentially 
methylated regions’ across 30 diverse human cell and tissue types may prove useful 
for human health diagnostics and disease prognosis (Ziller, Gu et al. 2013).  
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1.4.3  DNA methylation in cancer 
Aberrant patterns of DNA methylation are one of the characteristic features of 
cancer cells (Feinberg and Tycko 2004, Esteller 2007). Specifically, it was shown that 
cancer genomes are hypomethylated while promotors of tumour suppressor genes 
are often hypermethylated when compared to non-cancerous cells (Figure 1.7) 
(Feinberg and Vogelstein 1983, Jones and Baylin 2002). Global DNA 
hypomethylation alters chromatin architecture leading to activation of oncogenes 
and transposable elements whereas promoter hypermethylation represses the 
expression of tumour suppressor genes. Consequently, these epigenetic events 
provide cancer cells with a growth advantage, increasing their genetic instability 
and allowing them to metastasize (Herman and Baylin 2003, Esteller 2008). In fact, 
promoter hypermethylation and the resulting silencing of tumour suppressor genes 
as well as global loss of genomic methylation are frequent and early events in 
cancer and in some instances correlate with disease severity and metastatic 
potential (Chan, Broaddus et al. 2002, Widschwendter, Jiang et al. 2004). 
 
 
Figure 1.7 Schematic representations of DNA methylation patterns in normal and 
cancer cells. In normal cells (top), CpG islands associated with promoter regions usually 
remain unmethylated allowing gene transcription and methylation of repetitive sequences 
prevents genomic instability. In cancer cells (bottom), promoter regions become methylated 
resulting in transcriptional repression of many genes whereas global loss of methylation 
triggers genomic instability and aberrant transcriptional initiations.  
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1.4.4  DNA methylation in gastric cancer 
Epigenetic alterations contribute significantly to the development and progression 
of gastric cancer (Gigek, Chen et al. 2012, Kang, Song et al. 2014). Aberrant DNA 
methylation in gene promoters is the most well-defined epigenetic hallmark in 
gastric cancer. A large number of genes with different biological functions have 
been found to be methylated including genes involved in DNA repair, cell cycle, cell 
adhesion, invasion, migration, growth, differentiation, apoptosis, transcriptional 
regulation and other processes (Qu, Dang et al. 2013, Tahara and Arisawa 2015). In 
addition, aberrant methylation of a number of genes has been significantly 
associated with clinicopathological features and clinical outcomes (Qu, Dang et al. 
2013, Tahara and Arisawa 2015). Significantly, recent reports have indicated that 
infection with H. pylori is associated with elevated levels of aberrant DNA 
methylation (Shin, Kim et al. 2011) and that DNA methylation transcriptionally 
regulate the number of microRNAs in gastric cancer (Bae, Kang et al. 2015). Given 
that aberrant DNA methylation is more frequent than mutations and can drive the 
pathogenesis of gastric cancer and contribute to the molecular heterogeneity of 
gastric cancers, a lot of effort has been put into defining promoter methylation 
signatures that can be used for early detection and diagnosis of gastric cancer in 
biopsy specimens and non-invasive body fluids such as serum and gastric washes as 
well as for prognostication and the prediction of treatment responses 
(Abbaszadegan, Moaven et al. 2008, Watanabe, Kim et al. 2009, Sapari, Loh et al. 
2012, Schneider, Mera et al. 2015).  
 
1.4.5  Epigenetic cancer therapy 
Unlike genetic mutations, epigenetic alterations are potentially reversible. Several 
epigenetic drugs that target enzymes controlling epigenetic modifications have 
already shown promising anti-tumorigenic activity in some malignancies and are 
currently being tested in clinical trials (Egger, Liang et al. 2004, Mund and Lyko 
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2010). Epigenetic drugs that have already been approved by FDA for use in certain 
types of cancer are described below.  
 
1.4.5.1  DNA methyltransferase inhibitors 
DNA methyltransferase (DMNT) inhibitors, such as 5-azacytidine (azacytidine) and 
5-aza-2'-deoxycytidine (decitabine) are cytidine analogues that function as 
demethylating agents. They are incorporated into DNA during replication and form 
a covalent bond with DNMT1, which triggers the degradation of the enzyme and 
leads to widespread reductions in DNA methylation (Santi, Norment et al. 1984, 
Egger, Liang et al. 2004). As these compounds integrate into DNA during replication, 
rapidly dividing cancer cells are more susceptible to their effects. Both 5-azacytidine 
(azacytidine) and 5-aza-2'-deoxycytidine (decitabine) have already been approved 
by the FDA for use in certain haematological malignancies (Kaminskas, Farrell et al. 
2005, Malik and Cashen 2014).  
 
1.4.5.2  Histone deacetylase inhibitors 
Histone deacetylases (HDACs) catalyse the removal of acetyl groups from amino-
terminal lysine residues of histones, which results in chromatin condensation and 
transcriptional repression. Histone deacetylase (HDAC) inhibitors form a diverse 
group of compounds. They inhibit not only HDACs but also a large number of non-
histone transcription factors and transcriptional co-regulators modified by 
acetylation (Yoo and Jones 2006). HDAC inhibitors have been found to induce 
different phenotypes in various transformed cells, including growth arrest, 
activation of apoptosis, autophagic cell death, reactive oxygen species-induced cell 
death, mitotic cell death and senescence (Xu, Parmigiani et al. 2007). Two 
structurally unrelated HDAC inhibitors, vorinostat and istodax, have been approved 
by the FDA for the treatment of cutaneous T cell lymphoma (Grant, Easley et al. 
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2007, Bertino and Otterson 2011). Significantly, HDAC inhibitors have been found to 
sensitize cancer cells to a variety of cytotoxic drugs (Mataga, Rosenthal et al. 2012) 
thus they can be used in combinational therapy with other anti-cancer drugs which 
is expected to increase cancer cell drug specificity and reduce side effects (Sarkar, 
Goldgar et al. 2013).  
 
1.5  Personalized cancer therapy  
The latest advances in ‘omics’ technologies have led to some major breakthroughs 
in cancer research, which will have the potential to influence clinical practice and 
reshape how the disease is characterized and treated. This includes gastric cancer. 
 
Personalized cancer therapy offers a tailored treatment strategy that aims to either 
increase the efficacy of the individual patient treatment or lower the potential side 
effects by selecting the appropriate treatment based on the patient’s unique 
genetic characteristics and tumour related biomarkers.  
 
1.5.1  Gene expression profiling 
Numerous studies have recently used high-throughput large-scale gene expression 
profiling technology to identify unique ‘gene expression signatures’ that can be 
used to classify gastric tumours, determine response to treatments and predict 
patient survival (Brettingham-Moore, Duong et al. 2011, Lin, Zhao et al. 2015). Shah 
et al. demonstrated that distinct subtypes of gastric cancer, classified by 
histopathologic and anatomic criteria as proximal, diffuse and distal, can also be 
classified based on their unique gene expression profiles (Shah, Khanin et al. 2011). 
In this study, gene expression analysis of 36 primary gastric adenocarcinoma 
samples identified gene signatures that successfully distinguish the three gastric 
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cancer subtypes with more than 85% accuracy (Shah, Khanin et al. 2011).                 
In a different study, gene expression profiling was used to identify gastric cancer 
intrinsic subtypes that might be associated with differences in patient survival and 
response to chemotherapy. The analysis of 37 gastric cancer cell lines identified 
gene signature that can predict two major intrinsic genomic subtypes: genomic 
intestinal (G-INT) and genomic diffuse (G-DIF), which were found to be partially 
associated with Lauren’ histopathologic classification. The G-INT cell lines were 
significantly more sensitive to 5-fluorouracil and oxaliplatin, but more resistant to 
cisplatin, than the G-DIF cell lines (Tan, Ivanova et al. 2011). 5-Fluorouracil, 
oxaliplatin, and cisplatin are drugs presently used in the adjuvant and first-line 
palliative gastric cancer treatment. Notably, gene expression profiling was also used 
to predict the likelihood of relapse after gastric cancer surgery. Cho et al. analysed 
65 gastric adenocarcinoma samples and developed a risk score based on the gene 
signature associated with relapse, which was successfully tested in an independent 
cohort (Cho, Lim et al. 2011).  
 
1.5.2  DNA methylation profiling  
The genome-wide DNA methylation profiling technologies allow interrogation of 
DNA methylation status over large genomic regions and are now commonly used to 
characterise epigenomes of human cancers and identify clinically useful diagnostic 
biomarkers. Notably, Yamanoi et al. demonstrated that distinct DNA methylation 
profiles, which may determine tumour aggressiveness and patient outcome, have 
already become established in non-cancerous tissue at the precancerous stage and 
may be inherited by gastric carcinomas themselves (Yamanoi, Arai et al. 2015).    
The genome-wide differential DNA methylation analysis of 109 non-cancerous 
gastric mucosa and 105 gastric tumour tissues identified widespread alterations of 
DNA methylation between the two groups. Using the identified DNA methylation 
signature of 3861 differentially methylated loci they clustered the normal mucosa 
samples into three subgroups: A, B1 and B2. Gastric carcinomas belonging to 
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subgroup B1 showed tumour aggressiveness more frequently than those belonging 
to subgroups A and B2. The recurrence-free and overall survival rates of patients in 
subgroup B1 were lower than those of patients in subgroups A and B2. Multivariate 
analyses revealed that DNA methylation level in tumour samples was a significant 
prognostic factor, being independent of clinicopathological parameters (Yamanoi, 
Arai et al. 2015). 
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1.6  Objectives and Aims 
In this study, an integrated genomics, transcriptomics and proteomics approach 
was used to understand regulation and crosstalk in the tumour microenvironment. 
The primary objective of this work was to identify and characterise genome-wide 
DNA methylation patterns in primary cancer-associated myofibroblasts (CAMs) 
derived from gastric tumours and establish the extent to which DNA methylation 
may regulate gene expression in these cells. The secondary objective of this work 
was to identify and characterise the consequences of tumour hypoxia on the ability 
of stromal cells to induce gastric cancer cell migration and proliferation.  
Specific aims were:  
 To identify DNA methylation and gene expression changes in primary  
gastric myofibroblasts purified from different tissue microenvironments: 
CAM (cancer), ATM (adjacent tissue) and NTM (normal tissue) and to 
investigate how these differential DNA methylation and gene expression 
signatures contribute to the tumour-promoting properties of gastric CAMs.   
 To determine the effects of CAM and NTM hypoxia-induced secretory 
factors on gastric cancer cell migration and proliferation. 
 To identify hypoxia-induced gene expression signatures in gastric CAMs, 
ATMs and NTMs and investigate their potential biological consequences.  
 To identify and quantify hypoxia-induced CAM and NTM secretomes and 
integrate them with hypoxia-induced CAM and NTM gene expression 
signatures.  
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2.1  Materials  
Table 2.1 List of materials used in this study. 
Material Supplier 
AGS Gastric Adenocarcinoma Cell Line 
American Type Culture 
Collection (VA, USA) 
MKN45 Gastric Adenocarcinoma Cell Line 
Riken BioResource          
(Wako, Japan) 
Dulbecco’s Modified Eagle’s Medium (DMEM), Fetal Bovine  
Serum (FBS), Penicillin–Streptomycin (10 000U/ml), Antibiotic–
Antimycotic (100x), MEM Non-Essential Amino Acid Solution 
(100x), Dulbecco’s Phosphate Buffered Saline (PBS) (10x),   
Trypsin–EDTA (0.25%), Click-iT EdU Alexa Fluor 488 Imaging Kit, 
ProLong Gold Antifade Reagent, Quant-iT PicoGreen  dsDNA Assay 
Kit, TaqMan Universal Master Mix II, TaqMan assays 
Life Technologies 
(Paisley, UK) 
BD BioCoat Control Inserts with 8.0 um PET Membrane in Two 24 
Well Plates. 
SLS                                   
(Hessle, UK) 
Reastain Quick-Diff Kit 
Reagena                    
(Takojantie, Finland) 
miRNeasy Mini Kit, DNase I, Proteinase K, RNase A, HotStarTaq 
Master Mix Kit, dNTPs, QuantiTect Reverse Transcription Kit 
Qiagen                    
(Manchester, UK) 
Wizard SV Genomic DNA Purification System 
Promega 
(Southampton, UK) 
EZ DNA Methylation-Gold Kit 
Zymo Research 
(CA, USA) 
Custom Primers 
Eurofins MWG         
(Ebersberg, Germany) 
Agilent 2100 Bioanalyzer and RNA 6000 Nano kit 
Agilent Technologies 
(Stockport, UK) 
Sepharose Beads 
GE Healthcare         
(Amersham, UK) 
Agarose 
Bioline 
(London, UK) 
Lambda DNA/HindIII Marker New England Biolabs 
(Hitchin, UK) 
Formaldehyde 16% Solution Agar Scientific 
(Essex, UK) 
Chloroform, Absolute Ethanol, Triton X-100, Bovine Serum 
Albumin 
Sigma-Aldrich 
(Dorset, UK) 
Hypoxystation H35 
Don Whitley Scientific 
Limited 
(West Yorkshire, UK) 
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2.2  Tissue Culture  
2.2.1   Generation of human primary gastric myofibroblasts  
Human primary myofibroblasts were derived from resected gastric tumours (CAMs) 
and matched adjacent tissue (ATMs) obtained from patients undergoing gastric 
cancer surgery at Department of Surgery, University of Szeged (Hungary). 
Myofibroblasts were prepared in the Department of Medicine, University of Szeged, 
(Hungary) as previously reported (McCaig, Duval et al. 2006). Tumour and adjacent 
tissues were characterized using the TNM classification. Normal tissue 
myofibroblasts (NTMs) were generated from deceased transplant donors with 
normal gastric morphology. The list of patient-matched CAM and ATM 
myofibroblast cell lines and normal tissue myofibroblast (NTM) cell lines used in  
this study is shown in Table 2.2 and Table 2.3, respectively. For histopathological 
assessments, myofibroblasts were defined as stellate/spindle-shaped cells with 
consistent α-SMA and vimentin co-expression (Holmberg, Quante et al. 2012). 
Smooth muscle fibres were excluded based on their characteristic morphology. The 
study was approved by the Ethics Committee of the University of Szeged (Hungary).  
2.2.2  Gastric myofibroblast cell culture 
Primary human gastric myofibroblasts (CAMs, ATMs and NTMs) were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% Fetal     
Bovine Serum (FBS), 1% penicillin-streptomycin, 1% antibiotic-antimycotic and                   
1% non-essential amino acid solution. This is referred to as growth media unless 
otherwise stated. Cells were incubated at 37°C in a humidified atmosphere with   
5% CO2 and were split when they reached 80-90% confluence by washing in           
1x Dulbecco’s Phosphate Buffered Saline (PBS) twice before adding 0.25% trypsin 
then the cell passage number was noted. The growth media was changed 
approximately every 60 hours. In all experiments cells were not passaged beyond 
passage 12.  
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Table 2.2 Patient information relating to age, gender, tumour location and tumour clinical assessment for gastric cancer patients who provided 
CAM and ATM cells used in this study. Tumour staging is defined in terms of pathology of tumour (pT) where 0 defines no sign of tumour and 3 maximum 
size and/or extensions. Similarly, the involvement of local and metastasis to proximal lymph nodes is stated as N0-N3 and metastasis severity by M0, no 
metastasis and M, distal metastasis. 
 
Patient 
ID 
Age Gender Location of Tumour Lauren 
Classification 
H.pylori 
status 
Prognostic 
Score 
Tumour 
Staging 
Survival 
(months) 
Adjacent Tissue 
192 49 F antrum corpus border diffuse + 11 pT3N1M0 22 chronic gastritis 
308 51 M antrum corpus border mixed + 12 pT1N3M0 9 chronic gastritis 
305 59 F antrum and corpus diffuse + 12 pT3N2M0 17 chronic gastritis 
42 72 M antrum corpus border medullar  
(non-Lauren) 
- 5 pT1N0M0 75 intestinal metaplasia, atrophy 
45 82 M antrum intestinal - 11 pT4N2M0 2 intestinal metaplasia, 
 chronic gastritis 
271 72 M corpus mixed - 12 pT3N1M0 24 chronic gastritis 
268 76 M antrum intestinal + 11 pT4N2M0 15 intestinal metaplasia, atrophy, 
chronic gastritis 
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Table 2.3 Information relating to age, gender and cell origin for post-mortem organ 
donors who provided NTM cells used in this study. The donors had no known underlying 
medical conditions.  
Sample ID Origin Age Gender 
196/2 gastric corpus 67 M 
279/22 gastric antrum 60 M 
334/22 gastric antrum 52 F 
261/22 gastric antrum 52 F 
 
2.2.3  Gastric cancer cell culture 
Human gastric adenocarcinoma cell lines AGS and MKN45 were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% Fetal Bovine 
Serum (FBS), 1% penicillin-streptomycin and 1% antibiotic–antimitotic solution. This 
is referred to as growth media unless otherwise stated. The cells were incubated at 
37°C in a humidified atmosphere with 5% CO2 and were passaged or growth media 
was changed approximately every 48-72 hours. In all experiments cells were used 
between passages 18 and 28. 
 
2.3  Integrated multi-omics experiments 
2.3.1  Patient information 
Gastric cancer patient-matched CAM and ATM samples as well as NTM samples 
were cultured in parallel for integrated genome-wide DNA methylation, gene 
expression and secretome profiling. A full list of primary myofibroblast cell lines 
used in these experiments is shown in Table 2.4. Corresponding information 
relating to patient age, gender and tumour clinical assessment is provided in     
Table 2.2 and Table 2.3. Selection of primary myofibroblast cell lines for use in 
integrated multi-omic experiments was based on trends observed in a previous 
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bioinformatics analysis of comparative gene expression profiles in 12 patient-
matched CAM and ATM samples (Dr Helen Smith, manuscript in preparation). This 
analysis identified two distinct groups of patients according to prognosis score that 
was determined using the semi-quantitative scoring system (Supplementary     
Table S2.2). Patients with prognosis score below 9 were classified as group A               
(good prognosis) and patient with prognosis score above 9 were classified as   
group B (bad prognosis). Dr Smith defined a subset of differentially expressed  
genes in CAM vs ATM that followed the patient prognosis scores and based on 
expression of these genes she noticed the patients within bad prognosis group 
(group B) could be further divided into two independent subgroups: subgroup B 
with detected H. pylori infection and subgroup B with undetected H. pylori 
infection. In this study 3 patients from bad prognosis subgroup with detected         
H. pylori infection were chosen for more detailed investigation. 
 
2.3.2  Myofibroblast cell culture 
In order to generate myofibroblast conditioned media 500 x 103 of selected 
myofibroblast cell lines were seeded in 75cm2 flasks. Growth media was replaced 
after 24 hours and cells were incubated under normoxic (21% O2) or hypoxic        
(1% O2) conditions for 48 hours. After this initial incubation, cells were washed 
three times in 1x PBS to remove serum-derived proteins and 13ml of freshly 
prepared serum-free DMEM supplemented with 1% penicillin-streptomycin, 1% 
antibiotic-antimycotic and 1% non-essential amino acid solution was added and 
conditioned for 24 hours under normoxic or hypoxic conditions. Conditioned media 
and cell lysates for DNA and RNA extraction were collected after 24 hours for use in 
Illumina Infinium HumanMethylation450k and HumanHT-12v4 Expression arrays as 
well as LC-MS/MS secretome analysis. 
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Table 2.4 List of samples used for integrated multi-omic experiments. 
Sample 
type 
Patient ID Sample ID Sample label Treatment 
CAM 
192 
192/1 
C1N normoxia 
C1H hypoxia 
ATM 192/2 
A1N normoxia 
A1H hypoxia 
CAM 
308 
308/1 
C2N normoxia 
C2H hypoxia 
ATM 308/22 
A2N normoxia 
A2H hypoxia 
CAM 
305 
305/1 
C3N normoxia 
C3H hypoxia 
ATM 305/22 
A3N normoxia 
A3H hypoxia 
NTM 279 279/22 
N1N normoxia 
N1H hypoxia 
NTM 261 261/22 
N2N normoxia 
N2H hypoxia 
NTM 334 334/22 
N3N normoxia 
N3H hypoxia 
 
2.3.3   Conditioned media preparation for secretome profiling 
Conditioned media from normoxic and hypoxic myofibroblast cells were 
centrifuged at 800g for 7 minutes to remove cell debris and supernatants were  
aliquoted and stored at -80°C prior to LC-MS/MS secretome analysis, which was 
performed by the Centre for Proteome Research (University of Liverpool). 
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2.3.4  DNA extraction for Illumina Infinium 
HumanMethylation450k array 
Genomic DNA was purified using a standard phenol/chloroform extraction method. 
Briefly, myofibroblast cells were washed with 1x PBS and directly lysed in 75cm2 
flasks by adding 2ml DNA Lysis Buffer (400mM Tris-HCl, pH 8, 10mM EDTA, 1% SDS, 
150mM NaCl). The cell lysates ware collected in 15ml Falcon tubes and stored in      
-80°C prior to further processing. Lysates were then thawed and heated for            
10 minutes at 60°C on a shaking platform. Proteinase K (Qiagen, cat. no. 19131) was 
then added to a final concentration of 100μg/ml and samples were incubated 
overnight at 37°C on a shaking platform before being incubated at 70°C for             
30 minutes. RNase A (Qiagen, cat. no. 19101) was then added to a final 
concentration of 100μg/ml and samples were incubated at 37°C for 1 hour. After 
treatment with RNase A, Proteinase K (final concentration of 100μg/ml) was again 
added to samples, which were then incubated for 2 hours at 37°C on a shaking 
platform. After protein digestion, 2ml phenol/CHCl3/isoamyl alcohol (50:49:1) was 
added to samples, which were mixed by repeated inversions for 15 minutes, prior 
to centrifugation at full speed for 5 minutes. The aqueous phase was then 
transferred to new Falcon tubes and 2ml of chloroform was added and mixed by 
inverting the tubes, then centrifuged at full speed for 5 minutes. The aqueous 
phase was transferred to new Falcon tubes and 2.5 volumes of absolute ethanol 
were added. Samples were left overnight at -20°C for DNA precipitation. The next 
day samples were centrifuged at full speed for 15 minutes and DNA pellets were 
washed twice in 70% ethanol and centrifuged at full speed for 10 minutes. DNA 
pellets were left to dry before being rehydrated in 150-200μl TE Buffer (10mM Tris 
pH 7.5/1mM EDTA). DNA sample purity and extent of degradation were determined 
by spectrophotometry at 260/280 nm and gel electrophoresis on 1% agarose gel, 
respectively. DNA quantity was assessed using PicoGreen fluorimetry (Life 
Technologies, cat. no. Q-33130). DNA sample quality information is shown in 
Supplementary Figure S2.1 and Table S2.1. All DNA samples were normalized to the 
concentration of 50ng/μl in 25μl TE Buffer and prepared according to                     
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the Gen-Probe Life Sciences (Molecular Genetic Services, Manchester) sample 
requirements. Before the DNA samples were sent to Molecular Genetic Services 
(Gen-Probe Life Sciences, Manchester) for DNA methylation analysis with Illumina 
Infinium HumanMethylation450k array they were randomized with respect to 
patient origin and treatment to avoid potential batch effects. 
 
2.3.5  RNA extraction for Illumina Human HT-12 v4 array 
Total RNA was purified using miRNeasy Mini Kit (Qiagen, cat. no. 217004)             
and a modified version of the manufacturer’s instructions was used. Briefly, 
myofibroblast cells were washed with 1x PBS and directly lysed in 75cm2 flasks by 
adding 1ml QIAzol Lysis Reagent. Cell lysates ware collected into Eppendorf tubes 
and homogenized by vortexing for 1 minute. The homogenized lysates were stored 
at -80°C prior to further processing. Total RNA was extracted by phase separation 
after addition of 140μl chloroform to the homogenized lysates. Homogenates   
were centrifuged at 12,000 rcf and 4°C for 15 minutes. The upper aqueous phase 
was collected and mixed with 1.5 volumes of absolute ethanol. Then the samples 
were transferred to the RNeasy Mini spin column and centrifuged at 8,000 rcf for 
15 seconds, followed by a 15 minutes on-column DNase I digestion (Qiagen, cat. no. 
79254). The RNeasy Mini spin column membrane was washed twice with 500μl 
Buffer RPE and centrifugation at 8,000 rcf for 15 seconds and 4 minutes, 
respectively. Columns were then transferred to new collection tubes and 
centrifuged at full speed for 3 minutes to eliminate any possible carryover of   
Buffer RPE. RNA was then eluted in 50μl RNase-free water and tested for 
degradation and purity using the Agilent 2100 Bioanalyzer and RNA 6000 Nano kit 
(Agilent Technologies, cat. no. 5067-1512). Samples RIN values and 260/280 ratios 
are shown in Supplementary Table S2.1. All RNA samples were normalized to the 
concentration of 40ng/μl in 25μl RNase-free water and prepared according to the 
Gen-Probe Life Sciences (Molecular Genetic Services, Manchester) sample 
requirements. Samples were randomized with respect to patient origin and 
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treatment to minimize batch processing effects prior to sending to Molecular 
Genetic Services (Gen-Probe Life Sciences, Manchester) for gene expression 
analysis using Illumina HumanHT-12 v4 array. 
 
2.4  Myofibroblast conditioned media preparation  
2.4.1  Standard conditioned media 
To prepare CAM, ATM or NTM conditioned media (CM), 1.5 x 106 myofibroblast 
cells were seeded in 75cm2 tissue culture flasks and left to attach for 24 hours. The 
next day the cells were washed three times in 1x PBS to get rid of any serum-
derived factors. Then growth media was replaced with 15ml freshly prepared 
serum-free DMEM supplemented with 1% penicillin-streptomycin, 1% antibiotic-
antimycotic and 1% non-essential amino acid solution and incubated for 24 hours  
at 37 °C in a humidified atmosphere with 5% CO2. The next day CM was collected 
and centrifuged at 800g for 7 minutes to get rid of cell debris. The freshly prepared 
supernatants were immediately used for cancer cell migration and proliferation 
assays. 
 
2.4.2  Hypoxic conditioned media  
In order to generate CAM or NTM hypoxic conditioned media (CAM-hypoxic-CM or 
NTM-hypoxic-CM) and CAM or NTM normoxic conditioned media (CAM-ctrl-CM or 
NTM-ctrl-CM), 5 x 105 of selected myofibroblast cell lines were seeded in 75cm2 
flasks and left to attached for 24 hours in growth media. The next day the media 
was replaced and cells were subjected to either normoxia (21% O2) or hypoxia (1% 
O2) for 48 hours incubation in serum-supplemented DMEM. After 48 hours the cells 
were washed three times in 1x PBS to get rid of any serum-derived factors and 13ml 
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freshly prepared serum-free DMEM supplemented with 1% penicillin-streptomycin, 
1% antibiotic-antimycotic and 1% non-essential amino acid solution was added to 
the cells. The serum-free media was incubated with the cells for 24 hours in normal 
(21% O2) and hypoxic (1% O2) conditions. The following day myofibroblast ctrl-CM 
and hypoxic-CM were collected and centrifuged at 800g for 7 minutes to get rid of 
cell debris. The freshly prepared CAM or NTM hypoxic-CM and ctrl-CM were 
immediately used for cancer cell migration and proliferation assays. 
 
2.5  Cancer cell based assays 
2.5.1  Cancer cell migration assay  
The effects of myofibroblast conditioned media (CM) on gastric cancer cells 
migration was measured in vitro using trans-well Boyden chamber assay (SLS; cat. 
no. 354578). Briefly, 1 x 104 AGS cells in 500μl of serum-free DMEM medium were 
added to the BioCoat Control Inserts with 8μm pore PET membrane (upper 
chambers). The lower chambers contained either 750μl serum-free media, or 
myofibroblast CM to serve as a chemoattractant. Cells were incubated at 37°C and 
allowed to migrate overnight. Thereafter, AGS cells were removed from the upper 
surface of the membrane by scrubbing with cotton swabs. Cells migrating through 
the membrane were fixed and detected on the lower surface using Reastain     
Quick-Diff Kit (Reagena; cat. no. 102164) and then examined under a bright-field 
microscope. Values for cancer cell migration were obtained by counting fifteen 
fields per membrane (20x objective) and represent an average of at least three 
independent membranes.  
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2.5.2  Cancer cell proliferation assay  
The effects of myofibroblast conditioned media (CM) on gastric cancer cell 
proliferation was assessed by incorporation of 5-ethynyl-2’-deoxyuridine (EdU) 
(Salic and Mitchison 2008) and detected using the Click-iT EdU Alexa Fluor 488 
Imaging Kit (Life Technologies; cat. no. C10337). Briefly, 1 x 104 AGS cells were 
plated onto cover glasses in 24-well plate and left for 24 hours at 37°C to attach. 
The next day, growth media was replaced with serum-free DMEM supplemented 
with 1% penicillin-streptomycin and 1% antibiotic-antymycotic to synchronize the 
cells. After 24 hours cell synchronization, the media was replaced with 1ml of either 
serum-free media or myofibroblast CM containing 10μM EdU and cells were 
incubated overnight at 37°C, 5% CO2. Following incubation, the manufacturer’s 
protocol was applied to fix and permeabilize the AGS cells and detect EdU 
incorporation. Coverslips with cultured cells were washed three times in 1x PBS and 
fixed in 4% paraformaldehyde (PFA) for 15 minutes at room temperature. Then 
fixed cells were washed twice with 3% BSA in PBS before being incubated for         
20 minutes with 0.5% Triton X-100 in PBS to permeabilize the cells. After 
incubation, the cells were washed twice with 3% BSA in PBS and 500μl of freshly 
prepared Click-iT reaction cocktail was added on each coverslip in 24-well plate. The 
plate was incubated in dark at room temperature for 30 minutes. Then the cells 
were washed with 1x PBS and nucleic acid was stained with 1x Hoechst 33342 
solution for 30 minutes in dark at room temperature. Then the coverslips were 
washed twice in 1x PBS and left to dry before being mounted onto slides using 
ProLong Gold reagent (Life Technologies; cat. no. P36930).  
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2.6  Omics data processing and analysis  
2.6.1  Illumina Infinium 450k data processing  
The Illumina Infinium HumanMethylation450 BeadChip arrays were used to study 
genome-wide DNA methylation profiles in gastric and oesophageal stromal 
myofibroblasts. The Illumina 450k arrays for gastric and oesophageal 
myofibroblasts were performed independently. Table 2.2 provides information for 
gastric cancer patients who provided gastric CAM and ATM samples whereas 
Supplementary Table S2.3 provides information for oesophageal cancer patients 
who provided oesophageal CAM and ATM samples. DNA samples were processed 
commercially by Molecular Genetic Services (Gen-Probe Life Sciences, Manchester) 
who then provided raw data files (.IDAT) for further analysis.  
 
Data processing and analysis for both ‘gastric’ and ‘oesophageal’ Illumina 450k 
methylation arrays were conducted as part of this project. Raw DNA methylation 
data was processed and analysed using Bioconductor package RnBeads version 
0.99.17 (Assenov, Muller et al. 2014). RnBeads is an R package that builds upon 
existing software tools imported from other R/Bioconductor packages therefore 
providing a comprehensive analysis workflow for DNA methylation analysis. Briefly, 
raw data files (.IDAT) were imported directly into RnBeads. The comparison of   
non-CpG SNP probes present on the array (n=65) confirmed that CAMs and ATMs 
were sourced from the same patient as expected. The methylation level (β-value) 
for the interrogated CpG loci was computed by calculating the ratio of the 
methylated (M) probe signal intensity to the sum of both methylated (M) and 
unmethylated (U) probe signal intensities. β-values range from 0 to 1, 
corresponding to completely unmethylated and fully methylated loci, respectively. 
Prior to normalization, probes with p-value>0.01 in any sample and probes 
overlapping with single nucleotide polymorphisms (SNPs) in the probe sequence 
(Chen, Lemire et al. 2013) were removed followed by BMIQ normalization 
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(Teschendorff, Marabita et al. 2013, Wu, Joubert et al. 2014) and methylumi.noob 
background subtraction (Triche, Weisenberger et al. 2013). Experimental quality 
control using control probe information present on the array was also performed 
and quality control reports are presented in Appendix I. Subsequently probes 
outside of CpG context as well as probes on sex chromosomes were removed. The 
Illumina Infinium HumanMethylation450 BeadChip arrays processing and analysis 
workflow is presented in Figure 2.1A. Downstream ‘gastric’ data analysis was 
restricted to the remaining 424383 probes whereas ‘oesophageal’ data analysis was 
restricted to 424355 probes.  
 
2.6.2  Differential methylation analysis 
Differential methylation analysis between sample groups was conducted using the 
limma method (Smyth 2005) on individual CpG loci and genomic region level, 
including promoter, gene, island and tiling. CpG loci and genomic regions with 
|Δβ|>0.2, p-value<0.05 were considered differentially methylated. Appendix II 
contains lists of differentially methylated CpG sites (presented in Chapter III) and 
genomic regions identified in gastric (CAM vs ATM, CAM vs NTM, ATM vs NTM) and 
oesophageal (CAM vs ATM) comparisons. The heatmap representations for the 
genomic regions analysis in gastric and oesophageal CAM vs ATM comparisons     
are shown in Supplementary Figure S3.3 and Figure S3.4, respectively.  
 
2.6.3  Illumina HT-12 Expression data processing 
The Illumina HumanHT-12v4 Expression BeadChip arrays were used to quantify 
gene expression profiles in gastric stromal myofibroblasts. RNA samples were 
processed commercially by Molecular Genetic Services (Gen-Probe Life Sciences, 
Manchester) who then provided raw signal intensity data extracted using Illumina 
GenomeStudio software. The Bioconductor package lumi (version 2.18.0), which is 
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designed for Illumina Expression Bead array data (Du, Kibbe et al. 2008), was used 
to import the raw data into R. Background correction, variance stabilization 
transformation (Lin, Du et al. 2008), robust spline normalization and subsequent 
quality control were then performed using this package  (Appendix III). To assess 
the reproducibility of sample preparation, a biological replicate of one of the 
samples was included (R2= 0.9933573). Probes with a detection p-value < 0.01 
across all samples were considered to be non-detectable and were removed from 
subsequent analysis. To further reduce the number of probes, un-annotated probes 
were also removed, thereby restricting subsequent analysis to 18090 probes 
(corresponding to 13381 genes). The Illumina HumanHT-12v4 Expression BeadChip 
arrays processing and analysis workflow is presented in Figure 2.1B. 
 
2.6.4  Differential gene expression analysis  
The Bioconductor package limma (Smyth 2005, Smyth, Michaud et al. 2005) was 
used to identify differentially expressed transcripts between relevant sample 
groups (in total 6 comparisons were performed). The Benjamini and Hochberg 
method (Benjamini and Hochberg 1995) was used to control for false discovery 
rate. Probes with p-value < 0.05 were considered to be differentially expressed. 
Appendix IV contains lists of differentially expressed genes identified in all                  
6 comparisons (CAM vs ATM, CAM vs NTM, ATM vs NTM, CAM hypoxia vs CAM 
normoxia, ATM hypoxia vs ATM normoxia and NTM hypoxia vs NTM normoxia). 
 
 
Materials and Methods 
 
 
50 
 
2.6.5  Integration of DNA methylation and gene 
expression data  
The results from differential gene expression analysis were integrated with results 
from differential methylation analysis as described in details in Chapter IV (section 
4.3.4). Schematic representation of bioinformatics analysis workflow is shown in 
Figure 2.1. 
 
2.6.6  Secretome data processing  
Raw mass spectrometry data was analysed using MaxQuant software (Cox and 
Mann 2008) with Andromeda (Cox, Neuhauser et al. 2011) as a search engine 
against the reference human proteome (Uniprot proteome ID UP000005640, 
containing 42112 reviewed canonical and isoform protein entries, accessed        
April 2015) and 123 potential contaminants. Protein quantification was obtained 
using MaxQuant intensity-based label free quantification (LFQ) algorithm.   
Potential contaminants identified in the mass spectrometry data were manually 
examined and proteins associated with Fetal Bovine Serum (FBS) or trypsin were 
rejected. The LFQ algorithm extracts protein intensities form the raw data and 
performs appropriate normalization steps to allow between sample comparisons 
and remove any systematic errors during data acquisition. For simplicity, protein 
group was reported in all cases where a protein was identified by peptides that 
could not be assigned to individual protein unambiguously, for example in cases of 
highly homologous proteins, or protein isoforms. On average, each protein was 
quantified with 7 unique peptides and 22% sequence coverage was achieved. To 
compare CAM and NTM secretomes from different microenvironmental conditions 
four pair-wise comparisons were done using one-way analysis of variance (ANOVA) 
test as implemented in DanteR software (Taverner, Karpievitch et al. 2012). 
Proteins with a p-value < 0.05 were considered to be differentially secreted 
between the two conditions.  
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Figure 2.1 Bioinformatics analysis workflow – integration of DNA methylation and gene expression data. A. DNA methylation array data processing 
and analysis. B. Gene expression array data processing and analysis. 
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2.6.7  Integration of gene expression and secretome 
data  
The results from differential gene expression analysis were integrated with results 
from differential secretome analysis as described in details in Chapter VI (section 
6.3.4.4). Schematic representation of bioinformatics analysis workflow is shown in 
Figure 2.2. 
 
2.6.8  R/Bioconductor  
R statistical software (version 3.1.2) and Bioconductor (Gentleman, Carey et al. 
2004, Huber, Carey et al. 2015) were used to process and analyse genomics, 
transcriptomics and proteomics data. 
 
2.6.9  Ingenuity Pathway Analysis  
Ingenuity Pathway Analysis (IPA) is a commercial software application for the 
analysis, integration and interpretation of data derived from omics experiments. 
IPA uses the manually curated Ingenuity Knowledge Base (IKB), which provides        
a comprehensive database for identifying regulators, relationships, mechanisms, 
functions and pathways relevant to changes observed in an analysed dataset. In this 
study, IPA was used to analyse and interpret data from comparative gene 
expression analysis and comparative secretome profiles. The Ingenuity Knowledge 
Base (IKB) was used to functionally annotate genes identified in several different 
analyses, including DNA methylation, gene expression and correlation analysis 
(additional details are provided in relevant result sections) 
. 
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Figure 2.2 Bioinformatics analysis workflow – integration of gene expression and secretome data. A. Gene expression array data processing and 
analysis. B. Secretome data processing and analysis. 
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2.6.10  ConsensusPathDB 
ConsensusPathDB (CPDB) (Kamburov, Pentchev et al. 2011) is a freely available 
database that integrates interaction networks in Homo sapiens that originate from 
32 public resources, including KEGG (Kyoto Encyclopedia of Genes and Genomes) 
and Reactome. The ConsensusPathDB integrates protein-protein, biochemical, gene 
regulatory, genetic and drug-target interactions. In this study, ConsensusPathDB 
overrepresentation analysis was used to functionally annotate genes identified in 
several different analyses and to retrieve KEGG and Reactome pathways (additional 
details are provided in relevant result sections).  
 
2.7  DNA methylation data analysis 
2.7.1  Gene ontology enrichment analysis 
Enrichment analysis on differentially methylated CpG loci in gastric and 
oesophageal CAM vs ATM comparisons was conducted using gometh() function 
from the Bioconductor package missMethyl (Maksimovic, Gordon et al. 2012, 
Phipson and Oshlack 2014). This function maps CpG loci to Entrez Gene IDs and 
tests for GO term enrichment using a hypergeometric test, taking into account the 
number of methylation probes per gene on the Illumina 450k array. Previously, 
Geeleher et al. showed that a severe bias exists when performing enrichment 
analysis for genome-wide DNA methylation data that occurs due to differing 
number of methylation probes per each gene (Geeleher, Hartnett et al. 2013).     
For differentially methylated CpG loci in gastric and oesophageal CAM vs ATM,     
the background was set to 424383 and 424355 probes, respectively.  
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2.7.2  Associating differentially methylated CpG loci with 
genes  
The Genomic Regions Enrichment of Annotations Tool (GREAT version 3.0.0) 
(McLean, Bristor et al. 2010) was used to associate differentially methylated        
CpG loci identified in gastric and oesophageal CAM vs ATM comparisons with 
nearby genes and assign the distance to their transcription start sites. GREAT 
measures distances to transcription start site (TSS) using single TSS of a gene’s 
canonical isoform. Briefly, lists of differentially methylated CpG loci were uploaded 
to GREAT and GRCh37/hg19 human genome assembly was used together with 
‘basal plus extension’ as an association rule. The output lists of (i) CpG site to 
gene(s) and (ii) gene to CpG site(s) were used to integrate differentially methylated 
loci with gene expression profiles. 
 
2.7.3  Pathway Analysis for common differentially 
methylated genes in gastric and oesophageal CAMs 
Ingenuity Pathway Analysis (IPA) and ConsensusPathDB (CPDB) (Kamburov, 
Pentchev et al. 2011) overrepresentation analysis was used to assess biological 
relevance of common differentially methylated genes in gastric and oesophageal 
CAMs. The list of identified 2223 common genes was uploaded to IPA and CPDB. 
For IPA analysis the background list was set to Ingenuity Knowledge Base (IKB) 
whereas for CPDB analysis the default background was generated by CPDB based 
on the type of accession ID used for the input list.  
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2.8  Gene expression data analysis 
2.8.1  Gene ontology enrichment analysis 
Gene ontology (GO) enrichment analysis was performed on differentially expressed 
gene sets identified in CAM vs ATM comparison using GOrilla (Gene Ontology 
enRIchment anaLysis and visuaLizAtion tool) (Eden, Navon et al. 2009). Target genes 
were compared to background gene set of 13381 genes found to be expressed in 
myofibroblast cells. Enriched GO terms were identified using a hypergeometric 
model and p-value < 0.001 threshold. The Benjamini and Hochberg method 
(Benjamini and Hochberg 1995) was applied to correct for multiple testing. Results 
were visualized using DAG (directed acyclic graph) trees in order to examine         
GO terms relations. The web server REVIGO (Supek, Bošnjak et al. 2011) was used 
to reduce redundancy within the identified enriched lists of GO terms.  
 
2.8.2  Gene set enrichment analysis 
Gene set enrichment analysis (GSEA v5.0) (Mootha, Lindgren et al. 2003, 
Subramanian, Tamayo et al. 2005) was performed on differentially expressed genes 
identified in CAM vs ATM and CAM vs NTM comparisons using the Molecular 
Signatures Database (MSigDB v5.0) and the hallmark gene set subcollection 
(Subramanian, Tamayo et al. 2005). The identified gene profiles were separated 
into two phenotypes for GSEA: CAM and ATM or CAM and NTM. For gene list 
ranking, multiple probes matching the same gene were sorted according                  
to p-value and the probe with the lowest p-value was retained for the analysis. 
Genes were ranked using the provided signal-to-noise ranking statistic and GSEA 
was run using a default weighted enrichment statistics and evaluated for statistical 
significance by comparison to results obtained using 1 000 random permutations of 
each gene set. Default settings were used for all other GSEA parameters.  
Materials and Methods 
 
 
57 
 
2.9  Comparative transcriptome and secretome 
analysis 
2.9.1  Gene ontology enrichment analysis 
Gene Ontology (GO) enrichment analysis (Khatri and Drăghici 2005) was performed 
on hypoxia-induced gene expression profiles identified in CAMs, ATMs and NTMs 
and hypoxia-induced CAM and NTM secretome profiles using GOrilla (Gene 
Ontology enRIchment anaLysis and visuaLizAtion tool) (Eden, Navon et al. 2009). 
For gene expression profiles, the target set of genes were compared to background 
gene set of all expressed and normalized genes from the HT-12v4 Illumina 
experiment whereas for secretome profiles, proteins were ranked according to 
their p-value with proteins identified as differentially secreted being at the top of 
the rank. The enriched GO terms in individual CAM, ATM, NTM hypoxia-induced 
gene expression profiles were discovered using a hypergeometric model whereas 
the enriched GO terms in ranked CAM and NTM differentially secreted protein 
profiles were discovered using mHG statistic (Eden, Lipson et al. 2007, Eden, Navon 
et al. 2009), p-value < 0.001 was applied and the results were corrected for multiple 
testing using the Benjamini and Hochberg method (Benjamini and Hochberg 1995). 
In order to examine GO terms relations the results were visualized using DAG 
(directed acyclic graph) trees. To reduce redundancy within the identified enriched 
lists of GO terms web server REVIGO (Supek, Bošnjak et al. 2011) was used.  
 
2.9.2  Gene set enrichment analysis 
Gene set enrichment analysis (GSEA v5.0) (Mootha, Lindgren et al. 2003, 
Subramanian, Tamayo et al. 2005) was used to characterize and interpret the 
identified unique- CAM, ATM or NTM and universal hypoxia-induced gene 
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expression profiles. The Molecular Signatures Database (MSigDB v5.0) 
(Subramanian, Tamayo et al. 2005) that contains collection of biologically 
predefined gene sets was used to determine statistically enriched gene sets present 
in the analysed gene expression data. The identified unique- CAM, ATM or NTM and 
universal hypoxia-induced gene expression profiles were separated into two 
phenotypes for GSEA: hypoxia and normoxia. For gene list ranking, multiple probes 
matching the same gene were sorted according to p-value and the probe with the 
lowest p-value was retained for the analysis. Genes were ranked using the provided 
signal-to-noise ranking statistic and GSEA was run using a default weighted 
enrichment statistics and evaluated for statistical significance by comparison to 
results obtained using 1 000 random permutations of each gene set. Default 
settings were used for all other GSEA parameters.  
 
2.9.3  Ingenuity Pathway Analysis 
Ingenuity Pathway Analysis (IPA) software was used to analyse and interpret the 
hypoxia-induced gene expression profiles identified in CAMs, ATMs and NTMs and 
hypoxia-induced CAM and NTM secretome profiles. Gene expression profiles were 
compared against IPA predefined Illumina HT-12v4 reference set whereas 
secretome profiles were compared against Ingenuity Knowledge Based (IKB).        
For gene expression data, IPA canonical pathway and downstream effects analyses 
were performed whereas for secretome data IPA downstream effects and upstream 
regulator analyses were performed. In each case p-value was assigned using 
Fisher’s exact test which indicates the probability of overlap between the 
pathway/phenotype and input genes. 
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2.10  Pyrosequencing DNA methylation analysis 
2.10.1  DNA extraction 
DNA samples for pyrosequencing analysis were extracted from 7 patient-matched 
CAM and ATM samples and 4 unrelated NTM samples. DNA extraction was 
performed using the Wizard SV Genomic DNA Purification System (Promega, cat. 
no. A2360) following a modified version of the manufacturer’s protocol. Briefly, 
myofibroblasts were seeded at the same density in 10cm2 tissue culture dishes and 
grown to 80-90% confluence followed by 24 hours synchronisation in serum-free 
DMEM supplemented with 1% penicillin-streptomycin, 1% antibiotic-antimycotic 
and 1% nonessential amino acid solution. Cells were then washed with 1x PBS 
before being lysed in 150μl Wizard SV lysis buffer. Cell lysates were stored at -80°C 
prior to further processing. Cell lysates were thawed and transferred to Wizard SV 
minicolumns, which were centrifuged at 13,000g for 3 minutes. Column 
membranes were washed four times with Column Washed Solution (CWS) and 
centrifuged at 13,000g for 1 minute. Between the CWS washes, 2μl RNase A (final 
concentration 100μg/ml) solution was added to the membrane for 10 minutes. 
After the last CWS wash the membrane was dried by additional centrifugation at 
13,000g for 2 minutes. DNA was then eluted in 250μl nuclease-free water and 
stored at -20°C. DNA quality and quantity was assessed by spectrophotometry at 
260/280 nm.  
 
2.10.2  Pyrosequencing analysis  
For pyrosequencing DNA methylation analysis, 1μg of genomic DNA was treated 
with sodium bisulfite using the EZ DNA Methylation-Gold Kit (ZymoResearch, cat. 
no. D5005) following the manufacturer’s protocol. Primers were designed using the 
Pyromark Assay Design Software 2.0 (Qiagen) and synthesized by Eurofins MWG 
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(Germany). A full list of assays, primer sequences and annealing temperatures is 
shown in Table 2.5. Pyrosequencing templates were prepared by PCR amplification 
using HotStarTaq Master Mix Kit (Qiagen, cat. no. 203603), 5μM biotinylated 
primer, 5-10μM non-biotinylated primer (corresponding to 1:1 or 1:2 ratio in    
Table 2.5), 5mM dNTPs (Qiagen, cat. no. 201900) and 3 μl (~60 ng)                
bisulfite-treated DNA. The PCR thermal profile consisted of initial denaturation       
at 95oC for 5 min, followed by 40 cycles including 95oC for 30 sec, annealing 
temperature (Table 2.5) for 30 sec, 72oC for 30 sec. A final extension step of 72oC 
for 10 min was also included. The quality of the PCR product was confirmed            
by 2% agarose gel electrophoresis before pyrosequencing analysis. After PCR,       
the biotinylated PCR product was purified and made single stranded to act as           
a template in a pyrosequencing reaction run. The PCR products were bound to 
streptavidin-coated Sepharose beads (GE Healthcare, cat. no. 17-5113-01), after 
which beads containing the immobilized PCR products were purified, washed, and 
denatured using a 0.2M NaOH solution. Thereafter, 0.5uM pyrosequencing primers 
were annealed to the purified single-stranded PCR product, and pyrosequencing 
was carried out using the Pyromark 96ID System (Qiagen). The methylation index 
for the analysed genomic region was calculated as the mean value of mC/(mC + C) 
for all examined CpG sites in the interrogated genomic region.  
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Table 2.5 Nucleotide sequences of PCR primer sets and sequencing primers used for 
pyrosequencing DNA methylation assays; NA – no CpG loci corresponding to Illumina 
450k probe is interrogated by the pyrosequencing assay. 
Assay 
Name 
Sequence 5’ -> 3’ 
Primers 
ratio 
Annealing 
temp 
450k probe 
ID 
FOXF1/ 
FENDRR 
R: 5’-biotin-CCCAAACCTATAACCTCCAC-3’ 
1:2 54°C NA F: 5’-GGGAAAAATTTGAGAATAGATAG-3’ 
S: 5’-TTTGAGAATAGATAGGGG-3’ 
MUC2 
R: 5’-biotin-CAAACCCTAAAACCTAATACTAAC-3’ 
1:2 54°C cg06472341 F: 5’-TGTTGTTTAGATTTAGGGTTTG-3’ 
S: 5’-TTAGATTTAGGGTTTGGGA-3’ 
ZNF536 
R: 5’-biotin-CAAAACTAACCTCAACAAAATC-3’ 
1:2 54°C cg00386405 F: 5’-GTTTATAAGTGGTTTGTTGGG-3’ 
S: 5’-AAGTGGTTTGTTGGGAG-3’ 
HOXA5 
R: 5’-GTCAAATTCCATACACTTTTATAACC-3’ 
1:2 57°C 
cg08070327 
F: 5’-biotin-GATGAAGATTTTTTAGGTTGGATA-3’ cg14658493 
S: 5’-ATTCCATACACTTTTATAAC-3’ cg25506432 
mir802/ 
RUNX1 
R: 5’-CTCTACAACCTCTTATATCATTTCA-3’ 
1:2 54°C cg00871610 F: 5’-biotin-GATGAATTTTTGTTATTGATTGTA-3’ 
S: 5’-AAAAATACCATATACCCATTA-3’ 
NKAIN3/ 
ASPH 
R: 5’-biotin-AAAATAATTCTCTCTAACTCCTC-3’ 
1:2 52°C 
cg07926952 
cg13380112 
F: 5’-GTATTTGTAGTTTTGGAGAAAG-3’ 
S: 5’-TTTGTAGTTTTGGAGAAAGT-3’ 
FOXC1/ 
FOXF2 
R: 5’-ACCCAACTACCCTATCCC-3’ 
1:1 55°C cg10759602 F: 5’-biotin-TGTGGTTTAGGATTTGTTATTAG-3’ 
S: 5’-ACCCAACTACCCTATCCC-3’ 
SPON2 
R: 5’-ACCATCCCCACTCATCT-3’ 
1:1 53°C cg23543318 F: 5’-biotin-TGTTTGATGTTTTGTTGTGG-3’ 
S: 5’-CATCCCCACTCATCTCA-3’ 
CD47 
R: 5’-biotin-TAAACATTATTACCTATAAACACC-3’ 
1:2 51°C cg11741004 F: 5’-GAATAATTTTGTTGGTGGG-3’ 
S: 5’-GGTGGGGATGTGTTGGATA-3’ 
SMAD3 
(p1) 
R: 5’-biotin-ATTTTCAAAAACTACTCCAAA-3’ 
1:1 52°C cg23731272 F: 5’-GGGAGATTTTTGTTGTTAAA-3’ 
S: 5’-ATAAAGGGTTTAGATAT-3’ 
SMAD3 
(p2) 
R: 5’-CAACAACAAACCAATTAACA-3’ 
1:2 53°C cg02486855 F: 5’-biotin-GAGGGGTTTGGAGTAGTT-3’ 
S: 5’-AACAACAAACCAATTAACAC-3’ 
B4GALT6 
R: 5’-biotin-ACCTAAATTAATAAATCCCC-3’ 
1:2 52°C 
cg02930996 
cg07027513 
F: 5’-TGAAGGTAAGTTTTGGTATAAG-3’ 
S: 5’-TAAGTTTTGGTATAAGG-3’ 
VPS28 
R: 5’-biotin-AATTTATTCCCTAAAACCTACC-3’ 
1:1 51°C cg11882377 F: 5’-GGGGAAGAGGGTAGATTT-3’ 
S: 5’-GGGGAAGAGGGTAGAT-3’ 
LINE-1 
R: 5’-AACTCCCTAACCCCTTAC-3’ 
1:1 58°C NA F: 5’-biotin-TAGGGAGTGTTAGATAGTGG-3’ 
S: 5’-CAAATAAAACAATACCTC-3’ 
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2.11  TaqMan gene expression analysis 
2.11.1  RNA extraction 
RNA samples for TaqMan assays were extracted from 6 patient-matched CAM and 
ATM samples. Total RNA was purified using miRNeasy Mini Kit (Qiagen, cat. no. 
217004) according to modified version of manufacturer’s instructions. Briefly,      
the cells were seeded at the same density in 10cm2 tissue culture dishes and   
grown to 80-90% confluence. Cells were then washed with 1x PBS before being 
lysed in 700ul QIAzol Lysis Reagent. Cell lysates ware collected into Eppendorf tubes 
and homogenized by vortexing for 1 minute. Homogenized lysates were then stored 
in -80°C prior to further processing. Total RNA was extracted by phase separation 
after addition of 140μl chloroform to homogenized lysates. Homogenates were 
centrifuged at 12,000 rcf, 4°C for 15 minutes and the upper aqueous phase was 
collected and mixed with 1.5 volumes of absolute ethanol. Samples were then 
transferred to the RNeasy Mini spin column and centrifuged at 8,000 rcf for            
15 seconds followed by a 15 minutes on-column DNase I digestion (Qiagen, cat. no. 
79254). The RNeasy Mini spin column membrane was washed twice with 500μl 
Buffer RPE and spin sequentially at 8,000 rcf for 15 seconds and 4 minutes.           
The column was then transferred to the new collection tube and centrifuged at full 
speed for 3 minutes to eliminate any possible carryover of Buffer RPE. Finally,    
RNA was eluted in 50μl RNase-free water. RNA samples quality and quantity was 
assessed by spectrophotometry at 260/280 nm and samples were stored at -80°C. 
 
2.11.2  TaqMan qPCR analysis 
TaqMan gene expression assays were used to quantify mRNA levels of target genes 
in patient-matched CAM and ATM samples. The QuantiTect Reverse Transcription 
Kit (Qiagen, cat. no. 205311) was used for cDNA synthesis. Briefly, following 
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removal of genomic DNA contamination, the reverse transcription reaction    
utilised an optimized mix of oligo-dT and random primers to convert                  
900ng of total RNA to cDNA in a total reaction of 20l. The latter was then       
diluted with 80μl ddH2O to give 100μl cDNA working stock. This was      
subsequently used for the qPCR assays selected for the target genes. qPCR was 
performed on the StepOne system (Applied Biosystems). The amplification mixture 
was contained 7.5μl of 2x TaqMan Universal Master Mix II (Life Technologies,      
cat. no. 4440042), 0.75μl of 20x TaqMan probe and primers, 1.25μl 10x ACTB,      
2μl of the cDNA and 3.5μl ddH2O, giving a final volume of 15μl. Samples were 
analysed in triplicate, and experiments were repeated at least 2 times with 
independent RNA cell lysates. TaqMan assays were either designed using           
Oligo 7.0 software (Molecular Biology Insights Inc, USA) and synthesized by  
Eurofins MWG (Germany) or purchased as predesigned assays from Life 
Technologies (UK). A full list of assays, nucleotide sequences and PCR product sizes 
are shown in Table 2.6. The amplification mixtures were processed using standard 
conditions (50°C for 2 minutes and 95°C for 10 minutes followed by 45-50 cycles    
at 95°C for 15 seconds and 60°C or 61°C for 1 minute). β-actin was used as the 
endogenous control. The comparative ΔΔCt method was used to compute relative 
levels of target gene expression by subtracting the Ct values of the endogenous 
control (β-actin) and comparing values to a calibrator sample, where the calibrator 
sample = 1.0 and other samples were expressed as n-fold relative to the calibrator.  
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Table 2.6 List of TaqMan assays and nucleotide sequences used in this study. 
Gene 
TaqMan 
Assay ID 
Amplicon 
Length 
(bp) 
Forward Primer        
5’ -> 3’ 
Reverse Primer         
5’ -> 3’ 
Probe 5’-> 3’ 
DEPTOR 
Hs00224437
_m1 
82 
Proprietary sequence 
Life Technologies 
Proprietary sequence 
Life Technologies (FAM) 
ZNF536 
Hs01100020
_m1 
70 
Proprietary sequence 
Life Technologies 
Proprietary sequence 
Life Technologies (FAM) 
SULF1 
Hs00290918
_m1 
65 
Proprietary sequence 
Life Technologies 
Proprietary sequence 
Life Technologies (FAM) 
SULF2 
Hs01016476
_m1 
85 
Proprietary sequence 
Life Technologies 
Proprietary sequence 
Life Technologies (FAM) 
HOXA5 
Hs00430330
_m1 
127 
Proprietary sequence 
Life Technologies 
Proprietary sequence 
Life Technologies (FAM) 
FOXF1 
Hs00230962
_m1 
69 
Proprietary sequence 
Life Technologies 
Proprietary sequence 
Life Technologies (FAM) 
SMAD3 
Hs00969210
_m1 
87 
Proprietary sequence 
Life Technologies 
Proprietary sequence 
Life Technologies (FAM) 
SPON2 
Hs00202813
_m1 
104 
Proprietary sequence 
Life Technologies 
Proprietary sequence 
Life Technologies (FAM) 
FENDRR 
v1 
custom 92 
AAGTGAAATACATGTA
GATGGGAT 
TGTGCCAAACTGAGTA
AACC 
CACCCTCTCTGGT
CTTCAGTTTCTCA 
(FAM) 
FENDRR 
v2 
custom 111 
GCTTCTGTCCAAGGCA
CT 
CAAGCTTGCTAACTTC
TTTGC 
AGCCTACTCGTCA
AAAGCCCGA 
(TAMRA) 
ACTB 
(TAMRA) 
custom 128 
GGCACCCAGCACAAT
GAAG 
CATACTCCTGCTTGCT
GATCCA 
CTCCTCCTGAGCG
CAAGTACTCCGTG 
(TAMRA) 
ACTB 
(VIC) 
4326315E 171 
Proprietary sequence 
Life Technologies 
Proprietary sequence 
Life Technologies (VIC) 
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3.1  Introduction 
While it is well established that epigenetic regulation plays a key role in cancer 
progression (Jones and Baylin 2002), little is known about the pattern or 
consequence of epigenetic programming in cancer stromal cells. 
 
It was reported that cancer associated myofibroblasts (CAMs) isolated from the site 
of gastric tumours exhibit a global reduction in DNA methylation, when compared 
to adjacent tissue myofibroblasts (ATMs) (Jiang, Gonda et al. 2008). However,         
in contrast to cancer cells, CAM global DNA hypomethylation does not appear to be 
associated with chromosomal instability, as CAMs are non-neoplastic and continue 
to exhibit senescence in vitro. Other reports focus on gene – specific promoter 
methylation patterns in stromal and cancer cells, as reported for prostate tumour-
associated stromal cells (Hanson, Gillespie et al. 2006, Rodriguez-Canales, Hanson 
et al. 2007) and breast tumour-associated stromal cells (Fiegl, Millinger et al. 2006). 
Also, it is not known to what extent common mechanisms or patterns of DNA 
methylation operate in CAMs derived from different tumours. 
 
Significantly, primary CAMs have been shown to retain several cancer promoting 
properties following isolation (Orimo, Gupta et al. 2005). In particular, an ability to 
enhance cancer cell migration and proliferation, is commonly retained in low 
passage isolated gastric CAMs (Holmberg, Quante et al. 2012, Hu, Wang et al. 
2013). This phenotype was also reconfirmed for all primary low passage 
myofibroblast cell lines used in this study (Supplementary Figure S3.1 and Figure 
S3.2). Given that these properties of isolated CAMs appear to be inherent, we 
hypothesise that CAMs may have been epigenetically programmed by cancer cells.  
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To assess genome-wide DNA methylation changes in stromal myofibroblasts, 
Illumina Infinium HumanMethylation450 BeadChip arrays were performed on a 
collection of primary gastric and oesophageal patient-matched CAM and ATM 
samples. The Illumina 450k array interrogates over 480,000 CpG loci distributed 
across the genome at single base resolution, providing coverage of 98.9% UCSC 
RefGenes with a global average of 17.2 probes per gene region (Bibikova, Barnes et 
al. 2011).   
 
The Illumina 450k arrays for gastric and oesophageal myofibroblasts were 
performed independently by the Sanderson and Varro groups, respectively. Data 
processing and analysis for both Illumina 450k methylation arrays was conducted as 
part of this project.  
 
 
3.2  Aims 
 To compare global DNA methylation status of patient-matched CAM and 
ATM  samples isolated from either gastric or oesophageal cancers  
 To identify differential changes in DNA methylation in gastric and 
oesophageal myofibroblasts purified from different tissue 
microenvironments: CAM (cancer), ATM (adjacent tissue) and NTM (normal 
tissue) 
 To identify genomic loci which DNA methylation patterns might serve as 
proxy for gastric CAM identification 
 To investigate the extent to which common DNA methylation changes occur 
in gastric and oesophageal CAMs  
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3.3  Results 
3.3.1  Comparison of global DNA methylation between 
CAMs and ATMs from gastric and oesophageal cancers 
To assess the relative global DNA methylation status of CAMs and ATMs isolated 
from the site of gastric or oesophageal tumours, Illumina 450k probes that passed 
the filtering steps (as described in Methods section 2.6.1) were used to compute 
mean β-values (as define in Methods section 2.6.1). Analysis for gastric 
myofibroblasts was restricted to 424383 CpG sites whereas analysis for 
oesophageal myofibroblasts was restricted to 424355 CpG sites. Comparison of 
mean β-values in CAMs and ATMs from gastric and oesophageal cancers shows that 
in both cancer types, mean global DNA methylation is statistically lower in CAMs 
compared to mean global DNA methylation observed in corresponding ATMs 
(Wilcoxon test p-value < 2.2 x10-16) (Figure 3.1). 
 
3.3.2  Identification of differentially methylated loci       
in gastric CAMs, ATMs and NTMs  
Genome–wide differential DNA methylation analysis between gastric (i) CAM vs 
ATM, (ii) CAM vs NTM and (iii) ATM vs NTM were performed at both individual CpG 
loci and genomic regions. Figure 3.2 summarises the results from differential             
DNA methylation analysis at the individual CpG loci, while results from differential 
DNA methylation analysis at genomic regions for CAM vs ATM is provided in 
Supplementary Figure S3.3.  
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This analysis identified numerous loci showing consistent differential                    
DNA methylation in CAMs compared to ATMs (Figure 3.2A) or NTMs (Figure 3.2B). 
In total, 5688 differentially methylated CpG loci were identified in CAMs compared 
to ATMs, including 3404 hypomethylated and 2284 hypermethylated CpG loci. 
These differentially methylated loci were distributed throughout the genome with 
no obvious chromosomal bias (Figure 3.12). In the CAM vs NTM comparison, a total 
of 8104 CpG loci (including 4147 hypomethylated and 3957 hypermethylated in 
CAMs) were identified as differentially methylated whereas in the ATM vs NTM 
comparison only 4988 CpG loci were identified as differentially methylated 
(including 2078 hypomethylated and 2910 hypermethylated in ATMs). 
 
 
 
Figure 3.1 Global DNA methylation of gastric and oesophageal patient-matched CAMs 
and ATMs. Boxplots represent mean β-value for CAMs (n=3) and ATMs (n=3) isolated from:     
A. gastric cancer (mean β for 424383 CpG sites) and B. oesophageal cancer (mean β for 
424355 CpG sites); Wilcoxon test p-value < 2.2 x10
-16
. 
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Figure 3.2 Differentially methylated CpG loci in gastric myofibroblasts purified from 
different tissue microenvironments. Volcano plots represent differentially methylated  
CpG loci |Δβ| > 0.1; dashed lines |Δβ| > 0.2, p-value <0.05 identified in A. CAM vs ATM,     
B. CAM vs NTM and C. ATM vs NTM comparisons. Heatmaps represent differentially 
methylated CpG loci identified in respective comparisons |Δβ|>0.2, p-value <0.05. Heatmap 
shown in A. represents CpG loci identified in CAMs vs ATMs with projection including 
related values observed in NTMs. D. Venn diagram shows the relative overlap of identified 
differentially methylated CpG loci |Δβ| > 0.2, p-value <0.05 in CAM vs ATM, CAM vs NTM 
and ATM vs NTM comparisons. 
   
   
   
   
                      
           
44 
3076 
3325 
1962 
606 1013 
5085 
Identification of DNA Methylation Signatures in Gastric and Oesophageal CAMs 
 
 
71 
 
3.3.2.1  Characterization of differentially methylated loci 
in gastric CAMs compared to patient-matched ATMs 
As matched pairs of CAMs and ATMs were isolated from individual patients, these 
samples represent the closest matched controls that can be used for comparison of 
tumour-induced differential DNA methylation patterns.  
 
In this analysis differentially methylated CpG loci were compared to the CpG 
distribution in the Illumina 450k array. The array covers 98.9% of annotated   
RefSeq genes and shows a wide distribution of probes among CpG islands, shores 
(2kb flanking the islands), shelves (2kb flanking the shores) and seas (regions 
outside the previous three categories) (Bibikova, Barnes et al. 2011). 
Hypomethylated and hypermethylated loci in CAMs were preferentially located in 
CpG shores rather than islands (Figure 3.3A). The comparison with overall 
distribution of differentially methylated loci relative to RefSeq genes showed that 
hypomethylated CpG loci are overrepresented in promoters, gene bodies and 
intergenic regions (Figure 3.3B). Notably, a significant proportion of differentially 
methylated loci in CAMs were located in enhancer regions (36.36% of all identified 
loci whereas only 21.9% of all probes on the array are annotated to enhancer 
regions), differentially methylated regions (DMRs) associated with reprograming 
(rDMRs; 5.43% of all identified loci whereas only 2.62% of all probes on the array 
are annotated to rDMRs) and cancer (cDMRs; 2.6% of identified loci whereas only 
1.37% of all probes on the array are annotated to cDMRs).  
 
Alteration of DNA methylation in one CpG locus has the potential to regulate 
multiple genes. Equally, expression of any gene may be regulated by methylation 
changes in multiple CpG loci. To associate identified differentially methylated       
loci with genes, the Genomic Regions Enrichment of Annotations Tool (GREAT 
version 3.0.0) (McLean, Bristor et al. 2010) was used. The analysis revealed that    
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26 CpG loci (including 19 hypomethylated and 7 hypermethylated) were not 
associated with any genes, 1807 CpG loci (including 1119 hypomethylated and    
688 hypermethylated) were associated with only one gene, 3834 CpG loci (including 
2250 hypomethylated and 1584 hypermethylated) were associated with 2 genes, 
18 CpG loci were associated with 3 genes (including 15 hypomethylated and             
3 hypermethylated), 1 hypermethylated CpG loci was associated with 4 genes,         
1 hypomethylated CpG loci was associated with 5 genes and 1 hypermethylated loci 
was associated with 6 genes (Figure 3.4A). The analysis of the distance to 
transcription start site (TSS) of differentially methylated CpG loci associated with 
genes showed that most of the CpG loci are in region 50–500kb upstream of TSS 
and that hypomethylated CpG loci are slightly overrepresented in each TSS distance 
category (Figure 3.4B).  
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Figure 3.3 Distribution of differentially methylated CpG loci identified in gastric CAMs 
vs ATMs. A. in CpG islands, shores, shelves and sea regions or B. relative to RefSeq gene 
promoters, gene bodies and intergenic regions.  
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Figure 3.4 Genomic region and gene associations of differentially methylated         
CpG loci in gastric CAMs vs ATMs. A. Number of associated genes per identified CpG 
loci given in percentages (total 5688 CpG loci, including 3404 hypomethylated and         
2284 hypermethylated in CAMs). B. Distance to transcription start site (TSS) of identified 
CpG loci that were associated with genes; blue – hypomethylated CpG loci in CAMs;        
red – hypermethylated sites in CAMs. 
 
 
3.3.2.2  Technical validation of identified differentially 
methylated CpG loci 
Pyrosequencing assays were used to validate genomic loci identified to be 
differentially methylated by Illumina 450k arrays in comparative analysis of gastric 
CAMs, ATMs and NTMs. Figure 3.5 shows correlations between β-values and        
[%] methylation assessed by pyrosequencing in the 9 samples (including 3 CAMs,    
3 ATMs and 3 NTMs) from the array experiment. Correlations between the two 
types of DNA methylation assays for all 12 CpG loci interrogated were very good             
(R2 = 0.8177 - 0.9921, p-value = 7.08852 x 10-3 – 1.43492 x 10-7) thus increasing 
confidence in comparative differential DNA methylation trends identified in this 
study.  
 
Identification of DNA Methylation Signatures in Gastric and Oesophageal CAMs 
 
 
74 
 
 
 
 
 
Figure 3.5 Correlations between Illumina 450k array data and pyrosequencing 
analysis in gastric myofibroblasts; magenta–CAMs, purple–ATMs, navy–NTMs. 
Representative data for 12 single CpG site identified as differentially methylated by Ilumina 
450k array and validated by pyrosequencing analysis are shown. 
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3.3.2.3  Gene ontology enrichment analysis of 
differentially methylated loci identified in gastric CAMs 
compared to ATMs 
It was recently suggested that popular gene-set enrichment and pathway analysis 
methods developed for use with gene expression data can yield spurious results 
when used for DNA methylation array data (Geeleher, Hartnett et al. 2013, Harper, 
Peters et al. 2013), as these tools do not account for the differential number of 
methylation probes per gene on the Illumina 450k array. Therefore, to investigate 
the potential biological relevance of identified differentially methylated CpG loci in 
gastric CAMs, gene ontology (GO) enrichment analysis was performed using 
gometh() function from the Bioconductor package missMethyl (Maksimovic, 
Gordon et al. 2012, Phipson and Oshlack 2014), as this function was designed 
explicitly for Illumina450k data, taking into account the number of probes per gene 
on the array. As the background a total of 424383 CpG sites were used.  
 
The enrichment analysis of: (i) GO biological processes (BP) identified 120 GO 
terms, (ii) GO molecular functions (MF) identified 32 GO terms and (iii) GO cellular 
component (CC) identified 16 GO terms with p-value < 0.01. Table 3.1 shows a list 
of all GO terms with FDR p-value < 0.05. Other interesting GO biological process 
terms with p-value < 0.01 include: cell differentiation (GO:0030154, 741 genes,        
p = 9 x 10-5), chemotaxis (GO:0006935, 176 genes, p = 3.91 x 10-4), transmembrane 
transport (GO:0055085, 276 genes, p = 3.93 x 10-4), regulation of Rab protein signal 
transduction (GO:0032483, 124 genes, p = 1.33 x 10-3), regulation of GTPase activity 
(GO:0043087, 124 genes p = 1.33 x 10-3), regulation of calcium ion transport 
(GO:0051924, 53 genes, p = 1.89 x 10-3), detection of glucose (GO:0051594,              
4 genes, p = 4.53 x 10-3), synaptic transmission (GO:0007268, 178 genes,                    
p = 4.76 x 10-3), regulation of cholesterol biosynthetic process (GO:0045540,             
7 genes, p = 7.24 x 10-3), extracellular matrix organization (GO:0030198, 96 genes,  
p = 8.18 x 10-3). 
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Table 3.1 Gene ontology (GO) enrichment analysis for differentially methylated CpG 
loci identified in gastric CAMs compared to ATMs. BP - biological process; CC - cellular 
component; N - number of genes in the GO term; DE - number of genes that are 
differentially methylated 
GO ID GO Term Ontology N DE p-value FDR 
GO:0007399 nervous system development BP 1938 527 5.78E-10 1.12E-05 
GO:0022008 neurogenesis BP 1327 374 6.56E-08 2.16E-04 
GO:0048699 generation of neurons BP 1252 356 9.99E-08 2.42E-04 
GO:0030182 neuron differentiation BP 1147 328 2.42E-07 5.21E-04 
GO:0007156 
homophilic cell adhesion via 
plasma membrane adhesion 
molecules 
BP 135 60 4.02E-07 7.80E-04 
GO:0048666 neuron development BP 917 268 1.71E-06 2.55E-03 
GO:0048731 system development BP 3783 866 2.14E-06 2.96E-03 
GO:0098742 
cell-cell adhesion via plasma-
membrane adhesion 
molecules 
BP 187 70 4.32E-06 4.93E-03 
GO:0098609 cell-cell adhesion BP 188 70 4.84E-06 5.21E-03 
GO:0032501 
multicellular organismal 
process 
BP 6240 1266 5.11E-06 5.22E-03 
GO:0007275 
multicellular organismal 
development 
BP 4319 961 8.46E-06 8.20E-03 
GO:0048468 cell development BP 1843 467 8.92E-06 8.23E-03 
GO:0031175 
neuron projection 
development 
BP 793 234 1.24E-05 1.09E-02 
GO:0044707 
single-multicellular organism 
process 
BP 6019 1225 1.62E-05 1.37E-02 
GO:0048812 
neuron projection 
morphogenesis 
BP 616 192 2.00E-05 1.61E-02 
GO:0061564 axon development BP 561 176 3.14E-05 2.34E-02 
GO:0048856 
anatomical structure 
development 
BP 4536 994 3.78E-05 2.71E-02 
GO:0007409 axonogenesis BP 539 170 4.07E-05 2.80E-02 
GO:0071944 cell periphery CC 4513 950 2.85E-09 2.77E-05 
GO:0005886 plasma membrane CC 4425 930 4.47E-09 2.89E-05 
GO:0044425 membrane part CC 6002 1169 4.03E-08 1.95E-04 
GO:0097458 neuron part CC 920 265 6.67E-08 2.16E-04 
GO:0031224 
intrinsic component of 
membrane 
CC 5058 979 7.85E-08 2.17E-04 
GO:0016021 
integral component of 
membrane 
CC 4940 948 1.08E-06 1.91E-03 
GO:0042995 cell projection CC 1503 384 1.26E-06 2.04E-03 
GO:0016020 membrane CC 8174 1572 2.29E-06 2.96E-03 
GO:0043005 neuron projection CC 750 220 2.56E-06 3.11E-03 
GO:0044459 plasma membrane part CC 2248 495 2.29E-05 1.78E-02 
GO:0044295 axonal growth cone CC 13 11 4.19E-05 2.80E-02 
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3.3.2.4  Identification of CpG loci that might serve as 
proxies for gastric CAM identification 
Genome-wide and gene-specific methylation patterns may ultimately provide 
important signatures for distinguishing tumour derived myofibroblasts (CAMs) from 
non–tumour derived myofibroblasts (ATMs and/or NTMs). Identification of these 
genomic regions and DNA methylation patterns in CAMs may translate into new 
therapeutic strategies and prove useful as biomarkers for diagnosis and prognosis 
or tumour stratification. Therefore, CpG loci that distinguish CAMs from              
non-tumour derived myofibroblasts following differential methylation analysis at 
individual CpG loci in gastric CAM vs ATM (|Δβ|>0.2) and CAM vs NTM (|Δβ|>0.2) 
were compared (Figure 3.2D) and the overlap of 2006 CpG loci from these 
comparisons was selected to assess their methylation status. The analysis showed 
that these CpG loci have CAM-specific patterns of methylation as hypomethylated 
loci in CAMs were consistently found to be hypermethylated in both ATMs and 
NTMs. Conversely, hypermethylated loci in CAMs were consistently found to be 
hypomethylated in both ATMs and NTMs (Figure 3.6A). These loci are distributed 
across the genome (Figure 3.12). Notably, less stringent differential methylation 
analysis using a |Δβ|>0.1 cut-off identified 3824 loci that may be used as proxies to 
distinguish CAMs from both ATMs and NTMs (data not shown). Figure 3.6B shows 
CpG loci that were selected in the same fashion from CAM vs ATM, CAM vs NTM 
and ATM vs NTM |Δβ|>0.1 comparisons. As these CpG loci clearly show distinct 
patterns of DNA methylation in all studied myofibroblast populations, it is possible 
that these genomic regions may prove useful in distinguishing between different 
types of gastric myofibroblasts and different stages, or extents of tumour 
reprogramming. 
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Figure 3.6 Heatmap representations of CpG loci that may serve as proxies for gastric CAM, ATM and NTM identification.                                           
A. CpG loci that have CAM–specific methylation pattern and were identified in CAM vs ATM and CAM vs NTM |Δβ|>0.2 comparisons. B. CpG loci that have 
CAM- , ATM- and NTM- specific methylation pattern and were identified in CAM vs ATM, CAM vs NTM and ATM vs NTM |Δβ|>0.1 comparisons.  
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3.3.2.4.1  Characterization of identified CpG loci that might 
serve as proxies for gastric CAM identification 
The complement of CpG loci which DNA methylation status was found to 
distinguish CAMs from non-tumour derived myofibroblasts (ATMs and NTMs) were 
compared to the CpG distribution in the Illumina 450k array and subjected to 
GREAT analysis in order to provide insight into their genomic localisation. 
 
Hypomethylated loci were preferentially located in shelves rather than islands while 
hypermethylated loci were preferentially located in islands rather than shelves 
(Figure 3.7A). GREAT analysis revealed that 11 CpG loci (including 7 hypomethylated 
and 4 hypermethylated) were not associated with any genes, 609 CpG loci were 
associated with only one gene (including 350 hypomethylated and 259 
hypermethylated), 1382 CpG loci were associated with 2 genes (including 782 
hypomethylated and 600 hypermethylated), 3 CpG loci were associated with 3 
genes (including 2 hypomethylated and 1 hypermethylated) and 1 hypermethylated 
CpG loci was associated with 6 genes (Figure 3.7B). The analysis of the distance to 
transcription start site (TSS) of the identified pool of CpG loci associated with genes 
showed that most of these CpG loci are located 50–500kb upstream of TSS and that 
hypomethylated CpG loci are slightly overrepresented in each TSS distance category 
(Figure 3.7C).  
 
 
 
 
 
Identification of DNA Methylation Signatures in Gastric and Oesophageal CAMs 
 
 
80 
 
 
D
if
fe
re
n
ti
a
lly
 m
e
th
y
la
te
d
H
y
p
o
m
e
th
y
la
te
d
H
y
p
e
rm
e
th
y
la
te
d
0 %
5 0 %
1 0 0 %
1 5 0 %
Is land
S h o re
S h e lf
S e a
P
ro
p
o
ti
o
n
 o
f 
C
p
G
s
0 1 2 3 6
0 %
2 0 %
4 0 %
6 0 %
8 0 %
G
e
n
o
m
ic
 r
e
g
io
n
s
N u m b e r o f a s s o c ia te d  g e n e s
<
-5
0
0
-5
0
0
 t
o
 -
5
0
-5
0
 t
o
 -
5
-5
 t
o
 0
0
 t
o
 5
5
 t
o
 5
0
5
0
 t
o
 5
0
0
>
5
0
0
0 %
1 0 %
2 0 %
3 0 %
H yp e rm e th y la ted
H yp om e th y la ted
R
e
g
io
n
-g
e
n
e
 a
s
s
o
c
ia
ti
o
n
s
T S S
D is ta n c e  to  T S S  (k b )
A . B . C .
 
Figure 3.7 Genomic region and gene associations of CpG proxies that might be used 
to distinguish gastric CAMs from ATMs and NTMs. A. Distribution of identified CpG loci 
in CpG islands, shores, shelves and sea regions. B. Number of associated genes             
per identified CpG proxy given in percentages (total 2006 CpG loci, including                  
1141 hypomethylated and 865 hypermethylated). C. Distance to transcription start site (TSS) 
of identified CpG proxies; blue – hypomethylated CpG proxies; red – hypermethylated CpG 
proxies. 
 
3.3.3  Identification of differentially methylated loci       
in oesophageal CAMs and ATMs   
For comparative purposes genome–wide differential DNA methylation analysis was 
performed between oesophageal CAMs and patient-matched ATMs at both 
individual CpG loci and genomic regions. Figure 3.8 summarises the results from 
differential DNA methylation analysis at the individual CpG loci, while results from 
differential DNA methylation analysis at genomic regions is provided in 
Supplementary Figure S3.4.  
 
In total, 3611 differentially methylated CpG loci were identified in oesophageal 
CAMs compared to ATMs, including 2826 hypomethylated and 785 
hypermethylated CpG loci. Overall, differentially methylated loci were distributed 
throughout the genome.  
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3.3.3.1  Characterization of identified differentially 
methylated loci in oesophageal CAMs compared to ATMs 
Differentially methylated CpG loci were compared to the CpG distribution in the 
Illumina 450k array and subjected to GREAT analysis in order to assign genomic 
localisation. 
 
In the case of oesophageal CAMs, hypomethylated loci were preferentially located 
in shelves and seas rather than islands whereas hypermethylated loci were 
preferentially located in CpG islands and shores (Figure 3.9A). The GREAT analysis  
of these data revealed that 45 CpG loci (including 44 hypomethylated and                 
1 hypermethylated) were not associated with any genes, 1206 CpG loci (including 
967 hypomethylated and 239 hypermethylated) were associated with only one 
gene, 2351 CpG loci (including 1809 hypomethylated and 542 hypermethylated) 
were associated with 2 genes and 9 CpG loci (including 6 hypomethylated and          
3 hypermethylated) were associated with 3 genes (Figure 3.9B). The analysis of the 
distance to transcription start site (TSS) of the differentially methylated CpG loci 
associated with genes showed that most of the CpG loci are located 50–500kb 
upstream of TSS and that hypomethylated CpG loci are overrepresented in each TSS 
distance category (Figure 3.9C).  
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Figure 3.8 Differentially methylated CpG loci identified in oesophageal CAM vs ATM 
comparison. A. Volcano plot represents differentially methylated CpG sites |Δβ| > 0.1; 
dashed lines |Δβ| > 0.2, p-value <0.05. B. Heatmap represents differentially methylated  
CpG sites |Δβ|>0.2, p-value <0.05.  
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Figure 3.9 Genomic region and gene associations of differentially methylated         
CpG loci in oesophageal CAMs vs ATMs. A. Distribution of differentially methylated CpG 
loci in CpG islands, shores, shelves and seas. B. Number of associated genes per identified 
CpG site given in percentages (total 3611 sites, including 2826 hypomethylated and         
785 hypermethylated in CAMs). C. Distance to transcription start site (TSS) of identified  
CpG loci that were associated with genes; blue – hypomethylated CpG sites in CAMs;      
red – hypermethylated sites in CAMs. 
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3.3.3.2  Gene ontology enrichment analysis for differentially 
methylated loci in oesophageal CAMs compared to ATMs 
To investigate the potential biological relevance of identified differentially 
methylated CpG loci in oesophageal CAMs, gene ontology (GO) enrichment analysis 
was again performed using gometh() function from the Bioconductor package 
missMethyl (Maksimovic, Gordon et al. 2012, Phipson and Oshlack 2014), using       
a total of 424355 CpG sites as background.  
 
The enrichment analysis of: (i) GO biological processes (BP) identified 116 GO 
terms, (ii) GO molecular functions (MF) identified 19 GO terms and (iii) GO cellular 
component (CC) identified 15 GO terms with p-value < 0.01. Table 3.2 shows list of 
all GO terms with FDR p-value < 0.05. Other interesting GO biological process terms 
with p-value < 0.01 include: cell communication (GO:0007154, 741 genes,                 
p = 4.13 x 10-5), regulation of signalling (GO:0023051, 415 genes, p = 2.9 x 10-4), 
regulation of signal transduction (GO:0009966, 371 genes, p = 6.22 x 10-4), synaptic 
transmission (GO:0007268, 124 genes, p = 2.84 x 10-3), cell differentiation 
(GO:0030154, 48 genes, p = 2.88 x 10-3), regulation of cytokine biosynthetic process 
(GO:0042035, 18 genes, p = 4.20 x 10-3) and negative regulation of secretion by cell 
(GO:1903531, 26 genes, p = 5.18 x 10-3). 
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Table 3.2 Gene ontology (GO) enrichment analysis for differentially methylated CpG 
loci identified in oesophageal CAMs compared to ATMs. BP - biological process;               
MF - molecular function; CC - cellular component; N - number of genes in the GO term;    
DE - number of genes that are differentially methylated 
GO ID GO Term Ontology N DE p-value FDR 
GO:0007156 
homophilic cell adhesion via 
plasma membrane adhesion 
molecules 
BP 135 53 3.85E-10 7.46E-06 
GO:0098609 cell-cell adhesion BP 188 57 1.43E-07 9.21E-04 
GO:0098742 
cell-cell adhesion via plasma-
membrane adhesion molecules 
BP 187 57 1.29E-07 9.21E-04 
GO:0044707 
single-multicellular organism 
process 
BP 6017 822 1.21E-06 5.89E-03 
GO:0032501 
multicellular organismal 
process 
BP 6238 843 1.89E-06 7.32E-03 
GO:0022610 biological adhesion BP 1303 227 6.61E-06 2.13E-02 
GO:0007155 cell adhesion BP 1297 224 1.60E-05 3.45E-02 
GO:0048731 system development BP 3783 574 2.50E-05 4.85E-02 
GO:0005509 calcium ion binding MF 645 123 1.34E-05 3.25E-02 
GO:0071944 cell periphery CC 4511 614 1.25E-05 3.25E-02 
 
 
3.3.4  Identification of conserved DNA methylation 
patterns in gastric and oesophageal CAMs 
To identify patterns of DNA methylation that are retained in isolated gastric and 
oesophageal CAMs the results from differential methylation analysis in gastric and 
oesophageal CAM vs ATM comparisons (|Δβ|>0.2, p-value < 0.05) were compared 
at both individual CpG loci and gene level.  
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3.3.4.1  Conserved methylation pattern at the individual 
CpG loci in gastric and oesophageal CAMs  
Analysis of conserved differentially methylated CpG loci identified 230 susceptible 
CpG sites that are differentially methylated in both gastric and oesophageal CAMs 
when compared to patient-matched ATMs (Figure 3.10A). Notably, 172/230 of the 
identified CpG loci were changed in the same direction in gastric and oesophageal 
CAMs (Figure 3.10B). The conserved gastric and oesophageal CAM susceptible loci 
are distributed across the genome (Figure 3.12) and 65.22% of these loci are 
associated with 2 genes and 33.5% are associated with only one gene. 
 
Many studies have shown that methylation changes at only one CpG loci can 
perturb gene expression and introduce functional changes (Sohn, Park et al. 2010, 
Claus, Lucas et al. 2012). Figure 3.11 shows representative CpG loci that have 
universal methylation pattern in gastric and oesophageal CAMs compared to their 
patient-matched ATMs. Expression changes of genes associated with these CpG loci 
have been linked to gastric and gastroesophageal cancer (EHMT2, FOXF1, HS3ST6, 
PCDHGA8, PLAU, RGMA), extracellular matrix disruption (PLAU), extracellular matrix 
organization (COL9A3) and hedgehog signalling pathway (DHH, FOXF1).  
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Figure 3.10 Overlap of differentially methylated CpG sites identified in gastric and oesophageal CAMs vs ATMs.                                                          
A. Area-proportional Venn diagram representation of differentially methylated CpG loci identified in gastric and oesophageal CAMs. B. Bar chart 
representation of CAM susceptible loci differentially methylated in both gastric and oesophageal CAMs; |Δβ|>0.2, p-value < 0.05. 
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Figure 3.11 Representative conserved DNA methylation patterns in gastric and 
oesophageal patient-matched CAM and ATM samples. Probes highlighted in magenta 
are also identified as proxies for gastric CAMs. Numbers in brackets indicate the distance   
to transcription start site (TSS) of a given gene (indicated at the top of each plot);     
magenta – CAMs, purple – ATMs; |Δβ|>0.2, p-value <0.05.  
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Figure 3.12 Genome-wide overview of DNA methylation changes in stromal 
myofibroblasts. The outer ring represents human ideograms. The first tract shows 
differentially methylated CpG loci between gastric CAMs and patient-matched ATMs.       
The heatmap represents CpG loci that might serve as proxies for gastric CAM identification. 
The inner track represents conserved methylation patterns identified in gastric and 
oesophageal CAMs compared to patient-matched ATMs; red - hypermethylated loci in 
CAMs, blue - hypomethylated loci in CAMs; |Δβ|>0.2, p-value <0.05.  
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3.3.4.2 Identification of common differentially methylated 
genes in gastric and oesophageal CAMs 
To identify common differentially methylated genes in gastric and oesophageal 
CAMs, differentially methylated CpG loci in both sets of CAMs were assigned to 
genes as described in sections 3.3.2.1 and 3.3.3.1 and respective gene lists were 
compared. Differentially methylated CpG loci from gastric CAMs were assigned to 
5918 genes whereas differentially methylated oesophageal CAM CpG loci were 
assigned to 4105 genes. Comparison of these gene lists identified 2223 common 
genes, which may be regulated by DNA methylation in both gastric and 
oesophageal CAMs (Figure 3.13).   
 
 
 
 
Figure 3.13 Differentially methylated genes in gastric and oesophageal CAMs.      
Area-proportional Venn diagram of genes that were associated with differentially methylated 
CpG loci identified in gastric and oesophageal CAM vs ATM comparisons; |Δβ|>0.2,                    
p-value <0.05. 
 
 
        
            
3  5         3 
Identification of DNA Methylation Signatures in Gastric and Oesophageal CAMs 
 
 
90 
 
3.3.4.2.1  Universal pathways and processes affected by 
DNA methylation changes in both gastric and oesophageal 
CAMs   
To investigate the extent to which DNA methylation changes in gastric and 
oesophageal CAMs may affect common pathways and processes, the 2223 
commonly differentially methylated genes were subjected to Ingenuity Pathway 
Analysis (IPA) and ConsensusPathDB (Kamburov, Pentchev et al. 2011) over-
representation analysis.  KEGG and Reactome pathways with p-value < 0.01 are 
listed in Table 3.3. 
 
Table 3.3 KEGG and Reactome pathways affected by DNA methylation changes in 
gastric and oesophageal CAMs. 
Source Pathway p-value FDR 
K
EG
G
 
Hippo signalling pathway 1.28E-06 3.24E-04 
Type I diabetes mellitus 8.69E-05 9.13E-03 
PI3K-Akt signalling pathway 1.09E-04 9.13E-03 
Glycosaminoglycan biosynthesis - heparan sulfate / heparin 2.50E-04 1.14E-02 
Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan 
sulfate 
2.55E-04 1.14E-02 
Signalling pathways regulating pluripotency of stem cells 2.70E-04 1.14E-02 
Inflammatory bowel disease (IBD) 3.26E-04 1.17E-02 
Cell adhesion molecules (CAMs) 4.05E-04 1.27E-02 
Pathways in cancer 8.66E-04 2.42E-02 
Rap1 signalling pathway 1.21E-03 3.05E-02 
Circadian entrainment 2.33E-03 5.33E-02 
Allograft rejection 3.28E-03 6.41E-02 
MAPK signalling pathway 3.40E-03 6.41E-02 
Long-term depression 3.56E-03 6.41E-02 
Proteoglycans in cancer 4.26E-03 7.15E-02 
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Table 3.3 (Continued) KEGG and Reactome pathways affected by DNA methylation 
changes in gastric and oesophageal CAMs. 
Source Pathway p-value FDR 
K
EG
G
 
Hedgehog signalling pathway 6.30E-03 9.13E-02 
Tight junction 6.56E-03 9.13E-02 
Intestinal immune network for IgA production 7.00E-03 9.13E-02 
Phagosome 7.21E-03 9.13E-02 
Wnt signalling pathway 7.25E-03 9.13E-02 
Inflammatory mediator regulation of TRP channels 9.73E-03 1.17E-01 
R
ea
ct
o
m
e
 
Developmental Biology 1.39E-06 7.14E-04 
Transcriptional regulation of pluripotent stem cells 1.04E-05 7.14E-04 
Glycosaminoglycan metabolism 2.12E-05 7.14E-04 
POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation 7.78E-05 2.53E-03 
Axon guidance 1.22E-04 3.82E-03 
HS-GAG biosynthesis 6.43E-04 1.95E-02 
Diseases of glycosylation 1.51E-03 4.36E-02 
Signalling by FGFR mutants 1.53E-03 4.36E-02 
Regulation of Rheb GTPase activity by AMPK 2.10E-03 5.81E-02 
IRS-related events triggered by IGF1R 3.06E-03 8.21E-02 
Fatty acid, triacylglycerol, and ketone body metabolism 3.52E-03 9.17E-02 
IGF1R signalling cascade 4.63E-03 1.14E-01 
Signalling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) 4.63E-03 1.14E-01 
Chondroitin sulfate/dermatan sulfate metabolism 5.26E-03 1.26E-01 
Translocation of GLUT4 to the plasma membrane 5.42E-03 1.27E-01 
Signalling by FGFR1 mutants 5.56E-03 1.27E-01 
Regulation of lipid metabolism by Peroxisome proliferator-activated 
receptor alpha (PPARalpha) 
6.84E-03 1.48E-01 
Chondroitin sulfate biosynthesis 6.84E-03 1.48E-01 
Signalling by NOTCH 7.24E-03 1.53E-01 
Energy dependent regulation of mTOR by LKB1-AMPK 8.36E-03 1.65E-01 
EPH-Ephrin signalling 9.22E-03 1.65E-01 
Hedgehog ,off, state 9.34E-03 1.65E-01 
Hemostasis 9.64E-03 1.65E-01 
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Significantly, IPA analysis showed that these commonly differentially methylated 
genes are involved in digestive organ tumour (p = 1.67 x 10-17), expression of RNA  
(p = 3.46 x 10-12), transcription (p = 7.36 x 10-12), gastroesophageal cancer                
(p = 7.94 x 10-11), tumorigenesis of the tissue (p = 3.13 x 10-11), cell movement         
(p = 1.83 x 10-10), migration of cells (p = 2.18 x 10-9), proliferation of cells                   
(p = 1.28 x 10-8), invasion of cells (p = 3.43 x 10-6), generation of fibroblasts               
(p = 1.69 x 10-5) and growth of tumour (p = 4.97 x 10-5).  
The GO biological process (BP) terms enriched in gastric and oesophageal 
differentially methylated CpG loci as described in sections 3.3.2.3 and 3.3.3.2 
respectively were compared to get further insight into common biological 
processes affected by DNA methylation changes in both gastric and oesophageal 
CAMs. A list of 120 GO BP terms (p-value < 0.01) identified in the gastric CAM vs 
ATM comparison (|Δβ|>0.2, p-value < 0.05) and 116 GO BP terms (p-value < 0.01) 
identified in the oesophageal CAM vs ATM comparison (|Δβ|>0.2, p-value < 0.05) 
were compared, resulting in the identification of 32 unifying GO biological 
processes (Figure 3.14) which are presented in Table 3.4.  
 
 
Figure 3.14 Comparison of gene ontology (GO) biological process (BP) terms                    
identified for gastric and oesophageal differentially methylated CpG loci in respective     
CAM vs ATM comparisons (|Δβ|>0.2, p-value <0.05). Area-proportional Venn diagram; 
GO_BP p-value<0.01. 
                    
      3  
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Table 3.4 Common gene ontology (GO) biological process (BP) terms associated with gastric and oesophageal differentially methylated loci in 
CAMs compared to patient–matched ATMs. N - number of genes in the GO term; DE - number of genes that are differentially methylated 
  
Gastric Oesophageal 
GO ID GO Term N DE p-value FDR N DE p-value FDR 
GO:0007399 nervous system development 1938 527 5.78E-10 1.12E-05 1938 315 7.33E-03 1.00 
GO:0007156 
homophilic cell adhesion via plasma 
membrane adhesion molecules 
135 60 4.02E-07 7.80E-04 135 53 3.85E-10 7.46E-06 
GO:0098609 cell-cell adhesion 188 70 4.84E-06 5.21E-03 188 57 1.43E-07 9.21E-04 
GO:0032501 multicellular organismal process 6240 1266 5.11E-06 5.22E-03 6238 843 1.89E-06 7.32E-03 
GO:0007275 
multicellular organismal 
development 
4319 961 8.46E-06 8.20E-03 4319 633 8.55E-05 9.75E-02 
GO:0030154 cell differentiation 3302 741 9.00E-05 5.40E-02 3302 480 2.88E-03 9.67E-01 
GO:0022610 biological adhesion 1303 317 1.45E-04 7.41E-02 1303 227 6.61E-06 2.13E-02 
GO:0032502 developmental process 5100 1087 1.44E-04 7.41E-02 5100 726 4.67E-05 6.47E-02 
GO:0032012 
regulation of ARF protein signal 
transduction 
448 124 1.33E-03 3.68E-01 448 87 1.52E-03 7.55E-01 
GO:0032015 
regulation of Ran protein signal 
transduction 
448 124 1.33E-03 3.68E-01 448 87 1.52E-03 7.55E-01 
GO:0032483 
regulation of Rab protein signal 
transduction 
448 124 1.33E-03 3.68E-01 448 87 1.52E-03 7.55E-01 
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Table 3.4 (Continued) Common gene ontology (GO) biological process (BP) terms associated with gastric and oesophageal differentially 
methylated loci in CAMs compared to patient–matched ATMs. N - number of genes in the GO term; DE - number of genes that are differentially 
methylated 
  
Gastric Oesophageal 
GO ID GO Term N DE p-value FDR N DE p-value FDR 
GO:0032485 
regulation of Ral protein signal 
transduction 
448 124 1.33E-03 3.68E-01 448 87 1.52E-03 7.55E-01 
GO:0043087 regulation of GTPase activity 448 124 1.33E-03 3.68E-01 448 87 1.52E-03 7.55E-01 
GO:0035020 
regulation of Rac protein signal 
transduction 
453 125 1.39E-03 3.68E-01 453 88 1.37E-03 7.55E-01 
GO:0044699 single-organism process 12294 2281 1.52E-03 3.93E-01 12292 1484 2.37E-04 2.09E-01 
GO:0032487 
regulation of Rap protein signal 
transduction 
450 124 1.62E-03 4.08E-01 450 87 1.78E-03 8.18E-01 
GO:0032489 
regulation of Cdc42 protein signal 
transduction 
452 124 1.64E-03 4.09E-01 452 87 1.77E-03 8.18E-01 
GO:0043547 positive regulation of GTPase activity 421 116 1.98E-03 4.69E-01 421 80 3.84E-03 9.98E-01 
GO:0007268 synaptic transmission 691 178 4.76E-03 7.96E-01 691 124 2.84E-03 9.67E-01 
GO:0023052 signalling 5438 1063 9.34E-03 1.00E+00 5436 726 7.94E-05 9.75E-02 
GO:0044700 single organism signalling 5436 1062 9.94E-03 1.00E+00 5434 725 9.15E-05 9.85E-02 
 
Identification of DNA Methylation Signatures in Gastric and Oesophageal CAMs 
 
 
95 
 
3.4  Discussion 
This study is the first to examine genome-wide DNA methylation patterns at 
individual CpG resolution in primary gastric and oesophageal patient-matched CAM 
and ATM samples. Data presented in this Chapter provide strong evidence for  
CAM-specific DNA methylation signatures and show that tumour promoting 
properties of CAMs may in part be due to epigenetic programming. 
 
Comparative analysis of global DNA methylation between CAMs and               
patient-matched ATMs, isolated from gastric and oesophageal cancers showed   
that the mean global DNA methylation of CAMs is statistically lower than the mean 
global DNA methylation of corresponding ATMs which is in agreement with 
previous report that stromal gastric CAMs are characterised by global reduction in 
DNA methylation (Jiang, Gonda et al. 2008). Although this trend parallels the overall 
loss of DNA methylation that has been well documented in cancer cells from 
different tumours, it should be noted that net changes in global DNA methylation 
are subtle, and phenotypic cancer-induced signatures actually involve conserved 
gene-specific DNA methylation changes. The cause of genomic DNA demethylation 
in tumour cells is currently under intense investigation. There is evidence to suggest 
that global hypomethylation may be due to deficiency of circulating methyl donors 
in cancer tissue (Kim, Fawaz et al. 1998), a phenotype which can be reversed by 
physiological intakes of folic acid (Pufulete, Al-Ghnaniem et al. 2005). Study using a 
transgenic mouse model that is etiologically and histologically well matched with 
human gastric cancers showed beneficial effect of dietary folic acid 
supplementation, which prevented global loss of DNA methylation and markedly 
reduced gastric dysplasia and mucosal inflammation (Gonda, Kim et al. 2012).       
The study suggested that folic acid may protect against the loss of global             
DNA methylation both in the dysplastic gastric epithelial cells and in gastric stromal 
myofibroblasts.  
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Data from other projects in our laboratory indicates that cancer cells induce aerobic 
glycolysis (Warburg effect) in stromal myofibroblasts, which results in autophagic 
destruction of mitochondria in these cells. This phenomenon is well documented in 
breast cancer (Pavlides, Whitaker-Menezes et al. 2009, Martinez-Outschoorn, 
Sotgia et al. 2014). Superoxide signalling was proposed to play an important role in 
epigenetic processes such as DNA methylation, histone methylation and acetylation 
(Afanas'ev 2015). Mitochondria are known to alter DNA methylation by affecting 
folate metabolism leading to subsequent generation of S-adenosylmethionine 
(SAM), an important methyl donor. In addition, Smiraglia et al. showed that 
alterations in mitochondrial DNA copy number play an important role in regulating 
methylation of several nuclear genes that may contribute to tumorigenesis 
(Smiraglia, Kulawiec et al. 2008). Given these observations, it is possible that the 
global loss of DNA methylation in gastric and oesophageal CAMs might result from 
mitochondrial impairment in these cells.   
 
DNA methylation is a robust biomarker, more stable than RNA or proteins therefore 
identification of DNA methylation signatures in various human diseases, including 
cancer, may offer promise for the development of new approaches for diagnosis, 
prognosis and tumour stratification. In fact, DNA methylation has been proposed as 
a molecular marker for tumour microenvironment characterization and cell typing 
within tumours (Jeschke, Collignon et al. 2015). A large study in breast cancer 
demonstrated that differences in DNA methylation do not only originate from 
tumour cells but also from cells in the tumour microenvironment, such as     
tumour-inflicting lymphocytes (Dedeurwaerder, Desmedt et al. 2011). Data from 
this study have revealed distinct DNA methylation signatures in CAMs isolated from 
gastric and oesophageal cancers, which may serve as potential diagnostic 
biomarkers. In addition, identified universal patterns of DNA methylation present in 
gastric and oesophageal CAMs may provide new insights into the molecular 
mechanisms of myofibroblast programing, which promote tumour growth and 
metastasis in different tissues. 
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The genes targeted by DNA methylation in gastric and oesophageal CAMs have 
significant overlap with many of them being involved in digestive organ tumours, 
tumorigenesis, cell movement, migration and proliferation of cells, generation of 
fibroblasts and growth of tumours. Notably, most of signalling pathways targeted 
by these differentially methylated genes are either commonly dysregulated in 
human cancers such as Hippo signalling, PI3K-Akt signalling, MAPK signalling 
pathways; or are involved in transcriptional regulation of pluripotent stem cells and 
developmental processes (Hedgehog signalling, Wnt signalling and Notch signalling 
pathways). Interestingly, glycosaminoglycan metabolism and biosynthesis, an 
important component of extracellular matrix involved in cell signalling, cell function 
and cancer progression (Afratis, Gialeli et al. 2012), has been commonly targeted by 
DNA methylation changes in gastric and oesophageal CAMs together with fatty 
acid, triacylglycerol, and ketone body metabolism. It is of particular interest, as 
previous gene expression study conducted in our laboratory predicted an 
alternative type of ‘reverse Warburg effect’ where gastric CAMs are characterised 
by up-regulation of fatty acid metabolism resulting in increased ketone body 
production, which can be then supplied to cancer cells. ATMs do not exhibit this 
phenotype, probably due to the distance to cancer cells (Dr Helen Smith, 
manuscript in preparation). This provides a strong evidence for epigenetic 
programing of stromal myofibroblasts by cancer cells.  
 
Finally, most enriched biological processes targeted by DNA methylation changes in 
gastric and oesophageal CAMs included cell adhesion, cell differentiation, and 
developmental processes, signalling, regulation of signal transduction and       
GTPase activity. It was suggested that gastric stromal myofibroblasts have                 
a neuroendocrine-like phenotype characterized by Ca2+-dependent regulated 
secretion, dense-core secretory vesicles and expression of neuroendocrine marker 
proteins; loss of the phenotype is associated with advanced cancer (Balabanova, 
Holmberg et al. 2014). Interestingly, synaptic transmission and regulation of 
calcium transport were one of the significantly enriched biological processes 
targeted by DNA methylation changes in both gastric and oesophageal CAMs. 
Identification of DNA Methylation Signatures in Gastric and Oesophageal CAMs 
 
 
98 
 
 
In summary, this study is the first to examine genome-wide DNA methylation 
patterns at individual CpG resolution in primary gastric and oesophageal       
patient-matched CAM and ATM samples. Identified widespread alterations of    
DNA methylation in gastric and oesophageal CAMs can provide potential clues as to 
the molecular mechanism of cancer programing of stromal cells. In addition, 
multiple genomic loci identified as proxies for gastric CAM identification may prove 
useful as biomarkers for improved diagnosis and prognosis of gastric cancer.  
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Chapter IV 
Identification of Genes that Exhibit Correlated 
Changes in Gene Expression and DNA Methylation 
in Gastric Myofibroblasts 
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4.1  Introduction 
Growing evidence suggests that tumour derived myofibroblasts (CAMs) have 
distinct gene expression signatures in comparison to non-tumour derived 
myofibroblasts (ATMs or NTMs). In breast cancer, significant differences have been 
described between patient-matched CAMs and ATMs (Bauer, Su et al. 2010, Al-
Rakan, Colak et al. 2013, Peng, Zhao et al. 2013) or between CAMs and NTMs 
(Singer, Gschwantler-Kaulich et al. 2008). In non-small cell lung cancer, patient-
matched CAMs and ATMs show differential expression of genes relating to            
the TGF-β signalling pathway (Navab, Strumpf et al. 2011). In colon cancer, 
comparison of patient-matched CAMs and ATMs showed functional heterogeneity 
of CAMs that is associated with specific prognostic gene signatures (Herrera, Islam 
et al. 2013). Gene expression studies in stromal cells from oral squamous cell 
carcinoma identified two distinct CAM subtypes with differential tumour-promoting 
abilities (Costea, Hills et al. 2013) and showed that CAM expression profiles reflect 
the stage of tumour progression (Lim, Cirillo et al. 2011). 
 
Importantly, previous comparative gene expression study conducted in our 
laboratory showed that CAMs exhibit distinct global gene expression profiles 
compared to adjacent tissue myofibroblasts (ATMs) or normal tissue myofibroblasts 
(NTMs) (Dr Helen Smith, manuscript in preparation). In addition, more detailed 
analysis of these data showed that CAMs can be divided into two distinct        
groups of patients according to prognosis score, which was determined using       
the semi-quantitative scoring system (Supplementary Table S2.2). Patients with       
a prognosis score below 9 were classified as group A (good prognosis) and patient 
with a prognosis score above 9 were classified as group B (bad prognosis). CAMs 
from these prognosis related patient subgroups were found to have distinct gene 
expression profiles (Dr Helen Smith, manuscript in preparation). To identify 
potential epigenetically regulated gene expression profiles between CAMs and 
ATMs the expression profile needs to be consistent across all samples therefore for 
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this study only patients from the bad prognosis subgroup were selected for more 
detailed investigation (as described in Methods section 2.3.1). 
 
To assess the extent to which differences in DNA methylation (identified in   
Chapter III) may regulate CAM/ATM - specific gene expression profiles Illumina 
HumanHT-12v4 Expression BeadChip array studies were performed on a collection 
of primary gastric patient-matched CAM and ATM samples. The Illumina   
HumanHT-12 array targets more then 47 000 probes, therefore providing    
genome-wide transcriptional coverage of well-characterized genes, gene  
candidates and splice variants. In this study, samples for both genome-wide        
DNA methylation and gene expression analysis were prepared in parallel to 
minimize technical artifacts. 
 
4.2  Aims 
 To identify differentially expressed genes in gastric myofibroblasts isolated 
from different tissue microenvironments: CAM (cancer), ATM (adjacent 
tissue) and NTM (normal tissue) 
 To investigate how differential gene expression signatures may contribute 
to the tumor - promoting phenotype of gastric CAMs  
 To correlate differential DNA methylation and gene expression signatures 
observed for gastric CAMs and ATMs 
 To establish the extent to which differential DNA methylation may regulate 
gene expression in gastric CAMs  
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4.3  Results 
4.3.1  Identification of differential gene expression 
profiles in gastric CAMs, ATMs and NTMs 
 
Genome–wide expression analysis of gastric myofibroblasts isolated from different 
tissue microenvironments (CAMs, ATMs and NTMs) was performed using the 
Illumina HumanHT-12v4 Expression BeadChip arrays. The analysis revealed 13381 
expressed genes.  
 
Differential gene expression analysis between gastric (i) CAM vs ATM,                      
(ii) CAM vs NTM and (iii) ATM vs NTM identified 1215 (including 574 upregulated 
and 641 downregulated genes in CAMs), 987 (including 508 upregulated and       
479 downregulated genes in CAMs) and 713 (including 407 upregulated and         
306 downregulated genes in ATMs) differentially expressed genes, respectively 
(Figure 4.1).  
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Figure 4.1 Differential gene expression signatures in gastric myofibroblasts purified 
from different tissue microenvironments. A. CAM vs ATM B. CAM vs NTM C. ATM vs 
NTM. Heatmaps represent differentially expressed genes in respective comparisons FDR   
p-value < 0.05; volcano plots represent differentially expressed genes p-value <0.05; dashed 
lines 1.6 fold change. 
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4.3.2  Technical validation of identified differentially 
expressed genes 
To validate the results from the differential gene expression analysis, several 
candidate genes from CAM vs ATM and CAM vs NTM comparisons were selected 
(Table 4.1) and analysed by TaqMan qPCR assays (Figure 4.2). These genes were 
selected on the basis of statistical significance (ZNF536, DEPTOR), differential 
expression in both CAM vs ATM and CAM vs NTM comparisons (ZNF536, DEPTOR, 
SULF1, SULF2, SPON2) or the magnitude of observed differences in expression 
levels in respective comparisons (HOXA5, SPON2, SULF1, SULF2, DEPTOR, ZNF536). 
Triplicate reactions were conducted on each of 9 samples (including 3 CAMs,            
3 ATMs and 3 NTMs) from the array experiment, and the data were analysed using 
the comparative ΔΔCt method (as describe in Methods section 2.11.2). The relative 
quantification of validated candidate genes in gastric CAM, ATM and NTM samples 
confirmed the expression patterns observed by Illumina HT-12 array analysis thus 
increasing confidence in the identified comparative differential gene expression 
trends. 
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Table 4.1 List of Illumina HT-12 probes identified as differentially expressed in CAM vs ATM and CAM vs NTM comparisons that were validated    
by TaqMan qPCR assays. NA - not identified as differentially express in given comparison 
   CAM vs ATM CAM vs NTM 
Illumina HT-12 
probe ID 
EntrezID 
Gene 
Symbol 
Log2 FC FC p-value Log2 FC FC p-value 
ILMN_2150586 
9745 ZNF536 
-0.697 0.617 2.32E-11 -0.167 0.890 2.09E-02 
ILMN_1772155 -0.582 0.668 9.24E-09 NA NA NA 
ILMN_1756685 
64798 DEPTOR 
0.806 1.749 1.99E-06 1.053 2.075 8.88E-07 
ILMN_2172755 0.710 1.635 4.15E-06 0.982 1.976 8.23E-07 
ILMN_1702363 23213 SULF1 1.051 2.072 6.87E-03 2.185 4.548 5.51E-05 
ILMN_1667460 
55959 SULF2 
0.872 1.831 7.18E-03 0.862 1.818 2.67E-02 
ILMN_2345142 0.516 1.430 2.00E-02 0.567 1.482 3.61E-02 
ILMN_1676099 10417 SPON2 0.662 1.582 6.27E-03 1.025 2.034 1.04E-03 
ILMN_1753613 3202 HOXA5 NA NA NA 0.928 1.902 2.79E-02 
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Figure 4.2 Quantitative PCR validations of genes identified as differentially expressed 
in CAM vs ATM and CAM vs NTM comparisons (as shown in Table 4.1). Each TaqMan 
assay was done in triplicates for CAM (n=3), ATM (n=3) and NTM (n=3) samples. The 
comparative ΔΔCt method was used and samples were normalized to calibrator (as describe 
in Methods section 2.11.2). Error bars represent SEM; CAM vs ATM t-test ****p<0.0001; 
CAM vs NTM t-test ****p<0.0001,   **p<0.01, *p<0.05. 
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4.3.3  Potential biological significance of the identified 
changes in gene expression profiles 
Gene ontology (GO), gene set enrichment (GSE) and pathway analysis were 
performed in order to investigate how the identified differential gene expression 
profiles may contribute to CAM tumour-promoting phenotype. 
 
4.3.3.1  Gene ontology enrichment analysis 
Gene ontology (GO) enrichment analysis was performed on differentially expressed 
genes identified in CAM vs ATM comparison using Gene Ontology enRIchment 
anaLysis and visuaLizAtion tool (GOrilla) (Eden, Navon et al. 2009). All 13381 genes 
expressed in myofibroblast cells were used as a reference set. 
 
The enrichment analysis of: (i) GO biological processes (BP) identified 96 GO terms, 
(ii) GO molecular functions (MF) identified 11 GO terms and (iii) GO cellular 
component (CC) identified 16 GO terms with p-value < 0.001. List of GO biological 
process (BP) terms with FDR p-value < 0.05 is presented in Table 4.2 whereas 
results from GO cellular component (CC) enrichment analysis are represented as     
a DAG (directed acyclic graph) tree in Figure 4.3.  
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Table 4.2 Gene ontology (GO) biological process (BP) enrichment for differentially 
expressed genes identified in gastric CAM vs ATM comparison; FDR p-value <0.05. 
GO ID GO biological process (BP) term p-value FDR 
GO:0044699 single-organism process 6.91E-08 4.32E-04 
GO:0042221 response to chemical 4.45E-08 5.55E-04 
GO:0051239 regulation of multicellular organismal process 1.89E-07 7.86E-04 
GO:0032496 response to lipopolysaccharide 1.69E-06 3.52E-03 
GO:0044763 single-organism cellular process 2.88E-06 4.50E-03 
GO:0048513 organ development 3.63E-06 5.03E-03 
GO:0065008 regulation of biological quality 1.28E-05 1.33E-02 
GO:0071310 cellular response to organic substance 1.20E-05 1.37E-02 
GO:2000026 regulation of multicellular organismal development 1.53E-05 1.47E-02 
GO:1901700 response to oxygen-containing compound 1.78E-05 1.59E-02 
GO:0006984 ER-nucleus signalling pathway 2.51E-05 2.09E-02 
GO:0051241 
negative regulation of multicellular organismal 
process 
3.23E-05 2.24E-02 
GO:0006082 organic acid metabolic process 3.41E-05 2.24E-02 
GO:0070555 response to interleukin-1 3.20E-05 2.35E-02 
GO:2000378 
negative regulation of reactive oxygen species 
metabolic process 
4.95E-05 2.69E-02 
GO:0032680 regulation of tumour necrosis factor production 4.91E-05 2.79E-02 
GO:0048519 negative regulation of biological process 9.25E-05 3.61E-02 
GO:0032963 collagen metabolic process 9.58E-05 3.63E-02 
GO:0044707 single-multicellular organism process 9.10E-05 3.67E-02 
GO:0071347 cellular response to interleukin-1 1.07E-04 3.71E-02 
GO:0019752 carboxylic acid metabolic process 8.96E-05 3.73E-02 
GO:0001525 angiogenesis 1.07E-04 3.81E-02 
GO:0042493 response to drug 1.26E-04 4.26E-02 
GO:0030199 collagen fibril organization 1.36E-04 4.48E-02 
GO:0034976 response to endoplasmic reticulum stress 1.41E-04 4.52E-02 
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Figure 4.3 Gene ontology (GO) cellular component (CC) enrichment for differentially expressed genes identified in gastric CAM vs ATM 
comparison. DAG tree represent GO_CC terms relations; colors represent GO term p-value as shown in p-value color scale legend on top.   
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Other interesting GO terms with p-value < 0.001 include: regulation of transcription 
factor import into nucleus (GO:0042990, p = 1.79 x 10-4), morphogenesis of               
a branching structure (GO:0001763, p = 3.92 x 10-4), multicellular organismal 
metabolic process (GO:0044236, p = 3.83 x 10-4), monosaccharide biosynthetic 
process (GO:0046364, p = 3.61 x 10-4), positive regulation of cell proliferation 
(GO:0008284, p = 7.27 x 10-4), response to lipid hydroperoxide (GO:0006982,           
p = 8.35 x 10-4), sulfur compound binding (GO:1901681, p = 1.06 x 10-5) and 
proteoglycan binding (GO:0043394, p = 4.03 x 10-4). 
 
From this analysis, the extracellular region part (GO:0044421, p = 1.37 x 10-11)     
was found to be the most enriched GO_CC term. Interestingly, extracellular 
exosome (GO:0070062, p = 1.6 x 10-7) was one of the most enriched GO_CC terms         
(Figure 4.3). Exosome database, ExoCarta (Mathivanan, Fahner et al. 2012) (data 
released 29 May 2012) was used to check what molecules might be transferred via 
exosomes to tumour cells and other cells in the vicinity of tumour–programed 
stromal myofibroblasts. The analysis revealed that 20% of all differentially 
expressed genes identified in CAM vs ATM comparison have been found as 
components of human exosomes. Analysis of these genes, using Ingenuity 
Knowledge Base, showed that they are involved in tumorigenesis of tissue               
(p = 1.91 x 10-26), neoplasia of epithelial tissue  (p = 6.1 x 10-26), digestive organ 
tumour (p = 4.39 x 10-23), cell movement of tumour cell lines (p = 1.21 x 10-19), 
migration of tumour cell lines (p = 1.67 x 10-19), angiogenesis (p = 1.74 x 10-16), 
proliferation of cells (p = 3.66 x 10-16), differentiation of cells (p = 6.40 x 10-16), 
invasion of cells (p = 2.08 x 10-14), cell movement of tumour cells (p = 1.06 x 10-13), 
invasion of tumour cell lines (p = 5.59 x 10-13), progression of tumour                         
(p = 3.33 x 10-12), growth of tumour (p = 1.73 x 10-11) and chemotaxis                         
(p = 5.93 x 10-11). 
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4.3.3.2  Gene set enrichment analysis 
Gene set enrichment analysis (GSEA) (Mootha, Lindgren et al. 2003, Subramanian, 
Tamayo et al. 2005) was performed on differentially expressed genes identified in 
CAM vs ATM and CAM vs NTM comparisons using hallmark gene set subcollection 
from Molecular Signatures Database (MSigDB v5.0). The analysis identified 14 gene 
sets in CAM vs ATM comparison and 8 gene sets in CAM vs NTM comparison with                
p-value < 0.05. Table 4.3 shows list of all significantly enriched hallmark gene sets in 
CAM vs ATM phenotype with projection of these gene sets in CAM vs NTM 
phenotype.  
 
Notably, the most enriched gene set in CAM vs ATM from the entire MSigDB 
collection was HELLER_SILENCED_BY_METHYLATION_DN (Figure 4.4A), which is       
a curated gene set (Heller, Schmidt et al. 2008). Figure 4.4 shows the GSEA analysis 
results for gene sets in which gene members are reported to be epigenetically 
regulated (Heller, Schmidt et al. 2008).  
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Table 4.3 GSEA results showing a list of significantly enriched hallmark gene sets in CAM and ATM phenotypes. The right-hand column represents a 
CAM vs NTM projection of gene sets identified in CAM vs ATM (left-hand column) comparison; NES – normalized enrichment score; NA – gene set not 
identified as significantly enriched in CAM vs NTM comparison.  
  
CAM vs ATM CAM vs NTM 
Phenotype HALLMARK GENE SET NAME SIZE NES p-value FDR  SIZE NES p-value FDR  
CAM HALLMARK_UNFOLDED_PROTEIN_RESPONSE 26 2.98 0 0 NA NA NA NA 
CAM HALLMARK_MTORC1_SIGNALING 38 2.60 0 0 NA NA NA NA 
ATM/NTM HALLMARK_TNFA_SIGNALING_VIA_NFKB 28 -2.38 0 0 26 -2.21 0 7.48E-04 
ATM/NTM HALLMARK_KRAS_SIGNALING_UP 20 -2.33 0 6.36E-04 19 -1.61 3.30E-02 7.22E-02 
CAM HALLMARK_GLYCOLYSIS 27 2.14 0 1.56E-03 16 1.02 4.40E-01 4.27E-01 
CAM HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION 28 1.85 4.99E-03 1.25E-02 29 1.99 0 1.03E-02 
ATM/NTM HALLMARK_ADIPOGENESIS 25 -1.88 1.64E-03 1.47E-02 21 -1.18 2.56E-01 3.12E-01 
ATM/NTM HALLMARK_INFLAMMATORY_RESPONSE 21 -1.88 3.26E-03 1.91E-02 18 -2.01 0 4.33E-03 
ATM/NTM HALLMARK_COMPLEMENT 17 -1.81 3.38E-03 2.06E-02 17 -1.82 6.79E-03 2.15E-02 
ATM/NTM HALLMARK_APOPTOSIS 20 -1.76 1.82E-02 2.29E-02 18 -1.10 3.40E-01 3.72E-01 
ATM HALLMARK_INTERFERON_GAMMA_RESPONSE 18 -1.76 2.02E-02 2.62E-02 NA NA NA NA 
ATM HALLMARK_XENOBIOTIC_METABOLISM 23 -1.71 1.46E-02 2.79E-02 NA NA NA NA 
CAM HALLMARK_HYPOXIA 30 1.60 3.67E-02 5.08E-02 18 1.19 2.44E-01 4.05E-01 
CAM HALLMARK_UV_RESPONSE_DN 24 1.63 2.93E-02 5.15E-02 NA NA NA NA 
 
 
 
Identification of Genes that Exhibit Correlated Changes in Gene Expression and  
DNA Methylation in Gastric Myofibroblasts 
 
 
113 
 
 
Figure 4.4 GSEA enrichment plots for gene sets enriched in CAM and ATM phenotypes, which gene members are reported to be epigenetically 
regulated. A. Members of this gene set are reported to be downregulated after treatment with the DNA hypomethylating agent (5-aza-2’-deoxycytidine); 
these genes are upregulated in CAMs compared to ATMs. B. Members of this gene set are reported to be downregulated after treatment with histone 
deacetylase inhibitor (TSA); these genes are upregulated in CAMs compared to ATMs. The green curves show the enrichment score reflecting the degree to 
which each gene set member/gene (black vertical line) is represented at the top or bottom of the ranked gene list. The horizontal heatmap underneath 
indicates the relative abundance (red/high to blue/low) of the genes specifically enriched in CAMs as compared to ATMs. Corresponding heatmaps on the 
right represent the expression values of the genes in the gene set (red – high expression, dark blue - low expression); FDR p-value < 0.01; ES - enrichment 
score, NES – normalized enrichment score. 
 
ES = 0.56
NES = 2.83
ES = 0.72
NES = 3.11
A. B.
Identification of Genes that Exhibit Correlated Changes in Gene Expression and  
DNA Methylation in Gastric Myofibroblasts 
 
 
114 
 
4.3.3.3  Pathway analysis 
Differentially expressed genes in CAM vs ATM comparison were subjected to 
Ingenuity Pathway Analysis (IPA) and ConsensusPathDB (Kamburov, Pentchev et al. 
2011) over-representation analysis. For Ingenuity Pathway Analysis, CAM vs ATM 
gene expression profile was compared against a predefined Illumina HT-12v4 
reference set, whereas for ConsensusPathDB an over-representation analysis 
reference set of all 13381 genes expressed in myofibroblast cells was used.  
 
Unfolded protein response (p = 3.77 x 10-2) was the most significant canonical 
pathway reported by IPA (Figure 4.5) confirming the results obtained from GSEA 
analysis (Table 4.3). The second most significant canonical pathway was Role of     
IL-17A in Arthritis (p = 4.01 x 10-2) followed by Dendritic Cell Maturation                    
(p = 7.64 x 10-2). 
 
KEGG (Kyoto Encyclopedia of Genes and Genomes) and Reactome pathways with  
p-value < 0.01 identified by ConsensusPathDB over-representation analysis are 
presented in Figure 4.6. 
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Figure 4.5 Unfolded protein response pathway - the most overrepresented Ingenuity 
Canonical Pathway in CAM vs ATM comparison; red – upregulated genes in CAMs, green – 
downregulated genes in CAMs. 
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Figure 4.6 Reactome and KEGG pathways overrepresented in CAM vs ATM comparison; p-value<0.01. 
 
*Defective CYP27A1 causes Cerebrotendinous xanthomatosis (CTX); Defective CYP1B1 causes Glaucoma; Defective CYP4F22 causes Ichthyosis, congenital, autosomal recessive 5 (ARCI5); Defective CYP11B2 causes 
Corticosterone methyloxidase 1 deficiency (CMO-1 deficiency); Defective CYP24A1 causes Hypercalcemia, infantile (HCAI); Defective CYP2U1 causes Spastic paraplegia 56, autosomal recessive (SPG56); Defective MAOA 
causes Brunner syndrome (BRUNS); Defective CYP7B1 causes Spastic paraplegia 5A, autosomal recessive (SPG5A) and Congenital bile acid synthesis defect 3 (CBAS3); Defective FMO3 causes Trimethylaminuria (TMAU); 
Defective CYP21A2 causes Adrenal hyperplasia 3 (AH3); Defective CYP11A1 causes Adrenal insufficiency, congenital, with 46,XY sex reversal (AICSR); Defective CYP2R1 causes Rickets vitamin D-dependent 1B 
(VDDR1B); Defective CYP17A1 causes Adrenal hyperplasia 5 (AH5); Defective CYP11B1 causes Adrenal hyperplasia 4 (AH4); Defective CYP19A1 causes Aromatase excess syndrome (AEXS); Defective CYP26B1 causes 
Radiohumeral fusions with other skeletal and craniofacial anomalies (RHFCA); Defective CYP26C1 causes Focal facial dermal dysplasia 4 (FFDD4); Defective CYP27B1 causes Rickets vitamin D-dependent 1A (VDDR1A); 
Defective TBXAS1 causes Ghosal hematodiaphyseal dysplasia (GHDD) 
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4.3.4  Integration of differentially methylated loci with 
differential gene expression profiles in gastric CAMs 
compared to ATMs 
Gene symbols were used as common identifiers to integrate DNA methylation and 
gene expression data. Firstly, identified differentially methylated CpG loci in gastric 
CAM vs ATM comparison were associated with genes as described in Chapter III 
(section 3.3.2.1). In summary, 5688 CpG loci were associated with 5917 genes. 
Secondly, identified differentially expressed probes in the CAM vs ATM comparison 
were mapped to gene symbols. For genes with multiple differentially expressed 
probes, the probe with the lowest p-value was used. In total, 1215 differentially 
expressed genes were identified. Then, both gene lists were compared (Figure 4.7A) 
and 419 genes showing changes in both expression and DNA methylation were 
subjected to further analysis (Figure 4.7B and Figure 4.7C). 
 
To identify the relationship between changes in DNA methylation and gene 
expression, p-values for each differentially methylated loci were compared to 
corresponding p-value from gene expression data. This analysis generated four 
groups of genes, which segregate according to the status of both DNA methylation 
and gene expression, identifying 144 genes that are hypomethylated and 
upregulated, 119 genes that are hypermethylated and upregulated, 129 genes that 
are hypomethylated and downregulated and 106 genes that are hypermethylated 
and downregulated (Figure 4.6B). 
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Figure 4.7 Identification of a subset of genes, which expression may be regulated by 
DNA methylation changes in gastric CAMs. A. Overlap of genes identified as differentially 
methylated (|Δβ| > 0.2, p-value < 0.05) and differentially expressed (p-value < 0.05) in 
gastric CAM vs ATM comparisons. B. Quadrant plot for genes showing changes in 
expression and DNA methylation in CAMs compared to ATMs. Vertical and horizontal 
dashed lines indicate p-value < 0.05. The four quadrants shown are: (i) top left – 
hypomethylated and upregulated in CAMs, (ii) top right – hypermethylated and upregulated 
in CAMs, (iii) bottom left – hypomethylated and downregulated in CAMs, (iv) bottom right – 
hypermethylated and downregulated in CAMs; navy - CpG sites downstream of  
transcription start site (-TSS); blue – CpG sites upstream of transcription start site (+TSS). 
C. Venn diagram representing differentially expressed genes that are regulated by changes 
in DNA methylation upstream (+TSS) and/or downstream (-TSS) of the transcription start 
site. 
                
                 
                
                
             
   
      
           
      -     
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4.3.4.1  Analysis of the relationship between DNA 
methylation and gene expression in gastric CAMs 
The relationship between DNA methylation and gene expression is complex. It is 
important to consider genomic location of differentially methylated loci when 
trying to relate these data to gene expression changes. It is generally accepted that 
methylation in promoter region is inversely correlated with gene expression, 
whereas methylation in gene-body is positively correlated with gene expression 
(Jones 1999, Jones 2012). 
 
Therefore, to focus the analysis on promoter and gene-body regions, identified 
differentially methylated loci were classified according to distance to transcription 
start site (TSS) of the associated gene (as described in Chapter III section 3.3.2.1).   
In summary, the analysis revealed that 230 genes have the potential to be 
regulated by altered DNA methylation downstream of TSS (promoter region) and 
254 genes may be regulated by altered DNA methylation upstream of TSS        
(gene-body region); 65 genes may be regulated by simultaneous methylation 
changes downstream and upstream of TSS (Figure 4.7C). An example of a gene 
where expression may be regulated by simultaneous methylation changes 
downstream and upstream of TSS is shown in Figure 4.8.  
 
Genes with inverse correlation between DNA methylation and gene expression in 
promoter region or genes with positive correlation between gene expression and 
DNA methylation in gene-body were selected for further analysis. 
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Figure 4.8 Simultaneous negative correlation between gene expression and DNA methylation in promoter region and positive correlation in gene 
body of TGFBR2 in patient-matched CAM and ATM samples. Individual sample methylation levels (β-value, X-axis) are plotted against individual sample 
gene expression levels (intensity, Y-axis) for 4 CpG loci (marked with red dots) associated with TGFBR2 regulation; magenta – CAMs, purple – ATMs; 
numbers in brackets indicate the distance to transcription start site of TGFBR2; r - Spearman’s rank correlation rho. 
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4.3.4.2  Identification of genes exhibiting correlated 
changes in promoter methylation and gene expression 
This analysis identified 124 genes with coordinated changes in promoter 
methylation and gene expression, including 69 hypomethylated and upregulated 
genes (Table 4.4) and 55 hypermethylated and downregulated genes (Table 4.5)    
in CAMs compared to ATMs. Representative data showing negative correlations 
between promoter methylation and gene expression are shown in Figure 4.9.  
 
Ingenuity Knowledge Base and ConsensusPathDB (Kamburov, Pentchev et al. 2011) 
over-representation analyses were performed to identify potential biological 
functions and processes that might be affected by the observed changes in the 
subsets of 69 hypomethylated-induced and 55 hypermethylated-repressed genes in 
gastric CAMs. 
 
Interestingly, hypermethylated and downregulated genes in CAMs were found to 
be involved in gastrointestinal adenocarcinoma (p = 1.31 x 10-3), gastrointestinal 
tract cancer (p = 1.99 x 10-3), gastro-oesophageal carcinoma (p = 8.48 x 10-3) and 
gastric cancer (p = 1.06 x 10-2) whereas hypomethylated and upregulated genes in 
CAMs are not associated with any of these types of cancer.  
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Figure 4.9 Negative correlations identified between gene expression and promoter 
methylation in patient-matched CAM and ATM samples. Individual sample methylation 
level (β-value, X-axis) is plotted against corresponding gene expression level (intensity,      
Y-axis); magenta – CAMs, purple – ATMs. Representative data for 15 genes are shown; 
numbers in brackets indicate the distance to transcription start site of a given gene 
(indicated at the top of each plot); r - Spearman’s rank correlation rho. 
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4.3.4.2.1  Analysis of hypomethylated genes that are 
upregulated in CAMs compared to ATMs 
The analysis of 69 hypomethylated-induced genes in CAMs using Ingenuity 
Knowledge Base showed that these genes are involved in cell spreading                   
(p = 2.71 x 10-4), transport of amino acids (p = 9.23 x 10-4), communication of breast 
cancer/melanoma cell lines (p = 3.61 x 10-3), secretion of neurotransmitter              
(p = 4.88 x 10-3), size of tumour cell lines (p = 8.71 x 10-3), dystrophy of muscle            
(p = 8.98 x 10-3), cell viability of brain cancer cell lines (p = 1.57 x 10-2), development 
of cardiovascular system (p = 1.77 x 10-2), cell movement (p = 2.61 x 10-2), secretion 
of molecule (p = 3.34 x 10-2), production of reactive oxygen species (p = 3.38 x 10-2) 
and transport of molecule (p = 3.78 x 10-2).  
 
Complementary gene ontology (GO) analysis revealed that these genes are part of 
endoplasmic reticulum lumen (GO:0005788, p = 6.5 x 10-4), extracellular vesicular 
exosome (GO:0070062, p = 9.13 x 10-3); take part in glycoprotein binding 
(GO:0001948, p = 3.396 x 10-3), and the following biological processes: exocytosis 
(GO:0006887, p = 2.293 x 10-3), carboxylic acid transport (GO:0046942,                      
p = 3.492 x 10-3), organic substance transport (GO:0071702, p = 3.53 x 10-3), 
morphogenesis of a branching epithelium (GO:0061138, p = 6.074 x 10-3), 
neurotransmitter transport (GO:0006836, p = 3.676 x 10-3) and membrane 
organization (GO:0061024, p = 5.677 x 10-3). 
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Table 4.4 Genes that are hypomethylated and transcriptionally induced in CAMs compared to ATMs. Table shows the top 10 transcriptionally changed 
genes that contain differentially methylated loci within their promoter region. 
   
Expression Methylation 
 
Gene Symbol HT-12 probe 450k probe Log2 FC FC p - value CAM β ATM β p - value 
Spearman 
correlation 
SULF1 
ILMN_1702363 cg10791884 1.051 2.072 6.87E-03 0.050 0.258 9.70E-04 -0.600 
ILMN_1702363 cg18545695 1.051 2.072 6.87E-03 0.055 0.394 1.42E-02 -0.600 
SLC6A9 ILMN_1714445 cg25387812 0.847 1.799 5.05E-04 0.597 0.891 8.99E-04 -0.829 
SGCG 
ILMN_1659649 cg00748494 0.815 1.759 3.23E-02 0.060 0.271 8.89E-03 -0.886 
ILMN_1659649 cg11067829 0.815 1.759 3.23E-02 0.331 0.603 1.40E-02 -0.943 
ILMN_1659649 cg07126559 0.815 1.759 3.23E-02 0.279 0.557 2.27E-02 -0.543 
SPARC ILMN_1796734 cg19939793 0.669 1.590 7.83E-03 0.055 0.322 6.04E-03 -0.543 
SPON2 
ILMN_1676099 cg13558774 0.662 1.582 6.27E-03 0.107 0.653 2.69E-03 -0.886 
ILMN_1676099 cg23543318 0.662 1.582 6.27E-03 0.032 0.288 8.08E-03 -0.600 
ILMN_1676099 cg13653809 0.662 1.582 6.27E-03 0.431 0.788 3.64E-02 -0.714 
ILMN_1676099 cg23127323 0.662 1.582 6.27E-03 0.174 0.622 3.73E-02 -0.600 
COL5A1 
ILMN_1706505 cg13478045 0.622 1.539 1.60E-03 0.358 0.777 2.53E-02 -0.829 
ILMN_1706505 cg00753924 0.622 1.539 1.60E-03 0.084 0.292 3.93E-02 -0.257 
SEL1L3 ILMN_1797822 cg25546651 0.614 1.530 1.02E-02 0.039 0.356 2.21E-02 -0.543 
SYNM ILMN_1712075 cg26942432 0.515 1.429 2.36E-02 0.625 0.953 1.33E-02 -0.600 
CHAC1 ILMN_1739241 cg07891971 0.477 1.392 3.87E-04 0.116 0.317 3.16E-02 -0.543 
CERCAM ILMN_1750563 cg21205865 0.458 1.374 1.90E-02 0.460 0.743 2.08E-02 -0.886 
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4.3.4.2.2  Analysis of hypermethylated genes that are 
downregulated in CAMs compared to ATMs 
The analysis of 55 hypermethylated-repressed genes in CAMs using Ingenuity 
Knowledge Base showed that these genes are involved in formation of membrane 
ruffles (p = 1.23 x 10-3), formation of actin filaments (p = 1.88 x 10-3), angiogenesis     
(p = 3 x 10-3), migration of connective tissue cells (p = 4.64 x 10-3), cell movement of 
tumour cell lines (p = 7.6 x 10-3), metabolism of reactive oxygen species                    
(p = 9.74 x 10-3), cell movement (p = 1.52 x 10-2), morphology of cells                         
(p = 1.66 x 10-2), advance malignant tumour (p = 1.7 x 10-2), formation of 
lamellipodia (p = 1.86 x 10-2), migration of cells (p = 1.92 x 10-2), differentiation of 
connective tissue cells (p = 2.4 x 10-2), proliferation of tumour cell lines (p = 4 x 10-2) 
and expression of RNA (p = 4.74 x 10-2). 
 
Gene ontology (GO) analysis revealed that these genes are involved in positive 
regulation of growth (GO:0045927, p = 2.749 x 10-4), cell activation (GO:0001775,      
p = 1.077 x 10-3), regulation of response to stimulus (GO:0048583, p = 2 x 10-3), 
morphogenesis of a branching structure (GO:0001763, p = 3.399 x 10-3), regulation 
of developmental process (GO:0050793, p = 4.48 x 10-3), nervous system 
development (GO:0007399, p = 5.39 x 10-3), regulation of signal transduction 
(GO:0009966, p = 5.627 x 10-3), cell fate commitment (GO:0045165,                            
p = 6.616 x 10-3) and embryo development (GO:0009790, p = 8.25 x 10-3).  
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Table 4.5 Genes that are hypermethylated and transcriptionally repressed in CAMs compared to ATMs. Table shows the top 10 transcriptionally 
changed genes that contain differentially methylated loci within their promoter region. 
   Expression Methylation  
Gene Symbol HT-12 probe 450k probe Log2 FC FC p-value CAM β ATM β p - value 
Spearman 
correlation 
STOM ILMN_1696419 cg14215970 -0.943 0.520 4.72E-03 0.791 0.590 2.51E-02 -0.257 
SEPP1 ILMN_1785071 cg12887985 -0.830 0.563 4.60E-02 0.870 0.620 3.25E-03 -0.657 
MGAT3 ILMN_1853824 cg03318904 -0.806 0.572 1.18E-02 0.446 0.181 6.23E-03 -0.029 
TBX2 ILMN_1792256 cg19457909 -0.726 0.605 2.75E-02 0.866 0.235 2.85E-02 -0.943 
WNT2B ILMN_1740269 cg04571584 -0.710 0.611 4.87E-02 0.912 0.577 1.49E-03 -0.429 
ZNF536 
ILMN_2150586 cg00386405 -0.697 0.617 2.32E-11 0.626 0.358 4.25E-02 -0.886 
ILMN_2150586 cg05804948 -0.697 0.617 2.32E-11 0.322 0.014 4.42E-02 -0.886 
SPRY1 ILMN_2329914 cg00137840 -0.590 0.664 2.73E-02 0.910 0.691 7.61E-03 -0.257 
TGFBR2 
ILMN_2384241 cg00807684 -0.587 0.666 2.38E-02 0.809 0.292 8.59E-04 -0.257 
ILMN_2384241 cg19142043 -0.587 0.666 2.38E-02 0.962 0.700 2.02E-02 -0.600 
FAT1 ILMN_3247578 cg03199366 -0.516 0.699 2.79E-02 0.717 0.456 1.05E-02 -0.314 
ABR 
ILMN_1672878 cg19807420 -0.452 0.731 4.74E-02 0.879 0.531 1.73E-02 -0.429 
ILMN_1672878 cg05856321 -0.452 0.731 4.74E-02 0.843 0.356 2.97E-02 -0.429 
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4.3.4.3  Identification of genes exhibiting correlated 
changes in gene-body methylation and gene expression 
This analysis identified 152 genes with coordinated changes in gene-body 
methylation and gene expression, including 79 hypomethylated and downregulated 
genes (Table 4.6) and 73 hypermethylated and upregulated genes (Table 4.7) in 
CAMs compared to ATMs. Representative data showing positive correlations 
between gene-body methylation and gene expression are shown in Figure 4.10.  
 
Ingenuity Knowledge Base and ConsensusPathDB (Kamburov, Pentchev et al. 2011) 
over-representation analyses were performed to identified potential biological 
functions and processes that may be affected by observed changes in the subsets of 
79 hypomethylated-repressed and 73 hypermethylated-induced genes in gastric 
CAMs. 
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Figure 4.10 Positive correlations identified between gene expression and gene-body 
methylation in patient-matched CAM and ATM samples. Individual sample methylation 
level (β-value, X-axis) is plotted against corresponding gene expression level (intensity,      
Y-axis); magenta – CAMs, purple – ATMs. Representative data for 12 genes are shown; 
numbers in brackets indicate the distance to transcription start site of a given gene 
(indicated at the top of each plot); r - Spearman’s rank correlation rho. 
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4.3.4.3.1 Analysis of hypomethylated genes that are 
downregulated in CAMs compared to ATMs 
Analysis of the subgroup of 79 hypomethylated-repressed genes in CAMs using 
Ingenuity Knowledge Base showed that these genes are involved in invasion of 
embryonic cell lines (p = 3.69 x 10-5), invasion of cells (p = 5.90 x 10-4), proliferation 
of breast cancer cell lines (p = 4.35 x 10-3), cell death (p = 4.60 x 10-3), formation of 
actin filaments (p = 6.78 x 10-3), transformation of tumour cell lines (p = 6.84 x 10-3), 
transport of molecule (p = 1.26 x 10-2), migration of cells (p = 1.26 x 10-2), 
proliferation of cells (p = 1.33 x 10-2), differentiation of cells (p = 1.48 x 10-2), 
angiogenesis (p = 1.66 x 10-2) and cell survival (p = 2.80 x 10-2). 
 
Gene ontology (GO) analysis of this subset of genes indicates that these genes are 
involved in regulation of cell adhesion (GO:0030155, p = 1.32 x 10-4), organ 
development (GO:0048513, p = 3.09 x 10-4), tissue morphogenesis (GO:0048729,       
p = 8.94 x 10-4), positive regulation of growth (GO:0045927, p = 1.492 x 10-3) and 
reactive oxygen species metabolic process (GO:0072593, p = 2.392 x 10-3). 
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Table 4.6 Top 10 genes that are hypomethylated in gene-body and transcriptionally repressed in CAMs compared to ATMs.  
 
  Expression Methylation  
Gene Symbol HT-12 probe 450k probe Log2 FC FC p - value CAM β ATM β p - value 
Spearman 
correlation 
AKR1B1 ILMN_1701731 cg26925463 -1.145 0.452 3.96E-03 0.276 0.760 1.76E-03 0.771 
LIMCH1 ILMN_2139761 cg03742238 -1.118 0.461 2.15E-02 0.027 0.308 1.13E-02 0.600 
ABCC4 ILMN_2194009 cg15896117 -0.978 0.508 1.50E-03 0.667 0.891 2.81E-03 0.657 
RSPO3 ILMN_1681983 cg10997634 -0.922 0.528 9.93E-03 0.542 0.858 1.00E-02 0.657 
CD248 ILMN_1726589 cg08924469 -0.884 0.542 1.77E-02 0.624 0.840 3.01E-02 0.829 
LAMA5 ILMN_1773567 cg04632997 -0.853 0.554 8.12E-03 0.487 0.717 4.99E-02 0.886 
RASIP1 
ILMN_1755657 cg02804819 -0.852 0.554 8.39E-03 0.107 0.478 6.39E-03 0.486 
ILMN_1755657 cg19420129 -0.852 0.554 8.39E-03 0.240 0.522 1.71E-02 0.943 
ILMN_1755657 cg07611790 -0.852 0.554 8.39E-03 0.087 0.531 1.84E-02 0.600 
RFTN1 ILMN_1800787 cg01336231 -0.847 0.556 1.22E-02 0.143 0.624 5.15E-03 0.543 
PPARG ILMN_1800225 cg07676920 -0.733 0.602 1.23E-03 0.675 0.901 2.22E-02 0.943 
DENND2A ILMN_1666503 cg11176169 -0.732 0.602 3.29E-02 0.342 0.554 2.14E-02 0.257 
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4.3.4.3.2  Analysis of hypermethylated genes that are 
upregulated in CAMs compared to ATMs 
Analysis of 73 hypermethylated-induced genes in CAMs using Ingenuity Knowledge 
Base showed that these genes are involved in metabolism of amino acids                 
(p = 5.59 x 10-3), metabolism of heparan sulfate proteoglycan (p = 7.63 x 10-3),            
O-glycosylation of peptide (p = 1.14 x 10-2), infection of cells (p = 1.37 x 10-2), 
transport of amino acids (p = 1.75 x 10-2), folding of protein (p = 1.88 x 10-2),        
cancer of secretory structure (p = 2.25 x 10-2), metabolism of protein                         
(p = 3.92 x 10-2) and proliferation of cells (p = 3.92 x 10-2). 
 
Gene ontology (GO) analysis of this subset of genes revealed that they are 
associated with extracellular vesicular exosomes (GO:0070062, p = 3.465 x 10-3);  
take part in the following processes: cellular amino acid biosynthetic process 
(GO:0008652, p = 2.28 x 10-4), one-carbon metabolic process (GO:0006730,                
p = 2.93 x 10-4), cellular amino acid metabolic process (GO:0006520,                           
p = 1.212 x 10-3), cell differentiation (GO:0030154, p = 2.198 x 10-3), organic acid 
biosynthetic process (GO:0016053, p = 4.91 x 10-3), organic acid metabolic process 
(GO:0006082, p = 5.374 x 10-3) and cell morphogenesis (GO:0000902,                         
p = 6.721 x 10-3). 
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Table 4.7 Top 10 genes that are hypermethylated in gene-body and transcriptionally induced in CAMs compared to ATMs.  
 
  Expression Methylation  
Gene Symbol HT-12 probe 450k probe Log2 FC FC p - value CAM β ATM β p - value 
Spearman 
correlation 
PSAT1 ILMN_1692938 cg13612583 2.029 4.080 7.99E-05 0.846 0.592 6.85E-03 0.886 
SLC7A5 ILMN_1720373 cg26569315 1.230 2.346 2.55E-04 0.746 0.422 3.46E-02 0.657 
KLF2 
ILMN_1735930 cg19280540 0.902 1.869 7.14E-03 0.819 0.613 1.73E-02 0.257 
ILMN_1735930 cg02668248 0.902 1.869 7.14E-03 0.860 0.657 4.65E-02 0.600 
MTHFD1L ILMN_1772521 cg00945443 0.897 1.862 8.83E-04 0.683 0.469 8.79E-03 0.886 
SULF2 ILMN_1667460 cg14286048 0.872 1.831 7.18E-03 0.530 0.226 4.59E-02 0.429 
SLC7A1 
ILMN_1683859 cg15955521 0.828 1.775 2.89E-04 0.811 0.608 8.49E-03 0.943 
ILMN_1683859 cg18091046 0.828 1.775 2.89E-04 0.897 0.314 4.62E-02 0.943 
SHMT2 ILMN_1661264 cg13433012 0.759 1.693 8.02E-04 0.457 0.106 2.15E-02 0.714 
TARS ILMN_1685480 cg15902864 0.675 1.596 2.75E-04 0.542 0.226 2.48E-02 0.886 
SPON2 ILMN_1676099 cg08462122 0.662 1.582 6.27E-03 0.772 0.428 4.95E-02 0.771 
FGFRL1 
ILMN_1795865 cg20518497 0.633 1.551 6.58E-04 0.833 0.625 8.26E-03 0.886 
ILMN_1795865 cg10825234 0.633 1.551 6.58E-04 0.862 0.529 2.92E-02 0.829 
ILMN_1795865 cg01321174 0.633 1.551 6.58E-04 0.778 0.571 3.66E-02 0.086 
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4.4  Discussion 
This study is the first to integrate genome-wide DNA methylation and gene 
expression profiles in patient-matched gastric CAM and ATM samples in order to 
assess the extent to which DNA methylation may contribute to CAM/ATM-specific 
gene expression profiles.  
 
In this study, the correlation analysis between DNA methylation and gene 
expression allowed identification of a number of novel epigenetically regulated 
candidate genes, which may contribute to the ability of stromal myofibroblasts to 
exert tumour-promoting properties. Notably, promoter DNA hypermethylation in 
CAMs emerged as a novel regulatory mechanism for transcriptional repression of 
genes involved in: the pathology of gastrointestinal cancers, cell activation, 
regulation of response to stimulus, regulation of developmental process and cell 
fate commitment. Promoter DNA hypomethylation in CAMs, on the other hand, 
emerged as an important regulatory mechanism for transcriptional activation of 
genes involved in secretion and transport of molecules, including extracellular 
vesicular exosomes. Importantly, the enrichment analysis of genes positively 
correlated with gene-body methylation in CAMs largely confirmed these trends 
supporting the hypothesis that tumour-promoting properties of CAMs may well be 
epigenetically programed. 
 
Comparative differential gene expression profiles in gastric myofibroblasts 
identified in this study confirm previous observations in gastric and other cancer 
types that tumour derived myofibroblasts (CAMs) and non-tumour derived 
myofibroblasts (ATMs and NTMs) have distinct gene expression signatures. 
Significantly, the most over-represented pathway in CAMs compared to ATMs was 
unfolded protein response (UPR) pathway. Activation of this pathway is a feature  
of specialized secretory cells and has been implicated in many diseases including 
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cancer, inflammatory disease, neurodegenerative disorders and metabolic 
disorders (Hetz, Chevet et al. 2013). Recent studies show that this pathway is also 
important in many other physiological processes that are not directly linked with 
protein folding, including lipid and cholesterol metabolism, energy control, 
inflammation and cell differentiation (Rutkowski and Hegde 2010, Wang and 
Kaufman 2012). The chaperone protein HSPA5 (also known as BIP or GRP78) is         
a key regulator of the endoplasmic reticulum (ER) stress response, critical for 
protein quality control and activation of the UPR pathway. Misfolded proteins bind 
and sequester HSPA5, and the resulting reduction in free HSPA5 activates signalling 
pathways to induce transcription of HSPA5 and other chaperones involved in UPR 
(Wang and Kaufman 2014). This is of particular significance as expression of HSPA5 
and other components of UPR pathway (CHAC1, XPOT, PSAT1, SLC7A5, TARS, 
SLC1A4, EIF4EBP1, ATF3) appear to be regulated by altered DNA methylation in 
gastric CAMs. In particular, promoter hypomethylation of HSPA5 is associated with 
transcriptional activation of HSPA5 in CAMs (Figure 4.8). Notably, upregulation of 
HSPA5 and other components of UPR pathway (CHAC1, ATF3) were also observed in 
a previous gene expression study on 12 patient-matched gastric CAM and ATM 
samples (Supplementary Figure S4.1).  
 
Extracellular region (GO:0044421) and extracellular exosome (GO:0070062) were 
the most overrepresented GO cellular component terms in CAM vs ATM 
comparison. Strikingly, the correlation analysis revealed that promoter                
DNA hypomethylation may be an important mechanism for transcriptional 
activation of genes associated with these GO_CC terms (YWHAZ, SPON2, SEMA5A, 
EHD4, CPM, HSPA5, TRAP1, SLC3A2, DHRS4, TTYH3, FBN1, ECH1, GNG4, COL5A1, 
RAP1GDS1, SLC1A4, GOT1 and VPS28; examples in Figure 4.9 and Table 4.3).           
In addition, a large proportion of these genes (SPON2, SEMA5A, HSPA5, SLC3A2, 
ECH1, GOT1) were also found to be upregulated in CAMs in a previous gene 
expression study on 12 patient-matched gastric CAM and ATM samples 
(Supplementary Figure S4.1) supporting the idea that transcriptional regulation of 
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these consistently changed genes may also be controlled by tumour-induced 
epigenetic programing. 
 
These data are of particular interest as there is mounting evidence to show that 
exosomes are important players in tumour-stroma communication. They carry 
biologically active molecules, such as microRNAs, mRNAs and proteins, which can 
be horizontally transferred to, and function in, recipient cells. Exosomes can 
function in an autocrine or paracrine manner to promote tumour-induced immune 
suppression, angiogenesis, and formation of pre-metastatic niche (Minciacchi, 
Freeman et al. 2015). Janowska-Wieczorek et al. showed that exosomes secreted  
by activated platelets induce expression of proangiogenic and invasive factors in 
lung cancer cells therefore promoting angiogenesis and metastasis (Janowska-
Wieczorek, Wysoczynski et al. 2005). Luga et al. reported that CAM-secreted 
exosomes promote breast cancer cell motility and metastasis by mobilizing 
autocrine Wnt-planar cell polarity (PCP) signalling in cancer cells (Luga, Zhang et al. 
2012). Several studies have reported that components of PCP pathway are 
upregulated in cancer and are involved in cancer progression (Wang 2009).          
This pathway was also identified in CAM vs ATM comparison by the Ingenuity 
Pathway Analysis (Supplementary Figure S4.2). Notably, 20% of all differentially 
expressed genes in CAM vs ATMs were identified as exosome components using 
ExoCarta (Mathivanan, Fahner et al. 2012). Largely, these genes are involved in 
tumorigenesis, cell movement, migration, angiogenesis, proliferation, invasion and 
tumour growth.  
 
The relationship between DNA methylation and gene expression is complex. 
Generally, the correlation between promoter-associated DNA methylation and 
gene expression is modest (Bock 2012). However, this may not be surprising, given 
that gene expression can also be regulated by other epigenetic factors, such as 
histone modifications and non-coding RNAs.  
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DNA methylation also controls expression of non-protein coding genes, including 
microRNAs (miRNAs) and long non–coding RNAs (lncRNAs), which can in turn 
impact global gene expression profiles (Lopez-Serra and Esteller 2012, Li, Zhang et 
al. 2015). Hence, alteration of DNA methylation patterns in CAMs can be 
responsible for aberrant regulation of microRNAs, which may consequently alter 
the expression of their target genes. In recent years, many studies have shown that 
microRNAs play an important role in the tumour-promoting properties of CAMs. 
Differential microRNAs expression profiles between patient-matched CAM and ATM 
samples were reported in breast cancer (Zhao, Sun et al. 2012), bladder cancer 
(Enkelmann, Heinzelmann et al. 2011) and gastric cancer (Yang, Yang et al. 2014). 
Recent work in gastric cancer showed that miR-149 modulates prostaglandin E2 
(PGE2) and interleukin 6 (IL-6) signalling in the crosstalk between tumour cells and 
stroma. The study suggested that H. pylori infection induces secretion of PGE2 from 
tumour cells and promotes the methylation of miR-149 in CAMs. This subsequently 
induces the expression of its target gene IL-6 in stromal myofibroblasts (Li, Shan et 
al. 2015). 
 
In summary, data presented in this Chapter suggest that DNA methylation is 
involved in an epigenetic regulation of biological pathways and processes involved 
in the tumour–promoting function of gastric CAMs. In particular, promoter         
DNA hypomethylation emerged as regulatory mechanism for transcriptional 
activation of genes involved in secretion and transport of molecules, including 
extracellular vesicular exosomes while promoter DNA hypermethylation emerged 
as regulatory mechanism for transcriptional repression of genes involved in 
pathology of gastrointestinal cancers and regulation of developmental processes.  
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Chapter V 
Validation of DNA Methylation Patterns that 
Correlate with CAM-specific Gene Expression 
Profiles 
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5.1  Introduction 
Combined genome–wide DNA methylation and gene expression profiling of gastric 
myofibroblasts has identified several interesting trends. To further validate 
observed differences in DNA methylation between gastric tumour derived 
myofibroblasts (CAMs) and non-tumour derived myofibroblasts (ATMs and NTMs)  
a targeted set of pyrosequencing assays were performed. In total 20 genomic CpG 
loci were chosen for verification in a set of 7 independent gastric patient-matched 
CAM and ATM samples and 4 unrelated gastric NTM samples. These 20 genomic 
loci selected are associated with the regulation of 15 genes reported to be involved 
in a range of functions, including development of the digestive system (ASPH, 
FOXC1, FOXF1, HOXA5, RUX1, SMAD3), chemotaxis of neuronal cell lines (CD47, 
SMAD3), transcription of DNA (ASPH, FOXC1, FOXF1, HOXA5, RUX1, SMAD3, 
ZNF536), cell migration (CD47, FOXC1, FOXF1, MUC2, RUX1, SMAD3, SPON2, 
VPS28), development of connective tissue (CD47, HOXA5, RUNX1, SMAD3), 
proliferation of cells (ASPH, B4GALT6, CD47, FOXC1, FOXF1, HOXA5, MUC2, RUNX1, 
SMAD3, VPS28), angiogenesis (FOXC1, FOXF1, HOXA5, RUNX1, SMAD3) and 
differentiation of cells (CD47, FOXC1, FOXF1, HOXA5, RUNX1, SMAD3, ZNF536). 
Finally, to assess whether differential DNA methylation in gene promoter regions 
effect transcriptional regulation of neighboring genes additional qPCR studies were 
also performed on selection of adjacent gene targets. 
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5.2  Aims 
 To validate DNA methylation patterns and gene expression profiles 
identified in genome-wide studies in independent gastric CAM, ATM and 
NTM samples  
 To verify if differently methylated CpG sites identified in gastric CAMs, ATMs 
and NTMs are concordant within methylation patterns in a border genomic 
region  
 To investigate whether locus specific changes in DNA methylation in gastric 
CAMs may also affect expression of neighbouring genes  
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5.3  Results 
5.3.1  Validation of CAM differentially methylated CpG 
loci by targeted pyrosequencing analysis 
Pyrosequencing is a widely used method for the exact simultaneous quantification 
of the DNA methylation status of multiple CpG loci within a region of up to 350bp 
(Tost and Gut 2007). Representative pyrograms of assays performed in this study 
are shown in Figure 5.1.  
 
In total 13 pyrosequencing assays were designed (Methods Table 2.5) to investigate 
multiple CpG loci, including the 20 CpG loci selected from genome-wide               
DNA methylation profiling with the Illumina 450k array. These genomic loci were 
selected on the basis of their differential methylation in both CAM vs ATM and  
CAM vs NTM comparisons (FOXF1, FOXC1, MUC2, SMAD3, SPON2, ZNF536, HOXA5), 
their localization within CpG islands (FOXF1, FOXC1, HOXA5) and their position 
downstream of the annotated transcription start site (TSS) of genes known to be 
implicated in cancer progression (HOXA5, B4GALT6, CD47, MUC2, VPS28, ASPH, 
SPON2, SMAD3, ZNF536). Other important criterion for target validation was the 
number of differentially methylated probes found to be associated with target 
genes in CAM vs ATM comparison. These include FOXF1 (23), FOXC1 (11),      
ZNF536 (10), HOXA5 (7), SMAD3 (4), SPON2 (4), ASPH (3) and B4GALT6 (2). 
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Figure 5.1 Representative pyrograms from comparative pyrosequencing                  
DNA methylation assays. The analysis of five CpG sites in the CD47 promoter region is 
shown as an example. X-axes show the nucleotide dispensation order while Y-axes show 
signal intensity levels. The percentage of methylation for individual CpG positions is shown 
above the respective positions (highlighted in blue). The C dispensation at position 21 
(highlighted in yellow) controls for the full bisulfite conversion of DNA. The top pyrogram 
represents one CAM sample, whereas the bottom pyrogram represents the patient-matched 
ATM sample (patient 192). Percentage values next to pyrograms represent methylation 
index, the overall methylation level of the interrogated region. Red box highlights the CpG 
loci identified to be differentially methylated following analysis of CAM vs ATM Illumina 450k 
array data.  
 
CAM 192
45.6%
ATM 192
63.2%
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5.3.2  Pyrosequencing analysis identifies concordant 
DNA methylation changes within interrogated regions of 
gastric CAMs 
 
A quantitative DNA methylation analysis was performed on 13 genomic regions in   
a set of 7 independent gastric patient-matched CAM and ATM samples and              
4 unrelated gastric NTM samples. Biological replicates of each assay were 
performed to ensure reproducibility of sample preparation (Supplementary      
Table S5.1). 
 
Significantly, pyrosequencing results confirmed the existence of distinct DNA 
methylation changes between CAMs and non-tumour derived myofibroblasts 
(ATMs and/or NTMs) in all of the 13 interrogated promoter regions thereby 
providing confidence that DNA methylation changes identified by the Illumina 450k 
arrays are concordant within a border region, which also includes neighbouring  
CpG sites (Figure 5.2, Figure 5.3B,C, Figure 5.4B,C, Figure 5.5B,C and Figure 5.6B,C). 
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Figure 5.2 Methylation changes at CpG loci identified in gastric CAMs and ATMs by Illumina 450k array are concordant within a broader local 
genomic region. Pyrosequencing assays were performed to interrogate the promoter regions of 8 genes. Gene names are indicated at the top of each plot. 
Numbers in bracket indicate distance to the annotated transcription start site (TSS) of a given gene. Mean methylation values are plotted for each examined 
CpG site in the interrogated regions of gastric CAMs (n=7), ATMs (n=7) and NTMs (n=4). X-axis indicates chromosomal position of examined CpG loci. 
Positions marked with * correspond to the Illumina 450k probe; magenta - CAMs, purple - ATMs, nave - NTMs. Error bars represent SEM. Boxplots represent 
methylation distribution and mean for all CpG sites in the interrogated promoter region in CAMs (n=7), ATMs (n=7) and NTMs (n=4).  
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Figure 5.2 (Continued) Methylation changes at CpG loci identified in gastric CAMs and ATMs by Illumina 450k array are concordant within              
a broader local genomic region. Pyrosequencing assays were performed to interrogate the promoter regions of 8 genes. Gene names are indicated at the 
top of each plot. Numbers in bracket indicate distance to the annotated transcription start site (TSS) of a given gene. Mean methylation values are plotted for 
each examined CpG site in the interrogated regions of gastric CAMs (n=7), ATMs (n=7) and NTMs (n=4). X-axis indicates chromosomal position of examined 
CpG loci. Positions marked with * correspond to the Illumina 450k probe; magenta - CAMs, purple - ATMs, nave - NTMs. Error bars represent SEM. Boxplots 
represent methylation distribution and mean for all CpG sites in the interrogated promoter region in CAMs (n=7), ATMs (n=7) and NTMs (n=4).  
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5.3.3  Locus specific changes in CAM DNA methylation 
also affect expression of neighbouring genes 
Four differentially methylated genomic regions spanning more than 600bp and up 
to 526,426bp identified by Illumina 450k array analysis were chosen for more 
detailed pyrosequencing and qPCR analyses, in order to assess if differential 
methylation levels also correlate with expression of neighbouring genes. The 
pyrosequencing and qPCR analyses were performed on a set of 7 independent 
gastric patient-matched CAM and ATM samples and 4 unrelated gastric NTM 
samples. 
 
5.3.3.1  Selection of target regions  
Genomic regions selected for further investigation are associated with the 
regulation of five genes (SMAD3, SPON2, ZNF536, FOXF1 and FENDRR), all of which 
have been previously implicated in cancer and tumour-stroma communication and 
were also found to be differentially methylated/expressed in this study.  
 
5.3.3.2  Promoter hypermethylation may repress SMAD3 
expression in gastric CAMs 
SMAD3 is an intracellular protein that functions as a signal transducer and 
transcriptional modulator. It is activated by TGF-β (transforming growth factor - β) 
and is thought to have a role in carcinogenesis (Pruitt, Brown et al. 2014). 
 
The SMAD3 gene is located on chromosome 15 and the longest isoform spans 
129,339 bp. Genome-wide DNA methylation analysis identified several differentially 
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methylated CpG loci between CAMs and non-tumour derived myofibroblasts (ATMs 
and NTMs) that are associated with SMAD3 regulation, including 3 CpGs in the 
promoter region (Figure 5.3A). Interestingly, these 3 CpGs are classified as 
reprogramming-specific differentially methylated regions (rDMRs) by Illumina 
annotation. In addition, SMAD3 was found to be downregulated in CAMs when 
compared to ATMs from gastric (previous gene expression study, Dr Helen Smith) 
and oesophageal (collaborative work with the Varro group, University of Liverpool) 
cancer (Supplementary Figure S5.1).  
 
To assess whether SMAD3 expression in gastric CAMs is regulated by promoter  
DNA methylation, two pyrosequencing assays were designed in SMAD3 promoter 
region and SMAD3 TaqMan assay were performed on an independent set of 
patient-matched gastric CAM and ATM samples, which were cultured and 
processed in parallel. The pyrosequencing assays cover 224bp region and are 
spanning 10 CpG sites, including 2 CpGs that were identified by Illumina 450k array 
(Figure 5.3B).  
 
This pyrosequencing analysis confirmed that the SMAD3 promoter region is 
hypermethylated in CAMs when compared to either ATMs or NTMs (Figure 5.3B, 
Figure 5.3C), whereas qPCR analysis showed that SMAD3 expression is 
downregulated in CAMs compared to ATMs (Figure 5.3D) confirming the previous 
observations in gastric and oesophageal CAMs (Supplementary Figure S5.1). 
Notably, DNA methylation levels in the SMAD3 promoter region were found to be 
very similar in ATMs and NTMs (Figure 5.3C) therefore this genomic region might be 
used as a biomarker for gastric CAMs. Taken together, these experimental data 
provide a strong indication that SMAD3 expression may be repressed by promoter 
DNA hypermethylation in gastric CAMs. Supplementary Figure S5.2A shows the 
observed correlation between SMAD3 expression and promoter methylation 
assessed by qPCR and pyrosequencing analysis.  
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Figure 5.3 DNA methylation in the SMAD3 promoter region regulates SMAD3 
expression in gastric CAMs and ATMs. A. Differentially methylated CpG loci identified by 
Illumina 450k array in the SMAD3 promoter region. Mean β values (n=3) for probes 
identified as differentially methylated in CAM vs ATM and CAM vs NTM comparisons are 
plotted. The X-axis indicates distance of Illumina 450k probes to SMAD3 transcription start 
site. Highlighted positions (in magenta and blue) are within the genomic region examined by 
pyrosequencing assays. B. Pyrosequencing analysis of the SMAD3 promoter region in 
patient-matched CAM (n=7) and ATM (n=7) samples. Methylation means for 10 individual 
CpG sites in the interrogated promoter region are plotted. The X-axis indicates the 
chromosomal position of examined CpG sites. Positions marked with * correspond to the 
Illumina 450k probes. C. The overall methylation level of the SMAD3 promoter region 
interrogated by pyrosequencing analysis. Boxplots represent methylation distribution and 
mean for 10 CpG sites in CAM (n=7), ATM (n=7) and NTM (n=4) samples. D. Quantitative 
PCR analysis of SMAD3 gene expression in CAM (n=6) and ATM (n=6) samples; t-test 
****p<0.0001. Error bars represent SEM. 
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5.3.3.3  Promoter hypomethylation may induce SPON2 
expression in gastric CAMs 
SPON2 is an extracellular matrix protein that has been implicated to have a role in 
axon guidance, cell adhesion and cellular response to lipopolysaccharide (Smith, 
Aleksic et al. 2012). It has been reported as a component of extracellular exosomes 
(Mathivanan, Fahner et al. 2012).  
 
The SPON2 gene is located on chromosome 4 and the longest isoform spans   
42,030 bp. Genome-wide DNA methylation analysis identified several differentially 
methylated CpG loci between gastric CAMs and non-tumour derived myofibroblasts 
(ATMs and NTMs) that are associated with SPON2 regulation, including 5 CpGs in 
the promoter region (Figure 5.4A). Notably, the genomic region associated with 
SPON2 regulation was also differentially methylated in oesophageal CAMs 
compared to their patient-matched ATMs, including 3 CpGs in the promoter region 
(Supplementary Figure S5.3). Genome-wide expression analysis showed that SPON2 
is upregulated in gastric CAMs compared to both ATMs and NTMs (Table 4.1 and 
Figure 4.2). Supplementary Figure S5.4 shows simultaneous negative correlation 
between SPON2 expression and promoter methylation and positive correlation in 
the gene body of SPON2 in patient-matched CAMs and ATMs, whereas 
Supplementary Figure S5.5 shows negative correlation between SPON2 expression 
and promoter methylation in CAMs, ATMs and NTMs.  
 
To assess whether SPON2 expression in gastric CAMs is regulated by promoter   
DNA methylation, a pyrosequencing assay was designed in the SPON2 promoter 
region and SPON2 TaqMan assay were performed on an independent set of 
patient-matched gastric CAM and ATM samples, which were cultured and 
processed in parallel. The pyrosequencing assay covers 117bp and is spanning          
7 CpG sites, including 1 CpG that was identified by Illumina 450k array (Figure 5.4B).  
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This pyrosequencing analysis confirmed that the SPON2 promoter region is 
hypomethylated in CAMs when compared to either ATMs or NTMs (Figure 5.4B and 
Figure 5.4C) and qPCR analysis showed that SPON2 expression is upregulated in 
CAMs compared to ATMs (Figure 5.4D) confirming the previous observations 
(Supplementary Figure S5.4 and Figure S5.5). Interestingly, pyrosequencing data 
from this study show that the extent of SPON2 promoter DNA methylation 
gradually changes in gastric stromal myofibroblasts, with low levels in CAMs, 
intermediate levels in patient-matched ATMs and highest levels being observed in 
NTMs (Figure 5.4C). Significantly, these trends show a good negative correlation 
with observed patterns of SPON2 gene expression in these cells (Figure 4.2). Taken 
together, these data provide a strong indication that SPON2 expression may be 
regulated by cancer-induced differential promoter DNA methylation in gastric 
CAMs, ATMs and NTMs. Supplementary Figure S5.2B shows the observed 
correlation between SPON2 expression and promoter methylation assessed by 
qPCR and pyrosequencing analysis.  
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Figure 5.4 DNA methylation in the SPON2 promoter region correlates with SPON2 
gene expression profiles in gastric CAMs and ATMs. A. Differentially methylated CpG 
sites identified by Illumina 450k array in the SPON2 promoter region. Mean β values (n=3) 
for probes identified as differentially methylated in CAM vs ATM and CAM vs NTM 
comparisons are plotted. The X-axis indicates distance of Illumina 450k probes to SPON2 
transcription start site. Position highlighted in magenta is within the genomic region 
examined by pyrosequencing assay. B. Pyrosequencing analysis of the SPON2 promoter 
region in patient-matched CAM (n=7) and ATM (n=7) samples. Methylation means for          
7 individual CpG sites in the interrogated promoter region are plotted. The X-axis indicates 
the chromosomal position of examined CpG sites. Position marked with * corresponds to the 
Illumina 450k probe highlighted in magenta. C. The overall methylation level of the SPON2 
promoter region interrogated by pyrosequencing analysis. Boxplots represent methylation 
distribution and mean for 7 CpG sites in CAM (n=7), ATM (n=7) and NTM (n=4) samples.   
D. Quantitative PCR analysis of SPON2 gene expression in CAM (n=6) and ATM (n=6) 
samples; t-test ****p<0.0001. Error bars represent SEM. 
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5.3.3.4  Promoter hypermethylation may repress ZNF536 
expression in gastric CAMs 
ZNF536 is a zinc finger protein that may be involved in transcriptional regulation, 
negative regulation of neuron differentiation and negative regulation of retinoic 
acid receptor signalling (Qin, Ren et al. 2009). Gene ontology enrichment analysis 
performed in Chapter IV showed that ZNF536 may have a role in advance malignant 
tumour, regulation of developmental process and regulation of signal transduction. 
 
The ZNF536 gene is located on chromosome 19. Genome-wide DNA methylation 
analysis identified several differentially methylated CpG loci between CAMs and 
non-tumour derived myofibroblasts (ATMs and NTMs) that are associated with 
ZNF536 regulation, including 4 CpGs in the promoter region (Figure 5.5A). 
Interestingly, some of these CpGs are classified as cancer-specific differentially 
methylated regions (cDMR) by Illumina annotation. Genome-wide expression 
analysis showed that ZNF536 is downregulated in CAMs compared to both ATMs 
and NTMs (Table 4.1, Figure 4.2). Supplementary Figure S5.6 shows simultaneous 
negative correlation between ZNF536 expression and promoter methylation and 
positive correlation in gene body of ZNF536 in patient-matched CAMs and ATMs, 
whereas Supplementary Figure S5.7 shows correlations in CAMs, ATMs and NTMs.  
 
To assess whether ZNF536 expression in gastric CAMs is regulated by promoter 
DNA methylation, a pyrosequencing assay was designed in ZNF536 promoter region 
and ZNF536 TaqMan assay were performed on an independent set of             
patient-matched gastric CAM and ATM samples, which were cultured and 
processed in parallel. The pyrosequencing assay covers 77bp and is spanning            
3 CpG sites, including 1 CpG that was identified by Illumina 450k array (Figure 5.5B).  
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This pyrosequencing analysis again confirmed the pattern of DNA methylation 
identified by Illumina 450k array in CAMs and non-tumour derived myofibroblasts 
(ATMs and NTMs; Figure 5.5B and Figure 5.5C). Also, qPCR analysis showed that 
ZNF536 expression is downregulated in CAMs compared to ATMs (Figure 5.5D), 
thus confirming previous observations (Supplementary Figure S5.6 and Figure S5.7). 
Notably, DNA methylation of CpG loci located in the promoter region 43bp 
downstream of ZNF536 transcription start site (TSS) was hypermethylated in CAMs 
compared to both ATMs and NTMs (Figure 5.5C). DNA methylation pattern at this 
locus was very similar in ATMs and NTMs thus this locus may represent a potential 
biomarker/signature component for gastric CAMs. Taken together, these 
experimental data provide a strong indication that ZNF536 expression may be 
regulated by promoter DNA methylation, in particular the methylation at CpG 
located 43bp downstream of ZNF536 TSS, in gastric CAMs, ATMs and NTMs. 
Supplementary Figure S5.2C shows the observed correlation between ZNF536 
expression and methylation at the CpG located 43bp downstream of ZNF536 TSS 
assessed by qPCR and pyrosequencing analysis.  
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Figure 5.5 DNA methylation levels within the ZNF536 promoter region correlate with 
ZNF536 gene expression profiles in gastric CAMs and ATMs. A. Differentially 
methylated CpG sites identified by Illumina 450k array in the ZNF536 promoter region. Mean 
β values (n=3) for probes identified as differentially methylated in CAM vs ATM and CAM vs 
NTM comparisons are plotted. The X-axis indicates distance of Illumina 450k probes to 
ZNF536 transcription start site. Position highlighted in magenta is within the genomic region 
examined by pyrosequencing assay. B. Pyrosequencing analysis of the ZNF536 promoter 
region in patient-matched CAM (n=7) and ATM (n=7) samples. Methylation means for          
7 individual CpG sites in the interrogated promoter region are plotted. The X-axis indicates 
chromosomal position of examined CpG sites. Position marked with * corresponds to the 
Illumina 450k probe highlighted in magenta. C. The overall methylation level of the ZNF536 
promoter region interrogated by pyrosequencing analysis. Boxplots represent methylation 
distribution and mean for 3 CpG sites in CAM (n=7), ATM (n=7) and NTM (n=4) samples.   
D. Quantitative PCR analysis of ZNF536 gene expression in CAM (n=6) and ATM (n=6) 
samples; t-test ****p<0.0001. Error bars represent SEM. 
0
2 0
4 0
6 0
8 0
c h r 1 9 : 3 0 ,8 6 3 ,2 6 1  -  3 0 ,8 6 3 ,2 8 2
%
 D
N
A
 m
e
th
y
la
ti
o
n
3
0
8
6
3
2
6
1
*
3
0
8
6
3
2
7
5
3
0
8
6
3
2
8
2
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
c h r1 9 : 3 0 ,7 0 9 ,5 2 7  -  3 0 ,8 6 3 ,3 5 0

 -
 v
a
lu
e
-1
5
3
7
9
1
-1
2
6
8
-4
3
3
1
-1
4
6
1
0
1
C AM   AT M
0
5
1 0
1 5
2 0
R
Q
****
   
      
C AM   AT M   N T M
0
2 0
4 0
6 0
8 0
%
 M
e
th
y
la
ti
o
n
 i
n
d
e
x
   
Validation of DNA Methylation Patterns 
 
 
154 
 
5.3.3.5  DNA hypermethylation may repress the 
expression of FOXF1 and FENDRR in gastric CAMs 
As mentioned in Chapter III (section 3.3.2), genome–wide differential DNA 
methylation analysis between CAMs and non-tumour derived myofibroblasts  
(ATMs and NTMs) was performed at individual CpG loci and genomic regions. Tiling 
analysis is one of the region-level analysis methods used to identify differentially 
methylated regions over the whole genome with a window size of 5 kilobases 
(Supplementary Figure S4.1D). A region on chromosome 16 (ch16: 86,012,085 – 
86,538,511) spanning 526,426bp was identified as one of the largest differentially 
methylated regions in gastric CAM vs ATM and CAM vs NTM comparisons       
(Figure 5.6A and Supplementary Figure S5.8). Notably, a smaller part of this region 
(ch16: 86,528,753 – 86,538,425) spanning 9,673bp was also identified as being 
differentially methylated in a parallel oesophageal CAM vs ATM comparison 
(Supplementary Figure S5.9 and Figure 3.11). Interestingly, many of the CpG loci 
within this region are classified as cancer-specific differentially methylated regions 
(cDMR) by Illumina annotation. Differential DNA methylation within this region may 
regulate the expression of FOXF1 and several long non-coding RNAs (lncRNAs), such 
as LOC146513, LINC00917 and FENDRR.  
 
FOXF1 belongs to the forkhead family of transcription factors; it may play a role in 
embryonic development however the specific function of this gene has not yet 
been determined (Pruitt, Brown et al. 2014). FENDRR is lncRNA that is transcribed 
bidirectionally with FOXF1 on the opposite strand (Pruitt, Brown et al. 2014). 
Significantly, FENDRR was recently found to play a role in the progression of gastric 
cancer (Xu, Huang et al. 2014). 
 
To assess whether FOXF1 and FENDRR expression in gastric CAMs might be 
regulated by DNA methylation within this region, a pyrosequencing assay was 
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designed in FOXF1 promoter region (that overlaps with FENDRR) and TaqMan 
assays for FOXF1 and FENDRR (splice variant 1 and 2) were performed on an 
independent set of patient-matched gastric CAM and ATM samples, which were 
cultured and processed in parallel. The pyrosequencing assay covers 104bp and is 
spanning 8 CpG sites, none of which were present on the Illumina 450k array 
(Figure 5.6B).  
 
This analysis confirms that the FOXF1 promoter region is hypermethylated in CAMs 
when compared to either ATMs or NTMs (Figure 5.6B and Figure 5.6C). In addition, 
qPCR analysis showed that FOXF1 and FENDRR expression are both downregulated 
in CAMs compared to ATMs (Figure 5.6D). Notably, the pyrosequencing analysis 
revealed that the FOXF1 promoter shows a gradual change in DNA methylation 
status (CAMs>ATMs>NTMs) in gastric stromal myofibroblasts (Figure 5.6C). Taken 
together, these data provide a strong indication that FOXF1 and FENDRR expression 
may be regulated by DNA methylation within this region in gastric CAMs and ATMs. 
Supplementary Figure S5.2D shows the observed correlation between FOXF1 
expression and promoter methylation assessed by qPCR and pyrosequencing 
analysis. 
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Figure 5.6 DNA methylation pattern in the genomic region associated with regulation 
of FOXF1 and FENDRR expression in gastric CAMs and ATMs. A. Differentially 
methylated CpG sites identified by Illumina 450k array in the region downstream of the 
FOXF1 transcription start site. Mean β values (n=3) for probes identified as differentially 
methylated in CAM vs ATM and CAM vs NTM comparisons are plotted. The X-axis indicates 
distance of Illumina 450k probes to FOXF1 transcription start site. B. Pyrosequencing 
analysis of the FOXF1 promoter region in patient-matched CAM (n=7) and ATM (n=7) 
samples. Methylation means for 8 individual CpG sites in the interrogated promoter region 
are plotted. The X-axis indicates chromosomal position of examined CpG sites.                   
C. The overall methylation level of the FOXF1 promoter region interrogated by 
pyrosequencing assay. Boxplots represent methylation distribution and mean for 8 CpG 
sites in CAM (n=7), ATM (n=7) and NTM (n=4) samples. D. Quantitative PCR analysis of 
FOXF1 and FENDRR gene expression in CAM and ATM samples; t-test FOXF1 (n=5) 
***p=0.0008; FENDRR v1 (splice variant 1; n=4) ****p<0.0001; FENDRR v2 (splice variant 2; 
n=4) **p=0.0028. Error bars represent SEM. 
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5.4  Discussion 
In order to further investigate correlated DNA methylation and gene expression 
profiles identified in earlier Chapters further pyrosequencing and qPCR studies 
were performed on an additional set of myofibroblast samples derived from gastric 
cancer patients, which were not included in our initial array profiling studies 
(Chapters III and IV). Data from these extended studies provide further strong 
evidence that CAM-specific promoter DNA methylation patterns may regulate the 
expression of associated genes. In addition, pyrosequencing analysis confirmed the 
existence of DNA methylation changes within border genomic regions, spanning 
several neighbouring CpG sites, between gastric CAMs and non-tumour derived 
myofibroblasts (ATMs and NTMs). 
 
The transforming growth factor-β (TGF-β) signalling pathway plays an important 
role in both development, and in the initiation and progression of cancer. It exerts 
various context-dependent effects on both epithelial cancer cells and stromal cells 
(Ikushima and Miyazono 2010, Calon, Tauriello et al. 2014). This study strongly 
suggests that DNA methylation may confer a mechanism for the transcriptional 
regulation of key TGF-β signalling components in gastric CAMs and ATMs.                
In particular, promoter hypermethylation may be associated with SMAD3 
downregulation in gastric CAMs compared to their patient-matched ATMs. Notably, 
the degree of SMAD3 promoter methylation was very similar in ATMs and NTMs, 
thus this genomic region might be used as a proxy for gastric CAMs identification. 
SMAD3 is an important intracellular mediator of TGF-β signalling. Upon TGF-β 
stimulation SMAD3 is activated by receptor-mediated phosphorylation and forms 
complexes with other SMAD proteins, which then are translocated to the nucleus 
where they, in cooperation with other transcription factors, co-activators and       
co-repressors, regulate the transcription of TGF-β-responsive genes. The activity 
and stability of SMAD proteins are carefully regulated by a plethora of                 
post-translational modifications (Heldin and Moustakas 2012). Significantly, a 
previous study in Smad3-null mice showed accelerated wound healing and an 
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impaired local inflammatory response (Ashcroft, Yang et al. 1999) consistence with 
CAM tumour-promoting properties. In addition, genome-wide DNA methylation 
analysis identified several differentially methylated CpG loci between CAMs and 
ATMs that are associated with TGFBR2 (the type II TGF-β receptor) regulation.        
In particular, the integration analysis (presented in Chapter IV) revealed that 
TGFBR2 is downregulated in CAMs compared to ATMs (TGFBR2 downregulation is 
also reported in previous gene expression study on 12 patient-matched CAMs and 
ATMs, Supplementary Figure S4.1) and its transcriptional repression might be 
mediated by simultaneous hypermethylation in promoter region and 
hypomethylation in gene-body (Figure 4.8). TGFBR2 is critical for initiation of the 
TGF-β signalling cascade therefore loss of this protein abrogates TGF-β signalling. 
Bhowmick et al. generated mice in which TGFBR2 was selectively ablated in stromal 
fibroblasts and demonstrated that upon loss of TGFβ responsiveness in stromal 
fibroblasts, these mice spontaneously developed neoplastic lesions which were 
accompanied by stromal expansion (Bhowmick, Chytil et al. 2004). Interestingly, 
components of TGF-β signalling pathway, including receptors (TGFBR2) and 
transcription factors (SMAD4), are often inactivated and silenced in cancer (Grady 
and Markowitz 2002) indicating that CAMs might acquire some of the cancer-like 
phenotype. Together, these data show that cancer-induced DNA methylation 
changes in CAMs might affect the expression of key TGF-β signalling components 
resulting in a possible weakened TGFβ-TGFβR2-SMAD3 signalling axis in gastric 
CAMs compared to their patient-matched ATMs.  
 
Long non-coding RNAs (lncRNAs) have recently emerged as important regulators of 
a wide variety of biological processes, including epigenetic silencing, transcriptional 
regulation, RNA processing, and RNA modification (Mercer, Dinger et al. 2009). 
Their aberrant expression has been reported in various cancers, including gastric 
cancer (Fang, Pan et al. 2015, Gu, Chen et al. 2015). DNA methylation is one of the 
mechanisms regulating the expression of lncRNAs (Lujambio, Portela et al. 2010). A 
recent study in breast cancer showed that aberrant DNA methylation patterns in 
the promoters of non-coding RNAs (microRNAs and lncRNAs) are more frequent 
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than aberrant DNA methylation patterns in promoters of protein-coding genes (Li, 
Zhang et al. 2015). The authors also predicted the potential biological functions of 
these aberrantly methylated non-coding RNAs and suggested that non-coding RNAs 
and protein-coding genes cooperatively mediate pathway dysregulation during the 
development and progression of breast cancer (Li, Zhang et al. 2015).  
 
In this study, the genomic region associated with the regulation of FENDRR and 
FOXF1 was investigated in detail in order to assess if there is a correlation between 
differential DNA methylation and expression of these genes in gastric CAMs and 
ATMs. FENDRR (FOXF1 adjacent non-coding developmental regulatory RNA) is 
lncRNA transcribed bidirectionally with FOXF1 on the opposite strand. It binds to 
polycomb repressive complex 2 (PRC2) to epigenetically regulate the expression of 
its target gene (Grote, Wittler et al. 2013). FOXF1 (forkhead box-F1) is a 
transcription factor that plays a key role in regulating embryonic development 
(Mahlapuu, Ormestad et al. 2001) and mesenchymal-epithelial interaction in lung 
and gut morphogenesis (Mahlapuu, Enerback et al. 2001). It has been suggested 
that FOXF1 may function as a tumour suppressor as it is inactivated by                 
DNA methylation in breast cancer (Lo, Lee et al. 2010) and its low expression was 
also reported in prostate cancer (Watson, Doggett et al. 2004). The experimental 
data presented in this Chapter showed that DNA hypermethylation within the 
interrogated region may lead to transcriptional repression and reduced expression 
of FENDRR and FOXF1 in gastric CAMs. Interestingly, this genomic region is 
commonly hypermethylated in gastric cancer (Supplementary Figure S5.10 and 
Figure S5.11) suggesting that CAMs might also acquire some of the cancer-like   
DNA methylation patterns. Supplementary Figure S5.10 shows gastric cancer cell 
lines data for the FOXF1 promoter region interrogated by pyrosequencing in AGS 
and MKN45 cells, whereas Supplementary Figure S5.11 represents stomach 
adenocarcinoma data from the Cancer Genome Atlas (TCGA) corresponding to the 
wider differentially methylated region identified by Illumina 450k array in CAMs 
compared to either ATMs or NTMs (as shown in Figure 5.6A). 
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Significantly, Xu et al. showed that FENDRR regulates gastric cancer metastasis and 
is downregulated in gastric cancer cells compared to normal gastric epithelial cells. 
Low expression of FENDRR was significantly correlated with poor prognosis and 
aggressive tumour characteristics, such as greater invasion depth, higher tumour 
stage, and lymphatic metastasis (Xu, Huang et al. 2014). Saito et al. demonstrated 
that FOXF1 regulates tumour-promoting properties of lung cancer-associated 
fibroblasts (CAFs), including upregulation of α-SMA, secretion of paracrine growth 
factors, induction of contractile and migration-stimulatory properties, and in vivo 
pro-tumorigenic effects. Using FOXF1 gain-and loss-of-function fibroblasts, they 
showed that FOXF1 controls the expression of hepatocyte growth factor (HGF) and 
fibroblast growth factor-2 (FGF-2), well-established CAM-derived stimulators of 
tumour growth. The expression of these factors was upregulated in FOXF1 
transduced cells and downregulated in the cells where FOXF1 was silenced (Saito, 
Micke et al. 2010). Interestingly, HGF was found to be downregulated in CAMs 
compared to ATMs in a gene-wide expression study presented in Chapter IV which 
is in agreement with lower FOXF1 expression in these cells. Together, these data 
suggest that cancer-induced DNA hypermethylation within the interrogated region 
in gastric CAMs may affect the expression of FENDRR and FOXF1 resulting in 
possible more aggressive cancer phenotype.  
 
The correlation analysis of the genome-wide DNA methylation and gene expression 
profiles in gastric CAMs compared to ATMs revealed that promoter 
hypomethylation in gastric CAMs may be an important mechanism for 
transcriptional activation of genes associated with extracellular region and 
exosomes. In this Chapter the SPON2 and VPS28 promoter regions were analysed 
by pyrosequencing. SPON2 and VPS28 were both identified as components of the 
extracellular vesicular exosomes as reported in ExoCarta database (Mathivanan, 
Fahner et al. 2012). SPON2 is an extracellular matrix protein that has been 
implicated in axon guidance, cell adhesion and cellular response to 
lipopolysaccharide, whereas VPS28 is part of the endosomal complexes that 
function in the transport and sorting of proteins into subcellular vesicles. SPON2 
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was detected in exosomes derived from prostate cancer cells, whereas VPS28 was 
detected in exosomes derived from multiple cancer types, including bladder, 
colorectal, melanoma, ovarian and prostate cancer. Pyrosequencing data from this 
study confirmed that SPON2 and VPS28 promoter regions are hypomethylated in 
gastric CAMs compared to either ATMs or NTMs (Figure 5.4 and Figure 5.2C).          
In addition, the qPCR analysis revealed that promoter hypomethylation may 
transcriptionally induce SPON2 expression in gastric CAMs. Notably, the 
methylation pattern of SPON2 promoter shows inverse correlation with the 
expression of SPON2 in CAMs, ATMs and NTMs with SPON2 being   
hypomethylated-induced in CAMs and hypermethylated-repressed in NTMs   
(Figure 5.4C, Figure 5.4D and Figure 4.2). This observation was also confirmed at  
the protein level (Chapter VI section 6.3.4). Comparative CAM vs NTM secretome 
profiling revealed that SPON2 protein was upregulated 3 fold in the CAM secretome 
compared to the NTM secretome.  
 
Gene ontology enrichment analysis of differentially methylated loci identified in 
gastric CAMs vs ATMs revealed that many of these differentially methylated loci 
might regulate genes involved in nervous system development and neurogenesis 
(Table 3.1). ZNF536 is a zinc finger protein that is specifically expressed in the brain 
and negatively regulates neuron differentiation by repressing retinoic acid-induced 
gene transcription. Overexpression of ZNF536 results in an inhibition of neuronal 
differentiation, while depletion or mutation of the ZNF536 gene results in enhanced 
differentiation (Qin, Ren et al. 2009). Genome-wide DNA methylation analysis 
identified several differentially methylated CpG loci between CAMs and               
non-tumour derived myofibroblasts (ATMs and NTMs) that are associated with 
regulation of this gene. Pyrosequencing analysis in ZNF536 promoter region showed 
that hypermethylation at CpG located 43bp downstream of ZNF536 transcription 
start site may repress ZNF536 expression in gastric CAMs as shown by qPCR 
analysis. Together, these observations suggest that gastric CAMs might exhibit 
some of the reported neuronal phenotypes.  
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In summary, the experimental data obtained using pyrosequencing and qPCR 
analysis performed on a larger set of patient CAM and ATM samples show for the 
first time that cancer-induced DNA methylation changes in gastric stromal 
myofibroblasts may have a functional role in regulating the expression of associated 
genes. In some instances these DNA methylation changes may prove to be useful 
signatures, which may be used in combination as molecular biomarkers for gastric 
CAMs identification, or patient stratification. In addition, the pyrosequencing 
analysis confirmed the DNA methylation patterns identified by Illumina 450k array 
in CAMs and non-tumour derived myofibroblasts (ATMs and NTMs). 
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Chapter VI 
Effects of Hypoxia on Gene Expression and 
Secretion of Pro-tumorigenic Factors in Gastric 
Stromal Myofibroblasts 
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6.1  Introduction 
Tumour hypoxia is another important microenvironmental factor contributing to 
aspects of tumour progression including tissue invasion and metastatic spread. As 
tumours grow and increase size sub-populations of both cancer cells and stromal 
cells are exposed to hypoxia. Reduced oxygen availability activates hypoxia-
inducible factors (HIFs), which turn on transcription of target genes, which encode 
proteins that play important roles in many aspects of cancer biology (Kaelin and 
Ratcliffe 2008, Casazza, Di Conza et al. 2014). A lot of effort has been devoted to 
studying the consequences of tumour hypoxia on cancer cells but relatively little is 
known about hypoxia-induced effects on the stromal component of the tumour 
microenvironment, including CAMs. Previously, it was proposed that hypoxia may 
have a role in modulating the differentiation and activity of these cells (Giaccia and 
Schipani 2010). Data presented in previous Chapters provide strong evidence for 
the existence of robustly maintained CAM-specific DNA methylation signatures. 
However, the extent to which exposure to hypoxia may contribute to or change 
myofibroblast epigenetic programing remains unexplored.    
 
Hypoxia is strongly associated with tumour progression, metastasis and resistance 
to therapy. Comito et al. demonstrated that stromal fibroblasts synergize with 
hypoxic oxidative stress to enhance melanoma aggressiveness. In this context, 
hypoxia-mediated oxidative stress was found to be mandatory for the activation of 
dermal ﬁbroblasts and secretion of cytokines and pro-migratory factors, as well as 
actively promoting the invasion and chemotaxis of melanoma cells (Comito, 
Giannoni et al. 2012). 
 
In this study, we attempt to address some of the outstanding questions relating to 
the modulation of stromal myofibroblast activity under hypoxic conditions. In 
particular: Does hypoxia induce a more aggressive CAM phenotype?; Do NTMs 
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become more aggressive or CAM-like under hypoxic conditions?; If so do DNA 
methylation patterns also change?; Does hypoxia induce common or selective 
changes in CAM, ATM and NTM gene expression profiles?; and finally, does hypoxia 
have a differential effect on the composition of CAM and NTM secretome profiles?  
 
In order to address these questions, an integrated multi-omics approach was used 
to obtain complementary data from primary gastric patient-matched CAM and ATM 
and unrelated NTM samples cultured under hypoxic or normoxic conditions. Firstly, 
the relative ability of secreted factors derived from hypoxic CAMs and NTMs to 
induce the migration and/or proliferation of AGS gastric cancer cells was measured. 
Genome-wide hypoxia-induced DNA methylation and gene expression profiles of 
CAMs, ATMs and NTMs used in these studies were explored using Illumina Infinium 
HumanMethylation450 BeadChip and Illumina HumanHT-12v4 Expression BeadChip 
arrays. Samples for both DNA methylation and gene expression were prepared in 
parallel in order to minimize technical artefacts. Finally, conditioned media from 
hypoxic CAMs and hypoxic NTMs were profiled by LC-MS/MS to identify 
myofibroblast secretome signatures that may contribute to hypoxia-induced CAM 
and NTM phenotype/properties. 
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6.2  Aims 
 To determine the relative ability of conditioned media (CM) from hypoxic 
CAMs or hypoxic NTMs to enhance cancer cell migration and proliferation 
 To identify hypoxia-induced gene expression signatures in gastric CAMs, 
ATMs and NTMs 
 To determine whether hypoxia - induced changes in CAMs, ATMs and NTMs 
gene expression profiles may be regulated by DNA methylation 
 To predict the relative biological effects of hypoxia on CAMs, ATMs and 
NTMs  
 To identify secreted proteins which may contribute to the pro-migratory and 
proliferative effects of hypoxic CAMs and NTMs based on their hypoxia-
induced gene expression signatures  
 To identify and quantify CAM and NTM hypoxia-induced secretomes 
 To correlate CAM and NTM hypoxia-induced gene expression and secretome 
profiles 
 To identify pathways and processes that may contribute to CAM-like 
properties of hypoxic NTMs. 
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6.3  Results 
6.3.1  Hypoxia enhances CAM-induced cancer cell 
migration and promotes CAM-like properties in NTMs 
Boyden chamber migration assays and EdU cell proliferation assays were used to 
assess the effects of hypoxia (1% O2) on the ability of CAMs or NTMs to enhance 
AGS cell migration or proliferation. AGS cell migration and proliferation assays were 
performed in parallel with fresh CAM or NTM conditioned media (CM) prepared 
under both hypoxic (hypoxic-CM) and normoxic (ctrl-CM) conditions (as described 
in Methods section 2.4.2 and section 2.5).  
 
6.3.1.1  Gastric cancer cell migration assays 
CAM and NTM conditioned media prepared under hypoxic conditions     
(CAM/NTM-hypoxic-CM) was found to enhance AGS cell migration compared to 
corresponding control conditioned media prepared under normoxic conditions 
(CAM/NTM-ctrl-CM) (Figure 6.1A) thereby demonstrating that hypoxia induces the 
expression of factors that enhance gastric cancer cell migration. Significantly, the 
group mean data of AGS cell migration assays show that the pro-migratory effect of 
CAM-hypoxic-CM is higher than that observed for NTM-hypoxic-CM (Figure 6.1B).  
 
6.3.1.2  Gastric cancer cell proliferation assays 
Data from this study show that both CAM and NTM conditioned media prepared 
under hypoxic conditions (CAM/NTM-hypoxic-CM) exert different effects on       
AGS cell proliferation compared to their respective control conditioned media 
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prepared in normal condition (CAM/NTM-ctrl-CM). Interestingly, our data shows 
that CAM-hypoxic-CM reduces AGS cell proliferation, whereas NTM-hypoxic-CM 
increases AGS cell proliferation when compared to their respective control 
conditioned media prepared in normal condition (CAM/NTM-ctrl-CM) (Figure 6.1C). 
Together these results indicate that hypoxia has a differential effect on the 
expression of cancer cell pro-proliferative factors in gastric CAMs and NTMs.  
 
6.3.2  Identification of hypoxia-induced gene expression 
signatures in gastric CAMs, ATMs and NTMs 
To identify hypoxia-induced gene expression signatures in gastric myofibroblasts 
purified from different tissue microenvironments Illumina HumanHT-12v4 
Expression BeadChip arrays were perform on three patient-matched CAM and ATM 
samples and three independent NTM samples, all of which were exposed to either 
hypoxia (1% O2) or normoxia (21% O2) for 72 hours (as described in Methods 
section 2.3.2) resulting in 13381 expressed genes. Differential gene expression 
analysis was then performed between hypoxic and control myofibroblasts, resulting 
in the identification of: (i) 2467 genes that were consistently differentially 
expressed in hypoxic CAMs compared to control CAMs (Figure 6.2A); (ii) 2722 genes 
that were constantly differentially expressed in hypoxic NTMs compared to control 
NTMs (Figure 6.2B) and (iii) 2561 genes that were constantly differentially 
expressed in hypoxic ATMs compared to control ATMs (Figure 6.2C). 
 
 
 
 
Effects of Hypoxia on Gene Expression and Secretion of Pro-tumorigenic Factors in Gastric 
Stromal Myofibroblasts 
 
 
169 
 
c
tr
l
C
A
M
 1
9
2
C
A
M
 3
0
8
C
A
M
 3
0
5
N
T
M
 2
6
1
N
T
M
 2
7
9
N
T
M
 3
3
4
0
5 0
1 0 0
1 5 0
2 0 0
H y p o x ic  C o n d itio n e d  M e d ia
%
 A
G
S
 p
r
o
li
fe
r
a
ti
o
n
c
tr
l
C
A
M
 1
9
2
C
A
M
 3
0
8
C
A
M
 3
0
5
N
T
M
 2
6
1
N
T
M
 2
7
9
N
T
M
 3
3
4
0
2 0 0
4 0 0
6 0 0
H y p o x ic  C o n d itio n e d  M e d ia
%
 A
G
S
 m
ig
r
a
ti
o
n
C A M
h yp o x ic  C M
N T M
h yp o x ic  C M
0
2 0 0
4 0 0
6 0 0
%
 A
G
S
 m
ig
r
a
ti
o
n
C A M
h yp o x ic  C M
N T M
h yp o x ic  C M
0
5 0
1 0 0
1 5 0
2 0 0
%
 A
G
S
 p
r
o
li
fe
r
a
ti
o
n
A .
C .
B .
D .
 
Figure 6.1 Differential effects of CAM / NTM hypoxic conditioned media (CM) on AGS 
gastric cancer cell migration or proliferation. A & B. CAM-hypoxic-CM (magenta) and 
NTM-hypoxic-CM (navy) induce AGS cell migration compared to respective CAM or NTM 
normoxic-control CM (grey). A. Individual patient data corrected for AGS basal migration 
(serum-free media) normalized to respective patient-specific control CM obtained from 
normoxia, t-test p-value<0.05; Error bars represent SEM of technical replicates. B. Group 
mean data of AGS cell migration in response to hypoxic-CM from CAMs (n=3) and NTMs 
(n=3). Error bars represent SEM. C & D. NTM-hypoxic-CM (navy) induces AGS cell 
proliferation whereas CAM-hypoxic-CM (magenta) reduces the ability of AGS cells to 
proliferate compared to respective CAM or NTM control CM (grey) obtained from normoxia.  
C. Individual patient data corrected for AGS basal proliferation (serum-free media) and 
normalized to respective patient-specific control CM obtained from normoxia (NTM-hypoxic-
CM vs NTM-ctrl-CM t-test p-value<0.05). Error bars represent SEM of technical replicates. 
D. Group mean data of AGS cell proliferation in response to hypoxic-CM from CAMs (n=3) 
and NTMs (n=3). Error bars represent SEM. 
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Figure 6.2 Hypoxia-induced gene expression signatures in gastric myofibroblasts 
purified from different tissue microenvironments. A. CAM hypoxia vs CAM normoxia    
B. NTM hypoxia vs NTM normoxia. C. ATM hypoxia vs ATM normoxia. Volcano plots 
represent differentially expressed genes in respective comparisons; FDR p-value < 0.05 
adjusted genes are shown in black; dashed lines 1.6 fold change. Heatmaps represent 
differentially expressed genes with FDR p-value < 0.05 (shown in black in volcano plots). 
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6.3.2.1  Differential hypoxia-induced myofibroblast 
phenotypes are not due to induced changes in                     
DNA methylation profiles 
To assess whether hypoxia induces DNA methylation changes in gastric 
myofibroblast cells Illumina Infinium HumanMethylation450 BeadChip arrays were 
performed on the same CAM (cancer), ATM (adjacent tissue) and NTM (normal 
tissue) patient samples used in Illumina HT-12 array studies (section 6.3.2). Cultures 
of primary myofibroblasts for use in both expression and methylation arrays were 
prepared in parallel and were exposed to either hypoxia (1% O2) or               
normoxia (21% O2) for 72 hours (as described in Methods section 2.3.2). 
 
Comparative genome–wide differential DNA methylation analyses performed 
between (i) CAM hypoxia vs CAM normoxia, (ii) ATM hypoxia vs ATM normoxia and 
(iii) NTM hypoxia vs NTM normoxia showed a striking similarity in DNA methylation 
profiles between matched hypoxia-treated and control samples (Figure 6.3). These 
data suggest that exposure to hypoxic conditions did not induce significant 
alterations in DNA methylation patterns, although differential hypoxia-induced 
gene expression profiles were observed in different myofibroblast populations. 
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Figure 6.3 Comparative global DNA methylation profiles of primary gastric 
myofibroblasts following exposure to hypoxic or normoxic conditions. A. Volcano plot 
showing significance versus Δβ values for 424383 methylation probes in hypoxia vs 
normoxia comparison (n=9). B. Scatter plot representing mean β values for normoxic and 
hypoxic myofibroblasts (n=9). Red dashed lines represent |Δβ|>0.2.  
 
 
6.3.3 Potential biological significance of hypoxia-induced 
gene expression signatures in CAMs, ATMs and NTMs 
Although cells appear to react to hypoxia via a common HIF-1 mediated 
mechanism (Wang, Jiang et al. 1995, Semenza 1998), net functional responses may 
be influenced by cell - type specific variations in epigenetic programming. With 
respect to gastric myofibroblasts, although DNA methylation profiles do not change 
in response to hypoxia, different myofibroblast populations have distinct patterns 
of DNA methylation, which may confer functional differences in their responses to 
hypoxia. Therefore, in order to identify common and population specific changes,       
hypoxia–induced gene expression profiles for CAMs, ATMs and NTMs, were 
systematically compared (Figure 6.4), in order to predict both common and distinct 
functional changes.  
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Figure 6.4 Comparison of hypoxia-induced gene expression signatures identified in 
gastric CAMs, ATMs and NTMs. Overlapping intersections represent common gene 
expression changes induced by hypoxia in stromal myofibroblasts. Unique CAM-, ATM- and 
NTM- hypoxia-induced gene signatures are shown in bold.  
 
6.3.3.1  Universal hypoxia-induced gene expression 
signatures in CAMs, ATMs and NTMs 
To establish if the overlapping gene profiles are associated with known universal 
hypoxia-induced biological processes, gene ontology (GO) and gene set (GSEA) 
enrichment analyses were performed on the universal hypoxia-induced gene 
subgroup identified in all three hypoxia vs normoxia comparisons (for CAMs, ATMs 
and NTMs). Supplementary Figure S6.1 shows that these genes are changed in the 
same direction in all myofibroblast types. The GO and GSEA analysis showed that 
various metabolic processes, characteristic for hypoxic cells, are universally altered 
in CAMs, ATMs and NTMs under hypoxia (Figure 6.5, Figure 6.6 and Table 6.1).  
 
            
                        
 02 
30  
    
    382 
   3 
     
Effects of Hypoxia on Gene Expression and Secretion of Pro-tumorigenic Factors in Gastric 
Stromal Myofibroblasts 
 
 
174 
 
 
 
0 5 1 0 1 5 2 0
p ro to n  t ra n s p o rt
R N A  p h o s p h o d ie s te r b o n d  h y d ro ly s is
re s p o n s e  to  h y p o x ia
o rg a n ic  s u b s ta n c e  c a ta b o lic  p ro c e s s
o rg a n ic  s u b s ta n c e  m e ta b o lic  p ro c e s s
a m in o  a c id  a c t iva t io n
4 -h y d ro x y p ro lin e  m e ta b o lic  p ro c e s s
n c R N A  p ro c e s s in g
p o s it ive  re g u la t io n  o f c e ll  d e a th
c e llu la r m e ta b o lic  p ro c e s s
n u c le o b a s e -c o n ta in in g  s m a ll m o le c u le  m e ta b o lic  p ro c e s s
fru c to s e  m e ta b o lic  p ro c e s s
m e ta b o lic  p ro c e s s
s in g le -o rg a n is m  b io s y n th e t ic  p ro c e s s
s in g le -o rg a n is m  m e ta b o lic  p ro c e s s
n c R N A  m e ta b o lic  p ro c e s s
c a rb o h y d ra te  c a ta b o lic  p ro c e s s
g e n e ra t io n  o f p re c u rs o r m e ta b o lit e s  a n d  e n e rg y
s m a ll m o le c u le  m e ta b o lic  p ro c e s s
o rg a n o n it ro g e n  c o m p o u n d  m e ta b o lic  p ro c e s s
m o n o s a c c h a rid e  b io s y n th e t ic  p ro c e s s
o rg a n ic  a c id  m e ta b o lic  p ro c e s s
o x id a t io n -re d u c t io n  p ro c e s s
A TP  m e ta b o lic  p ro c e s s
n u c le o t id e  p h o s p h o ry la t io n
n u c le o s id e  d ip h o s p h a te  m e ta b o lic  p ro c e s s
c o fa c to r m e ta b o lic  p ro c e s s
o x id o re d u c t io n  c o e n z y m e  m e ta b o lic  p ro c e s s
p y rid in e -c o n ta in in g  c o m p o u n d  m e ta b o lic  p ro c e s s
A D P  m e ta b o lic  p ro c e s s
N A D H  m e ta b o lic  p ro c e s s
g ly c o ly t ic  p ro c e s s
- lo g 1 0 (p -v a lu e )
 
Figure 6.5 Universal changes induced by hypoxia in gastric CAMs, ATMs and NTMs. 
Gene ontology (GO) biological process (BP) terms associated with genes that are 
universally changed under hypoxia in the same direction in CAMs, ATMs and NTMs. Only 
GO terms with FDR q-value <0.05 are shown.  
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Figure 6.6 GSEA enrichment plots for the most significantly enriched A. hallmark gene set 
(h.all) and B. canonical pathway (c2.cp) gene set presented in Table 6.1. ES - Enrichment 
Score, NES – Normalized Enrichment Score 
 
Table 6.1 GSEA result summary. Significantly enriched hallmark gene sets (h.all) and 
canonical pathways (c2.cp) are listed for universal CAM, ATM and NTM gene expression 
profiles, FDR q-value <0.05. ES - Enrichment Score, NES – Normalized Enrichment Score 
A. B.ES=0.75 ES=0.77
NORMOXIANORMOXIAHYPOXIA HYPOXIA
NES=3.45 NES=2.67
 
Phenotype GENE SET NAME SIZE ES NES p-value FDR 
h
.a
ll 
Hypoxia HALLMARK_HYPOXIA 43 0.75 3.45 0 0 
Hypoxia HALLMARK_GLYCOLYSIS 35 0.62 2.72 0 0 
Normoxia HALLMARK_UNFOLDED_PROTEIN_RESPONSE 17 -0.55 -2.04 4.65E-03 7.75E-03 
Normoxia HALLMARK_P53_PATHWAY 21 -0.46 -1.86 4.91E-03 1.28E-02 
Hypoxia HALLMARK_MTORC1_SIGNALING 44 0.38 1.78 6.70E-03 2.27E-02 
Hypoxia HALLMARK_IL2_STAT5_SIGNALING 23 0.45 1.69 1.43E-02 3.23E-02 
c 
.c
p
 
Hypoxia REACTOME_GLUCOSE_METABOLISM 17 0.77 2.67 0 0 
Hypoxia 
REACTOME_METABOLISM_OF_CARBOHYDRAT
ES 
26 0.65 2.60 0 0 
Hypoxia KEGG_GLYCOLYSIS_GLUCONEOGENESIS 19 0.69 2.53 0 0 
Normoxia 
REACTOME_METABOLISM_OF_AMINO_ACIDS
_AND_DERIVATIVES 
17 -0.55 -2.06 2.43E-03 2.95E-03 
Hypoxia NABA_MATRISOME 18 0.54 1.91 3.58E-03 1.06E-02 
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6.3.3.2  Unique CAM, ATM and NTM hypoxia-induced 
gene expression signatures 
Unique hypoxia-induced gene expression signatures identified in gastric CAMs, 
ATMs and NTMs were subjected to gene ontology (GO) analysis, gene set 
enrichment analysis (GSEA) and Ingenuity pathway analysis (IPA), in order to 
identify hypoxia-induced processes that may contribute to the observed effects of 
CAM-hypoxic-CM and NTM-hypoxic-CM on cancer cell migration and proliferation 
(Figure 6.1), and also to shed light on the broader spectrum of hypoxia-induced 
functional changes in these cells. 
 
6.3.3.2.1  Gene ontology enrichment analysis 
Gene ontology (GO) biological process (BP) enrichment analysis was performed on 
unique hypoxia-induced gene expression signatures identified in CAMs, ATMs and 
NTMs using Gene Ontology enRIchment anaLysis and visuaLizAtion tool (GOrilla) 
(Eden, Navon et al. 2009). All 13381 genes expressed in myofibrobalst cells were 
used as a reference set. The results from the respective GO analyses for CAMs, 
ATMs and NTMs are presented in Table 6.2. 
 
 
 
 
 
 
 
Effects of Hypoxia on Gene Expression and Secretion of Pro-tumorigenic Factors in Gastric 
Stromal Myofibroblasts 
 
 
177 
 
Table 6.2 Gene ontology (GO) biological process (BP) enrichment for unique   
hypoxia-induced gene expression signatures identified in CAMs, ATMs or NTMs.     
GO terms with FDR q-value <0.05 are highlighted in bold. 
 
GO ID GO biologicl process (BP) term p-value 
CAM GO:0006695 cholesterol biosynthetic process 1.40E-11 
GO:0008299 isoprenoid biosynthetic process 1.85E-05 
GO:0048679 regulation of axon regeneration 2.90E-04 
GO:0060011 Sertoli cell proliferation 4.88E-04 
GO:0009448 gamma-aminobutyric acid metabolic process 4.88E-04 
GO:0008202 steroid metabolic process 6.62E-04 
ATM GO:0044764 multi-organism cellular process 1.16E-05 
GO:0044267 cellular protein metabolic process 6.71E-05 
GO:0071360 cellular response to exogenous dsRNA 6.38E-05 
GO:0043412 macromolecule modification 8.45E-05 
GO:0016032 viral process 8.78E-06 
GO:0006464 cellular protein modification process 5.40E-05 
GO:0043122 regulation of I-kappaB kinase/NF-kappaB signalling 1.22E-04 
GO:0019538 protein metabolic process 1.18E-04 
GO:0044419 interspecies interaction between organisms 5.14E-05 
GO:0010324 membrane invagination 1.45E-04 
GO:0044260 cellular macromolecule metabolic process 4.51E-05 
GO:0051704 multi-organism process 1.83E-04 
GO:1903047 mitotic cell cycle process 2.54E-04 
GO:0051017 actin filament bundle assembly 3.13E-04 
GO:0040029 regulation of gene expression, epigenetic 4.09E-04 
GO:0010660 regulation of muscle cell apoptotic process 4.47E-04 
GO:0045087 innate immune response 5.07E-04 
GO:0030522 intracellular receptor signalling pathway 6.80E-04 
GO:0042059 
negative regulation of epidermal growth factor receptor 
signalling pathway 
9.07E-04 
GO:2000653 regulation of genetic imprinting 9.99E-04 
GO:0050851 antigen receptor-mediated signalling pathway 9.73E-04 
GO:0043170 macromolecule metabolic process 9.03E-04 
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Table 6.2 (Continued) Gene ontology (GO) biological process (BP) enrichment for 
unique hypoxia-induced gene expression signatures identified in CAMs, ATMs or 
NTMs. GO terms with FDR q-value <0.05 are highlighted in bold. 
 
GO ID GO biologicl process (BP) term p-value 
NTM GO:0034641 cellular nitrogen compound metabolic process 3.94E-06 
GO:0006807 nitrogen compound metabolic process 5.59E-06 
GO:0006139 nucleobase-containing compound metabolic process 2.93E-05 
GO:1901137 carbohydrate derivative biosynthetic process 8.49E-05 
GO:0090304 nucleic acid metabolic process 8.57E-05 
GO:0046483 heterocycle metabolic process 8.92E-05 
GO:0051252 regulation of RNA metabolic process 1.14E-04 
GO:0009058 biosynthetic process 1.20E-04 
GO:0010648 negative regulation of cell communication 1.29E-04 
GO:0009968 negative regulation of signal transduction 1.48E-04 
GO:0006725 cellular aromatic compound metabolic process 1.51E-04 
GO:1901576 organic substance biosynthetic process 2.77E-04 
GO:1901360 organic cyclic compound metabolic process 3.09E-04 
GO:0051171 regulation of nitrogen compound metabolic process 3.28E-04 
GO:0048585 negative regulation of response to stimulus 3.39E-04 
GO:0045786 negative regulation of cell cycle 3.76E-04 
GO:0023057 negative regulation of signalling 4.11E-04 
GO:0006750 glutathione biosynthetic process 4.34E-04 
GO:0006575 cellular modified amino acid metabolic process 6.32E-04 
GO:0044260 cellular macromolecule metabolic process 6.78E-04 
GO:0006309 apoptotic DNA fragmentation 7.41E-04 
GO:0035878 nail development 8.88E-04 
GO:0044238 primary metabolic process 9.40E-04 
GO:0006488 dolichol-linked oligosaccharide biosynthetic process 9.55E-04 
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6.3.3.2.2  Gene set enrichment analysis 
Unique CAM, ATM or NTM hypoxia-induced gene expression signatures were 
subjected to gene set enrichment analysis (GSEA) (Mootha, Lindgren et al. 2003, 
Subramanian, Tamayo et al. 2005) using the hallmark gene set subcollection from 
Molecular Signatures Database (MSigDB v5.0) to characterize biological states and 
processes that are unique for CAMs, ATMs or NTMs under hypoxic conditions. 
Results from these GSEA analyses are presented in Table 6.3 and representative 
GSEA enrichment plots for the most significant hallmark gene sets for each dataset 
are presented in Figure 6.7. In addition, Leading Edge Analyses (LEA) were 
performed on enriched gene sets from the complete MSigDBv5.0 collection 
obtained for unique CAM, ATM and NTM hypoxia-induced gene expression profiles, 
in order to identify genes that may have a key role in each of the three analysed 
phenotypes. The respective LEA results for CAMs, ATMs and NTMs are presented in 
Supplementary S6 (section S6.2, Table S6.1). 
 
6.3.3.2.3  Pathway analysis 
The unique hypoxia-induced gene profiles from respective hypoxia vs normoxia 
comparisons were subjected to Ingenuity Pathway Analysis (IPA), in order to 
identify CAM-, ATM- and NTM- specific pathways that are changed in response to 
hypoxic conditions.  In each case expression profiles were compared against the IPA 
predefined Illumina HT-12v4 reference set. Top 10 most significant pathways 
identified for respective unique hypoxia-induced gene profiles are presented in 
Figure 6.8. 
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Figure 6.7 GSEA enrichment plots for the most significantly enriched hallmark gene sets presented in Table 6.3. The most significant hallmark gene set for 
A. CAM unique hypoxia-induced gene expression profile; B. ATM unique hypoxia-induced gene expression profile; C. NTM unique hypoxia-induced gene 
expression profile. ES - Enrichment Score, NES – Normalized Enrichment Score 
 
 
C.A. B.ES=0.702 ES= 0.609ES= 0.581
HYPOXIA NORMOXIA HYPOXIA NORMOXIAHYPOXIA NORMOXIA
NES=2.72 NES=2.29NES=2.55
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Table 6.3 GSEA result summary. Significantly enriched hallmark gene sets are listed for CAM, ATM and NTM unique hypoxia-induced gene expression 
profiles, FDR q-value <0.05. ES - Enrichment Score, NES – Normalized Enrichment Score 
 
Phenotype HALLMARK GENE SET NAME SIZE ES NES p-value FDR 
CAM Hypoxia HALLMARK_CHOLESTEROL_HOMEOSTASIS 23 0.70 2.72 0 0 
Hypoxia HALLMARK_MTORC1_SIGNALING 25 0.61 2.41 0 0 
Hypoxia HALLMARK_FATTY_ACID_METABOLISM 19 0.53 1.96 0 5.17E-03 
Hypoxia HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION 16 0.53 1.90 4.62E-03 8.79E-03 
Hypoxia HALLMARK_E2F_TARGETS 19 0.46 1.71 1.80E-02 3.36E-02 
ATM Hypoxia HALLMARK_G2M_CHECKPOINT 23 0.58 2.55 0 0 
Hypoxia HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION 16 0.62 2.40 0 0 
Hypoxia HALLMARK_E2F_TARGETS 23 0.46 2.06 0 5.33E-03 
Hypoxia HALLMARK_MITOTIC_SPINDLE 24 0.42 1.92 1.14E-02 1.49E-02 
Hypoxia HALLMARK_APICAL_JUNCTION 26 0.38 1.73 1.62E-02 4.15E-02 
NTM Hypoxia HALLMARK_HYPOXIA 16 0.61 2.29 0 0 
Normoxia HALLMARK_XENOBIOTIC_METABOLISM 28 -0.54 -2.49 0 0 
Normoxia HALLMARK_UNFOLDED_PROTEIN_RESPONSE 18 -0.61 -2.32 0 0 
Hypoxia HALLMARK_MITOTIC_SPINDLE 17 0.58 2.18 0 1.84E-03 
Hypoxia HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION 21 0.55 2.24 0 2.38E-03 
Hypoxia HALLMARK_KRAS_SIGNALING_UP 17 0.49 1.86 3.85E-03 2.74E-02 
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Figure 6.8 IPA canonical pathways significantly enriched in unique CAM, ATM and 
NTM hypoxia-induced gene expression profiles. Top 10 pathways in respective     
hypoxia vs normoxia comparisons (indicated at the top of the bar chart) are shown; Fisher’s 
Exact test p-value. 
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6.3.3.3  Predicted biological effects of hypoxia on CAMs, 
ATMs and NTMs 
To predict the biological effects of hypoxia on gastric CAMs, ATMs and NTMs        
the IPA downstream effects analysis was performed on differentially expressed 
genes identified in the respective hypoxia vs normoxia comparisons.                       
The downstream effects analysis facilitates the prediction of functions and 
processes that are expected to be increased or decreased, based on the observed 
changes in gene expression in the respective datasets. The results from these 
analyses for CAMs, ATMs and NTMs are presented in Figure 6.9. Processes with an 
absolute z-score of ≥ |2| are reported irrespective of their p-value.  
 
6.3.3.4  Prediction of factors that may be secreted by 
hypoxic CAMs and NTMs 
To predict factors that may be secreted by hypoxic CAMs and hypoxic NTMs and 
have an effect on cancer cell migration and proliferation, the IPA downstream 
effects analysis was performed on differentially expressed genes identified in     
CAM hypoxia vs CAM normoxia and NTM hypoxia vs NTM normoxia comparisons. 
Genes annotated as being involved in cell migration and proliferation were selected 
and further analysed to identify genes that are known to encode extracellular 
proteins. The results from these respective analyses are shown in Figure 6.10.  
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Figure 6.9 Predicted biological effects of hypoxia on gastric CAMs, ATMs and NTMs. 
A. CAM hypoxia vs CAM normoxia. B. ATM hypoxia vs ATM normoxia. C. NTM hypoxia vs 
NTM normoxia; orange – predicted increase (z-score ≥ 2), blue – predicted decrease         
(z-score ≤ -2); Fisher’s Exact test p-value.    
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Figure 6.10 Predicted pro-migratory and pro-proliferative factors secreted by hypoxic CAMs and hypoxic NTMs. A. Extracellular molecules expressed 
by hypoxic CAMs. B. Extracellular molecules expressed by hypoxic NTMs. Molecules displayed in boxes are uniquely expressed in hypoxic CAM or hypoxic 
NTM. 
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6.3.4  Secretome analysis of CAM and NTM hypoxic 
conditioned media 
In order to identify secretory factors released by gastric CAMs and NTMs in 
response to hypoxia, CAM and NTM hypoxic and control conditioned media was 
profiled by LC-MS/MS. In total four different conditions were examined:                   
(i) CAM-ctrl-CM; (ii) CAM-hypoxic-CM; (iii) NTM-ctrl-CM; and (iv) NTM-hypoxic-CM. 
In each case CM was collected from CAMs (n=3) or NTMs (n=3) after 72 hours 
incubation under hypoxic (1% O2) or normoxic (21% O2) conditions as described in 
Methods section 2.4.2. 
 
6.3.4.1  Identification and quantification of CAM and NTM 
secreted proteins  
Altogether, 1169 protein groups were identified and quantified across all 12 CM 
samples. The complete table of quantified proteins is presented in Appendix V.  
 
A core of 702 proteins was detected in all 12 samples. These proteins were 
subjected to gene ontology enrichment analysis using the PANTHER Classification 
System (Mi, Muruganujan et al. 2013) in order to verify their cellular location. The 
identified proteins were significantly enriched in terms of annotation for 
extracellular region (p = 4.59 x 10-227) and extracellular vesicle (p = 1.74 x 10-200). 
The other top 10 most significantly enriched GO terms were also associated with 
extracellular structures confirming that the experimental strategy worked well.  
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In addition, the Metazoa Secretome and Subcellular Proteome Knowledge Base 
(MetazSecKB, released May 2014) (Meinken, Walker et al. 2015), MatrisomeDB 
(updated August 2014) (Naba, Clauser et al. 2012) and ExoCarta (released May 
2012) (Mathivanan, Fahner et al. 2012) were also used to further annotate the 
identified proteins present in CAM and NTM secretomes. The MetazSecKB search 
identified 295 proteins that are annotated as predicted secreted. The MatrisomeDB 
search identified 218 extracellular matrix (ECM) proteins and associated factors 
whereas ExoCarta search identified 752 proteins that were detected in exosomes 
released by various cell types. The overlap of these database searches is shown in 
Figure 6.11.  
 
 
 
Figure 6.11 Venn diagram representation of database searches used to classify 
proteins identified in CAM and NTM conditioned media obtained from normoxia and 
hypoxia.  
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6.3.4.2  Hypoxia–induced secretome signatures in gastric     
CAMs and NTMs  
To define hypoxia-induced secretome signatures statistical significance score was 
calculated for protein fold change in the following comparisons:                                 
(i) CAM-hypoxic-CM vs CAM-ctrl-CM, (ii) NTM-hypoxic-CM vs NTM-ctrl-CM,            
(iii) CAM-ctrl-CM vs NTM-ctrl-CM and (iv) CAM-hypoxic-CM vs NTM-hypoxic-CM.  
 
The analysis identified: (i) 43 proteins that were differentially secreted by hypoxic 
CAMs compared to control CAMs (Figure 6.12A); (ii) 225 proteins that were 
differentially secreted by hypoxic NTMs compared to control NTMs (Figure 6.12B); 
(iii) 84 proteins differentially secreted by CAMs compared to NTMs (Figure 6.12C); 
and (iv) 145 proteins differentially secreted by hypoxic CAMs compared to hypoxic 
NTMs (Figure 6.12D). Supplementary Figure S6.3 shows which of the differentially 
secreted proteins identified in respective CM comparisons were annotated as being 
secreted or extracellular, based on MetazSecKB, Matrisome and ExoCarta searches 
(as describe in section 6.3.4.1).  
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Figure 6.12 Volcano plots of differentially secreted proteins in the following 
comparisons: A. CAM-hypoxic-CM vs CAM-ctrl-CM B. NTM-hypoxic-CM vs NTM-ctrl-CM   
C. CAM-ctrl-CM vs NTM-ctrl-CM D. CAM-hypoxic-CM vs NTM-hypoxic-CM. Proteins 
highlighted in red are considered to be differentially secreted between the given conditions.  
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Comparative analysis of differently secreted proteins identified in CAM-hypoxic-CM 
and NTM-hypoxic-CM compared to respective normoxic-control CM revealed 
secretion of 14 proteins that are universally altered under hypoxia in both CAMs 
and NTMs (Figure 6.13). Significantly, this analysis confirmed some of the 
predictions made based on hypoxia-induced CAM and NTM gene expression 
profiles (Figure 6.10). In particular, gelsolin (GSN), vascular endothelial growth 
factor A (VEGFA), glucose-6-phosphate isomerase (GPI) were verified at protein 
level as universally-changed CAM and NTM secreted proteins under hypoxia 
(Supplementary Figure S6.4). In addition, lysyl oxidase (LOX), insulin-like growth 
factor-binding protein 3 (IGFBP3), insulin-like growth factor-binding protein 6 
(IGFBP6), thrombospondin-2 (THBS2) and angiopoietin-related protein 4 (ANGPTL4) 
were also verified at protein level as NTM unique hypoxia-induced secreted 
proteins (Supplementary Figure S6.5 and Figure S6.6). 
 
 
 
Figure 6.13 Comparison of differentially secreted proteins identified in CAM-hypoxic-CM 
and NTM-hypoxic-CM compared to their respective normoxic-control-CM. 
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6.3.4.3  Potential biological effects of the hypoxia-induced 
CAM and NTM secretomes 
Gene ontology (GO) enrichment analysis and IPA downstream effects analysis were 
performed to gain insight into possible biological effects of the identified      
hypoxia-induced CAM and NTM secretomes. 
 
6.3.4.3.1  Gene ontology enrichment analysis 
Gene ontology (GO) enrichment analysis was performed on CAM and NTM  
hypoxia-induced secretomes using GOrilla (Gene Ontology enRIchment anaLysis 
and visuaLizAtion tool) (Eden, Navon et al. 2009). Identified proteins were ranked 
according to their p-value with proteins identified as differentially secreted being at 
the top of the rank.  
 
The enrichment analyses of biological processes (BP) identified 12 GO terms and   
62 GO terms with p-value < 0.001 in CAM and NTM hypoxia-induced secretomes, 
respectively. List of GO biological process (BP) terms with FDR p-value < 0.01 
identified in NTM hypoxia-induced secretome is shown in Table 6.4.  
 
GO biological process (BP) terms with p-value < 0.001 identified in CAM hypoxia-
induced secretome include: regulation of cytoskeleton organisation (GO:0051493 , 
p = 4.08 x 10-4), regulation of actin filament-based process (GO:0032970,                   
p = 4.10 x 10-4), protein modification by small protein removal (GO:0070646,            
p = 5.30 x 10-4) and single-organism metabolic process (GO:0044710,                          
p = 7.23 x 10-4). Notably, extracellular exosome (GO:0070062, p = 1.07 x 10-4) was 
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one of the most enriched GO cellular component (CC) terms identified in CAM 
hypoxia-induced secretome. 
 
Table 6.4 Gene ontology (GO) biological process (BP) enrichment for differentially 
secreted proteins by hypoxic NTMs; FDR p-value < 0.01. 
GO ID GO biological process (BP) term p-value FDR 
GO:0006090 pyruvate metabolic process 2.94E-08 1.90E-04 
GO:0032787 monocarboxylic acid metabolic process 1.99E-07 6.42E-04 
GO:0044712 single-organism catabolic process 3.17E-06 1.20E-03 
GO:0006082 organic acid metabolic process 8.00E-07 1.29E-03 
GO:0046496 nicotinamide nucleotide metabolic process 2.90E-06 1.34E-03 
GO:0072524 pyridine-containing compound metabolic process 2.90E-06 1.44E-03 
GO:0016052 carbohydrate catabolic process 7.63E-06 2.35E-03 
GO:0006094 gluconeogenesis 1.97E-05 5.53E-03 
GO:0009167 purine ribonucleoside monophosphate metabolic process 2.33E-05 6.01E-03 
GO:0006091 generation of precursor metabolites and energy 3.88E-05 8.96E-03 
GO:0042157 lipoprotein metabolic process 3.85E-05 9.22E-03 
GO:0008380 RNA splicing 4.33E-05 9.33E-03 
 
 
6.3.4.3.2  IPA downstream effects analysis  
To predict the biological effects of hypoxia-induced CAM and NTM secretomes     
the IPA downstream effects analysis was performed on differentially secreted 
proteins identified in CAM-hypoxic-CM vs CAM-ctrl-CM and NTM-hypoxic-CM vs 
NTM-ctrl-CM comparisons. The downstream effects analysis facilitates 
identification of functions and processes that are expected to increase or decrease, 
based on the observed changes in protein levels in the given datasets. The results 
from these analyses are presented in Figure 6.14. Processes with an absolute          
z-score of ≥ |2| are reported irrespective of their p-value.  
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Notably, proteins secreted by hypoxic NTMs were predicted to be regulated by   
HIF-1α activation (z-score = 2.303, p = 4.76 x 10-9) as revealed by IPA upstream 
regulator analysis. These hypoxic NTM secreted proteins positively affect 
angiogenesis, migration of endothelial cells and proliferation of tumour cell lines 
(Figure 6.15). 
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Figure 6.14 Predicted biological effects of the hypoxia-induced CAM and NTM 
secretomes. A. CAM-hypoxic-CM vs CAM-ctrl-CM B. NTM-hypoxic-CM vs NTM-ctrl-CM; 
orange – predicted increase (z-score ≥ 2), blue – predicted decrease (z-score ≤ -2); Fisher’s 
Exact test p-value. 
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Figure 6.15 Predicted activation of HIF- α    u                 of proteins secreted 
by hypoxic NTMs. The hypoxic NTM secreted proteins positively affect angiogenesis, 
migration of endothelial cells and proliferation of tumour cell lines. 
 
6.3.4.4  Integration of hypoxia-induced CAM and NTM 
secretomes with CAM and NTM hypoxia-induced gene 
expression signatures 
The differentially secreted proteins identified in CAM-hypoxic-CM and                
NTM-hypoxic-CM compared to their respective control CM were integrated with 
CAM and NTM hypoxia-induced gene expression signatures in order to establish the 
correlation between CAM and NTM secreted proteins and their gene expression in 
respective comparisons.  
 
The integrative analysis showed that a good correlation exist between respective 
gene expression profiles and secreted protein levels (Pearson correlation:        
0.4231 – 0.8151, p < 2.073 x 10-12) (Figure 6.16). 
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Figure 6.16 Integration of secretome and gene expression data for A. CAM hypoxia vs 
CAM normoxia B. NTM hypoxia vs NTM normoxia C. CAM normoxia vs NTM normoxia      
D. CAM hypoxia vs NTM hypoxia; grey - differentially expressed gene and corresponding 
protein identified in given secretome, red – differentially expressed gene and corresponding 
differentially secreted protein identified in given CM comparison, r – Pearson correlation. 
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6.4  Discussion 
In this Chapter, an integrated multi-omics approach was used to understand 
modulation of stromal cells activity under hypoxia. The presented analysis of 
genomic and proteomic data provides an insight into the profile of changes in gene 
expression and protein secretion that result from exposure of normal gastric 
myofibroblasts (NTMs) or cancer associated gastric myofibroblasts (CAMs) to 
hypoxic conditions. 
 
Data presented in previous Chapters, show that gastric CAMs increase cancer cell 
migration and proliferation compared to both ATMs and NTMs (Supplementary 
Figure S3.1 and Figure S3.2) and that DNA methylation may contribute to the 
regulation of CAM-specific gene expression profiles and therefore may play an 
important part in the ability of CAMs to exert tumour-promoting properties. 
Functional studies presented in this Chapter show that hypoxia induces phenotypic 
changes in the effects that CAMs and NTMs exert on cancer cell migration and 
proliferation. In particular, data from this study show that under hypoxic conditions 
CAMs become more aggressive and NTMs acquire more CAM-like properties. 
Specifically, CAM-hypoxic-CM was found to increase CAM-induced cancer cell 
migration, while reducing the ability of CAMs to stimulate cancer cell proliferation 
suggesting that hypoxia enhances CAM secretion of pro-migratory factors.               
In contrast, NTM-hypoxic-CM stimulated both migration and proliferation of cancer 
cells suggesting that hypoxia activates NTMs and enhances secretion of both       
pro-migratory and pro-proliferative factors by these cells. Notably, migration of 
cancer cells was found to be greater towards CAM-hypoxic-CM then                   
NTM-hypoxic-CM.  
 
Surprisingly, genome-wide DNA methylation profiling of hypoxia-treated CAMs and 
NTMs showed that hypoxia does not alter DNA methylation patterns of these cells. 
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However, it is possible that longer hypoxia exposure may be needed to confer    
DNA methylation changes. Therefore, to assess whether longer-term hypoxia 
exposure could induce changes in NTM or cancer cells global DNA methylation,        
a further LINE-1 pyrosequencing assay was performed (Supplementary Figure S6.7). 
The results from these studies showed no further changes in global                       
DNA methylation in both NTMs and AGS cells even after 6 and 8 days hypoxia 
treatment, respectively. Taken together, these data suggest that presence               
of cancer cells, or possibly a combination of other microenvironmental factors may 
be needed to confer epigenetic reprograming of gastric myofibroblasts to exert 
tumour-promoting properties and hypoxia, as a single microenvironmental factor,  
is unlikely to impose CAM-like DNA methylation patterns in normal tissue 
myofibroblast (NTMs).  
 
Genome-wide transcriptional profiling revealed unique transcriptional responses   
to hypoxia among the different populations of gastric myofibroblasts used in this 
study. These unique transcriptional signatures of hypoxic CAMs, hypoxic ATMs and 
hypoxic NTMs most likely stem from differential epigenetic backgrounds. Notably, 
upregulation of cholesterol biosynthesis and fatty acid metabolism emerged as        
a unique feature of hypoxic CAMs. Cholesterol is an essential structural component 
of cell membranes that modulates their fluidity and permeability. It serves also as   
a precursor for many signalling molecules and plays a key role in membrane 
trafficking, transmembrane signalling processes (Simons and Gerl 2010) and cell 
proliferation (Fernandez, Lobo et al. 2004, Fernandez, Martin et al. 2005). 
Cholesterol biosynthesis is tightly regulated at multiple levels and is typically carried 
out in hepatocytes, adipocytes, brain tissue and lactating breast tissue. However, 
activation of de novo lipogenesis has been frequently observed in cancer 
(Menendez and Lupu 2007) and enhanced cholesterol biosynthesis has been 
implicated in development of prostate cancer (Hager, Solomon et al. 2006). 
 
Effects of Hypoxia on Gene Expression and Secretion of Pro-tumorigenic Factors in Gastric 
Stromal Myofibroblasts 
 
 
198 
 
The reduction of the oxygen level in gastric CAMs resulted in upregulation of all 
components of the superpathway for cholesterol biosynthesis (Appendix VI File 1), 
suggesting that hypoxia enhances production of cholesterol in gastric CAMs. 
Significantly, several studies have shown that adipocytes promote growth of cancer 
cells, including breast cancer (Klopp, Zhang et al. 2012) and prostate cancer 
(Tokuda, Satoh et al. 2003). Nieman et al. have shown that malignant cells induce 
increased lipolysis in adipocytes, which then secrete fatty acids that are taken up  
by the cancer cells to be used for energy production (Nieman, Kenny et al. 2011). 
Therefore it is possible that CAMs under hypoxia may contribute to the energy 
metabolism of cancer cells. Rapidly proliferating cancer cells require lipids for the 
generation of biological membranes and as a source of energy during times of 
nutrient depletion. The coupling of energy metabolism between CAMs and cancer 
cells may be mediated by fatty acid binding proteins, such as FABP1 and FABP3, 
which were upregulated in hypoxic CAMs or by exosomes that are secreted by 
CAMs (as demonstrated in previous Chapters), moreover their secretion is 
enhanced in hypoxic microenvironment (as shown in this study: GO:0070062 
extracellular exosome, p = 4.75 x 10-4 and has also been observed in other systems). 
King et al. showed that breast cancer cells release greater levels of exosomes when 
exposed to hypoxia and that these hypoxic exosomes contained higher levels of 
transported microRNA compared to normoxic exosomes (King, Michael et al. 2012). 
 
Exosomes are known to transport lipids in their membrane, or in their lumen. 
Exosomal lipids interact with receptors on target cell and are then internalized into 
endosomes where they concentrate the bioactive lipids that they carry (Record, 
Carayon et al. 2014). Notably, in ovarian cancer it has been shown that omental 
adipocytes are able to promote homing, migration and invasion of cancer cells at 
least in part through release of cytokines (Nieman, Kenny et al. 2011). This may 
explain why cancer cells preferentially migrate towards CAM-hypoxic-CM. Also, 
Hedgehog signalling, an important developmental pathway implicated to have an 
important role in cancer development, progression and metastasis, provides 
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another link between cholesterol and cancer. Cholesterol can be covalently bond to 
Hedgehog proteins (Kornberg 2011) which activate Hedgehog signalling by 
autocrine or paracrine mechanisms in cancer cells (Harris, Samant et al. 2011). 
Lastly, upregulation of cholesterol biosynthesis under hypoxia in CAMs may serve as 
adaptive mechanism that protects CAMs from oxidative damage. It has been 
reported that activation of de novo lipogenesis in cancer cells leads to increase 
membrane lipid saturation, resulting in higher levels of saturated and 
monounsaturated phospholipids, that potentially protects cancer cells from free 
radicals and chemotherapeutics (Rysman, Brusselmans et al. 2010). 
 
The transcriptional analysis of the unique gene expression profile identified in 
hypoxic ATMs revealed that low oxygen concentration induces the expression of 
genes involved in G2/M cell cycle checkpoint, mitotic spindle assembly and integrin 
signalling. Significantly, upregulated aurora kinase A (AURKA), which is commonly 
overexpressed in many types of tumours, emerged as a key regulator of the 
observed hypoxic ATM phenotype in GSEA leading edge analysis (Supplementary 
Table S6.1). AURKA is a serine-threonine kinase that plays a critical role in 
regulating cell cycle and mitosis and ensures correct spindle assembly in normal 
cells. It was reported that overexpression of AURKA directly leads to malignant 
transformation and tumour formation (Wang, Zhou et al. 2006). Interestingly, it has 
also been shown that AURKA regulates pluripotency of embryonic stem cells, in 
particular cell self-renewal, reprograming and differentiation (Lee, Su et al. 2012). 
This may suggest that AURKA functions as a regulator of cell stemness.  
Importantly, Klein et al. showed that hypoxia regulates AURKA expression at the 
transcriptional level in hepatoma cells (Klein, Fluegel et al. 2008). Recently, it was 
also shown that AURKA mediates ovarian cancer cell migration and adhesion      
(Do, Xiao et al. 2014). Integrin signalling plays an important role in cell adhesion, 
survival, proliferation, differentiation and migration. Integrins are transmembrane 
receptors that precipitate in cell–cell and cell-extracellular matrix adhesion. They 
allow cells to sense chemical and physical information in their local environment 
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and can modulate intracellular signalling pathways and gene expression in response 
to that (Parsons, Horwitz et al. 2010). Presented analysis revealed that hypoxia 
affects ATM cells’ motility in part via upregulation of talin, an integrin-actin linkage 
protein, and upregulation of α-actinin, an actin cross-linking protein (Appendix VI 
File 2). Collectively, these observations suggest that upregulation of AURKA and 
components of integrin signalling pathway under hypoxia increases ATM cells 
motility and cell cycle progression.  
 
Finally, the transcriptional analysis of the unique gene expression profile identified 
in hypoxic NTMs showed that these genes mainly contribute to signalling pathways 
related to hypoxia response and xenobiotic metabolism. The hypoxic 
microenvironment was previously reported to mediate fibroblast to myofibroblast 
differentiation (Misra, Fu et al. 2010, Robinson, Neary et al. 2012). In most studies 
these activated fibroblasts are referred to as cancer-associated 
fibroblasts/myofibroblasts (CAF/CAMs) since they express myofibroblast cell 
markers. 
 
The IPA downstream effect analysis predicted distinct biological effects of hypoxia 
among the gastric myofibroblast populations used in this study. This analysis 
complements the aforementioned observations. Significantly, activation of 
autophagy emerged as a key CAM-specific process that was enhanced in response 
to hypoxia, whereas processes such as organization of organelle, growth of 
microtubules and aneuploidy of cells appeared to be activated only in hypoxic 
ATMs. Interestingly, expression and transcription of RNA were the most 
significantly activated processes in hypoxic NTMs and the most significant 
processes among all studied myofibroblast populations. In addition, processes, such 
as mitosis, angiogenesis, invasion of cells, growth of axons, neoplasia of tumour cell 
lines and glycolysis of cells were predicted to be most active in hypoxic NTMs.  
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The secretome analysis confirmed some of the predictions made based on   
hypoxia-induced CAM and NTM gene expression profiles. Interestingly, lysyl oxidase 
(LOX), among others, was verified at the protein level as an NTM unique        
hypoxia-induced secreted protein. LOX is an extracellular amine oxidase that     
post-translationally modifies collagens and elastin in the extracellular matrix 
therefore catalyses the covalent crosslinking of fibers (Kagan and Li 2003). LOX is 
crucial for hypoxia-induced metastasis. It is highly expressed in hypoxic tumour 
cells, including breast cancer, where it remodels extracellular matrix in the lungs, 
leading to the formation of a metastatic niche (Erler, Bennewith et al. 2009).        
The comparative analysis of secretomes and gene expression profiles revealed that 
both expression and secretion of LOX is increased in CAMs compared to NTMs 
under normal conditions. However, when oxygen is limited LOX is induced in NTMs, 
both at the mRNA and protein level, but not in CAMs. Neither LOX mRNA transcript 
nor protein was identified as being differentially expressed/secreted in response to 
hypoxia in CAMs (Supplementary Figure S6.6) supporting the notion that NTMs 
acquire CAM-like phenotype under hypoxia. 
 
The differential analysis of proteins secreted by hypoxic CAMs compared to control 
CAMs and hypoxic NTMs compared to control NTMs revealed that hypoxia has        
a significantly bigger impact on protein secretion in NTMs than CAMs. This is           
in line with aforementioned IPA downstream effect analysis, which predicted 
expression (p = 2.02 x 10-15, z-score = 2.611) and transcription (p = 2.74 x 10-13,        
z-score = 3.081) of RNA as the most significantly activated processes in hypoxic 
NTMs and also the most significant when compared to hypoxic ATMs or hypoxic 
CAMs as transcription in hypoxic CAMs was activated to a lesser extend                    
(p = 3.34 x 10-7, z-score = 2.564). Taken together, these data may suggest that CAMs 
are somehow less responsive to low oxygen levels then NTMs. This notion can be 
supported by the GSEA results presented in Chapter IV which showed upregulation 
of hypoxia-induced genes in CAMs compared to both ATMs and NTMs (Table 4.2). 
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Significantly, proteins differentially secreted by hypoxic NTMs compared to control 
NTMs were predicted to be regulated by HIF-1α activation and enhance tumour cell 
proliferation, invasion, cell movement, angiogenesis, vasculogenesis and migration 
of endothelial cells. These data are consistent with the experimental data showing 
increased cancer cell migration and proliferation in response to NTM-hypoxic-CM 
compared to NTM-ctrl-CM. Proteins differentially secreted by hypoxic CAMs 
compared to control CAMs were predicted to reduce cell death, including necrosis 
and apoptosis. Taken together, these results are in line with gene expression 
analysis of hypoxia-induced NTM- and CAM-specific gene signatures.  
 
In summary, this study is the first to investigate in the integrative manner the 
effects of hypoxia on DNA methylation, gene expression and protein secretion of 
gastric primary myofibroblast cells derived from cancer tissue (CAMs),                  
pre-neoplastic tissue (ATMs) and normal tissue (NTMs). The analysis identified 
hypoxia-induced factors that may drive CAM-, ATM- and NTM- specific hypoxia 
response and therefore have differential effects on cancer cell migration and 
proliferation.  
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7.1  Summary and Conclusions 
The tumour microenvironment plays an important role in cancer development and 
progression therefore much effort has been made to understand the molecular 
alterations within tumour stroma and their effects on cancer cells. In this study, an 
integrated multi-omics approach was used to understand regulation and crosstalk 
in the tumour microenvironment. In line with the two main objectives of this study, 
several key findings have emerged:  
 Myofibroblasts derived from the site of gastric and oesophageal tumours 
(CAMs) have distinct genome-wide DNA methylation patterns compared to 
non-tumour derived myofibroblasts (ATMs and/or NTMs). These widespread 
alterations of DNA methylation in gastric and oesophageal CAMs can 
provide potential clues as to molecular mechanism of tumour programing of 
stromal cells. 
 DNA methylation patterns at multiple genomic loci were identified either as 
proxies for gastric CAM identification or as conserved signatures in both 
gastric and oesophageal patient-matched CAM and ATM samples. DNA 
methylation at these genomic loci may be used as stromal biomarkers with 
potential clinical relevance for gastric/oesophageal cancer. 
 DNA methylation is involved in the epigenetic regulation of biological 
pathways and processes involved in the tumour–promoting function of 
gastric CAMs. In particular, promoter DNA hypomethylation emerged as       
a regulatory mechanism for transcriptional activation of genes involved in 
secretion and transport of molecules while promoter DNA hypermethylation 
emerged as a regulatory mechanism for transcriptional repression                
of genes involved in pathology of gastrointestinal cancers and regulation    
of developmental processes.  
 Several potential gastric CAM biomarkers (SMAD3, SPON2, ZNF536, FOXF1, 
FENDRR) were validated on an independent set of patient-matched         
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CAM and ATM samples and unrelated NTM samples by pyrosequencing   
and qPCR. 
 Gastric myofibroblasts purified from different tissue microenvironments 
(CAMs, ATMs, NTMs) have distinct responses to hypoxia, which are in part 
due to differential epigenetic backgrounds. 
 Presented data provide a novel insight into the profile of changes in gene 
expression and protein secretion that result from exposure of normal 
(NTMs) or cancer-associated myofibroblasts (CAMs) to hypoxic conditions. 
Analyses performed in this study identified hypoxia-induced factors that 
may drive CAM-, ATM- and NTM- specific hypoxia responses and therefore 
have differential effects on cancer cell migration and proliferation. 
 
Taken together, this study identified distinct genome-wide DNA methylation 
signatures that are characteristic for gastric tumour derived stromal myofibroblasts 
(CAMs) and that distinguish these cells from non-tumour derived gastric 
myofibroblasts (ATMs and/or NTMs). The fact that CAMs retain their             
tumour-promoting properties and specific gene expression signatures in the 
absence of neighbouring tumour epithelium over several passages in vitro, suggests 
that tumour stroma is composed of specialized myofibroblast population, which has 
been epigenetically programmed by neighbouring neoplastic epithelium to function 
to its advantage and favour tumour growth and malignant progression (Figure 7.1). 
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Figure 7.1 Novel insights into molecular mechanisms underlying the                  
tumour-promoting phenotype of gastric CAMs that have emerged from this study.  
 
 
7.2  DNA methylation profiling of CAMs 
This study is the first to examine genome-wide DNA methylation patterns at 
individual CpG resolution in primary gastric and oesophageal patient-matched CAM 
and ATM samples. The identified widespread alterations of DNA methylation in 
gastric and oesophageal CAMs can provide potential clues as to the molecular 
mechanism of cancer programing of stromal cells and may serve as potential 
diagnostic biomarkers. In addition, multiple genomic loci identified as proxies for 
gastric CAM identification may prove useful as biomarkers for improved diagnosis 
and prognosis of gastric cancer.  
 
Neoplastic cells
CAMs
Cancer-induced genome-wide
DNA methylation changes
(effect on CAM transcriptome, including 
microRNA & long non-coding RNA)
cancer cell 
migration & proliferation
Potential stromal biomarkers:
CAM-derived factors
SMAD3 hypermethylated-repressed
SPON2 hypomethylated -induced
ZNF536 hypermethylated-repressed
FOXF1 hypermethylated-repressed
FENDRR hypermethylated-repressed
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Although, there is much knowledge about epigenetic alterations in cancer cells 
relatively little is known about epigenetic alterations within tumour stroma. Our 
knowledge of genome-wide epigenetic changes within tumour stroma is based 
largely on two pioneering studies (Hu, Yao et al. 2005, Jiang, Gonda et al. 2008).   
Hu et al. examined non-neoplastic stromal cells, including epithelial and 
myoepithelial cells, and stromal fibroblasts from normal breast tissue, and in situ 
and invasive breast carcinomas showing that distinct epigenetic alterations occur in 
all three cell types during breast tumorigenesis in a tumour stage– and cell type–
specific manner (Hu, Yao et al. 2005). This study suggested that epigenetic 
alterations have a role in the maintenance of the abnormal cellular 
microenvironment in breast cancer. Significantly, Jiang et al. reported that CAMs 
derived from gastric tumours are characterised by global loss of DNA methylation 
concomitant with focal gain of DNA methylation (Jiang, Gonda et al. 2008). 
Although this study is of particular interest to the work presented in this thesis, it 
did not examine the gene-specific patterns of DNA methylation in CAMs and 
ATM/NTM. As such, the present study is the first to provide strong evidence for 
CAM-specific DNA methylation signatures that may contribute to the regulation of 
CAM-specific gene expression profiles and therefore show that tumour promoting 
properties of CAMs may in part be due to epigenetic programming. 
 
7.3  Global hypomethylation in CAMs 
Comparative analysis of global DNA methylation between CAMs and patient-
matched ATMs, isolated from gastric and oesophageal cancers showed that the 
mean global DNA methylation of CAMs is statistically lower than the mean global 
DNA methylation of corresponding ATMs which is in agreement with the 
aforementioned study in gastric CAMs reported by Jiang, Gonda et al. 2008. 
Significantly, a recently published analysis of genome-wide DNA methylation 
profiling of primary lung CAMs also reported global DNA hypomethylation 
concomitant with focal gain of DNA methylation in CAMs compared to patient-
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matched control fibroblasts derived from non-small cell lung cancer (NSCLC) 
(Vizoso, Puig et al. 2015). Taken together, these findings support the notion that 
global loss of DNA methylation concurrent with focal DNA hypermethylation        
can be used as a defining epigenetic biomarker of CAMs derived from different solid 
tumours and may underlie their tumour-promoting phenotype.  
 
Interestingly, the global DNA hypomethylation in CAMs parallels the overall loss of 
DNA methylation that has been well documented in cancer cells. However, in 
contrast to cancer cells, CAM global DNA hypomethylation does not appear to be 
associated with chromosomal instability as CAMs are non-neoplastic and exhibit 
senescence in vitro. This phenomenon was also reported by Jiang, Gonda et al. 
2008. They also reported lack of obvious changes in DNMTs expression in CAMs and 
concluded that reduced expression of DNMTs probably does not explain the global 
loss of DNA methylation in CAMs (Jiang, Gonda et al. 2008). Notably, Merry et al. 
recently demonstrated that deregulation of lncRNAs associated with DNMT1 
contributes to global changes in DNA methylation patterns without any detectable 
mutations or changes in the expression of DNMTs (Merry, Forrest et al. 2015). They 
identified a subset of lncRNAs that interact with DNMT1 in colon cancer cells. One 
lncRNA named DACOR1 (DNMT1-associated Colon Cancer Repressed lncRNA 1) was 
shown to be repressed in a panel of colon tumours and patient-derived colon 
cancer cell lines. Induction of DACOR1 in colon cancer cell lines impaired growth 
and colony formation, and affected global gene expression. Significantly, DACOR1 
induction resulted in downregulation of cystathionine β-synthase, which is known 
to lead to increased levels of S-adenosyl methionine (SAM), the key methyl donor 
for DNA methylation (Merry, Forrest et al. 2015). These findings suggest that 
DNMT1, through its interaction with lncRNA DACOR1, indirectly regulates the 
cellular levels of SAM and subsequent genome-wide DNA methylation in colon 
tissue. Notably, accumulating studies have shown that lncRNAs play an active role 
in gastric cancer tumorigenesis, metastasis, prognosis and drug resistance (Fang, 
Pan et al. 2015, Gu, Chen et al. 2015). However, given that many lncRNAs have 
tissue-specific expression patterns and are poorly conserved, it remains to be 
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elucidated whether dysregulation of lncRNAs contributes to global DNA 
hypomethylation in other types of cancer and whether similar mechanism exists in 
CAMs derived from these tumours.  
 
7.4  DNA methylation in CAMs from different tissues  
Data presented in this thesis show that epigenetic changes can provide a potential 
mechanism for gastric CAMs to acquire their tumour-promoting phenotype. 
However, it is not clear whether these epigenetic changes are conserved in CAMs 
derived from different tumours and whether they target the same genes and/or 
genomic regions.  
 
The genome-wide DNA methylation profiling of gastric and oesophageal CAMs 
identified 230 susceptible CpG loci that are differentially methylated in both gastric 
and oesophageal CAMs when compared to patient-matched ATMs. Notably, 
172/230 of the identified CpG loci were changed in the same direction in gastric 
and oesophageal CAMs. The conserved gastric and oesophageal CAM susceptible 
loci are distributed across the genome and 65.22% of these loci are associated with 
2 genes and 33.5% are associated with only one gene. Notably, the analysis on a 
gene level identified 2223 common differentially methylated genes in gastric and 
oesophageal CAMs. These genes were found to largely target signalling pathways 
that are either commonly dysregulated in human cancers or are involved in 
transcriptional regulation of pluripotent stem cells and developmental processes. 
Importantly, aberrant promoter methylation of a number of genes (e.g. ZMIZ1, 
EYA4, SLC22A18AS, WIPF1, FAM49A, RUNX3, ESRRG) found in both gastric and 
oesophageal CAMs were also reported in CAMs derived from lung cancer (Vizoso, 
Puig et al. 2015) indicating that epigenetic changes may contribute to the aberrant 
expression of these common genes in CAMs derived from different tumours and 
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ultimately disrupt the same signalling pathways. However, further studies on much 
bigger sample sets are needed to determine whether that is the case.  
 
Data presented in this study (Chapter V) strongly suggests that DNA methylation 
may confer a mechanism for the transcriptional regulation of key TGF-β signalling 
components in gastric CAMs. Specifically, promoter hypermethylation may be 
associated with SMAD3 downregulation in gastric CAMs. Notably, SMAD3 was also 
downregulated in oesophageal CAMs; however the methylation status of SMAD3 
promoter in oesophageal CAMs needs to be examined. Interestingly, Vizoso et al. 
also found promoter hypermethylation-associated SMAD3 silencing in CAMs 
derived from lung cancer. The SMAD3 hypermethylation was associated with 
hyperresponsiveness to exogenous TGF-β1 in terms of contractility and ECM 
deposition. They examined the expression of a panel of wound-related ECM genes 
and showed that COL1A1, EDA-FN, LOX and SPARC are upregulated in CAMs 
compared to patient-matched control fibroblasts after 5 days of treatment with 
TGF-β1 (Vizoso, Puig et al. 2015). Significently, we also observed the upregulation of 
COL1A1, SPARC and LOX in gastric CAMs compared to ATM in our gene expression 
data. Collectivly, based on these observation promoter hypermethylation-
associated SMAD3 silencing may potentially be a major contributor to CAM 
aberrant phenotype and may underlie tumour-promoting properties of CAMs 
derived from different tissues. Further studies are needed to determine whether 
promoter hypermethylation-associated SMAD3 silencing may be used as define 
epigenetic biomarker of CAMs derived from different tumours and to assess its 
function in cancer-specific CAM programming.  
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7.5  Stromal DNA methylation signatures  
In this study, genome-wide DNA methylation profiling identified stromal DNA 
methylation signatures that may potentially be used in clinical practice as 
biomarkers for improved diagnosis and prognosis of gastric cancer.  
 
Significantly, region on chromosome 16 that spans 526,426 bp was identified as one 
of the largest hypermethylated region in gastric CAMs compared to both ATMs and 
NTMs. Interestingly, this region is commonly hypermethylated in gastric tumours 
and gastric cancer cell lines (Supplementary Figure S5.10 and Figure S5.11). DNA 
methylation within this region may regulate the expression of lncRNA FENDRR 
(Figure 5.6). Significantly, Xu et al. reported that expression of FENDRR is 
downregulated in gastric cancer cells compared to normal gastric epithelial cells 
(Xu, Huang et al. 2014) which is in line with aforementioned TCGA data. Low 
expression of FENDRR was significantly correlated with poor prognosis and 
aggressive tumour characteristics, such as greater invasion depth, higher tumour 
stage, and lymphatic metastasis (Xu, Huang et al. 2014). Although, further studies 
are needed to correlate the hypermethylation of FENDRR with patient prognosis in 
CAM, DNA methylation of this region may potentially be used as biomarkers for 
improved diagnosis and prognosis of gastric cancer given that generally in clinical 
practice whole tumour tissue samples are profiled rather than isolated neoplastic 
cells. Therefore this finding may translate into clinically useful biomarker of gastric 
tumours that may also aid patient stratification and prognosis.  
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7.6  Limitations of the study 
Although microarray technologies are widely used in biomedical research they have 
several limitations that should be kept in mind when interpreting the results. In this 
study, Illumina Infinium HumanMethylation450 BeadChip and HumanHT-12v4 
Expression BeadChip arrays were used to profile genome-wide DNA methylation 
and gene expression of primary patient-matched CAM and ATM samples. Albeit, 
both Illumina 450k and HumanHT-12 arrays provide good genome-wide coverage as 
they allow investigation of DNA methylation levels of many previously identified 
CpG sites and expression levels of many well-characterised genes, they are limited 
to the pre-designed probe set therefore do not allow discovery of novel transcripts, 
including microRNAs and long non-coding RNAs as well as ‘novel’ methylation 
signatures that may be located outside of the pre-determined regions. More 
comprehensive next generation sequencing-based approaches, such as RNA- and 
bisulfite DNA sequencing address some of these limitations and can provide a 
better understanding of the epigenetic changes that contribute to CAM aberrant 
phenotype. 
 
Cell culture conditions and cell proliferation rate may affect DNA methylation 
patterns (Wilson and Jones 1983, Jiang, Gonda et al. 2008). In this work,      
genome-wide DNA methylation analysis was performed on early-passage primary 
myofibroblast cultures and patient-matched CAM and ATM pairs were always 
cultured in parallel to reduce cell culture-induced artifacts. However, some specific 
limitations stemming from in vitro cell propagation were not addressed. Also, it is 
not known whether there are any differences in proliferation rate between patient-
specific CAM and ATM pairs and whether these differences if present would have 
effect on DNA methylation changes.  
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7.7  Concluding remarks 
Findings presented in this thesis shed light on the molecular alterations underlying 
the aberrant phenotype of gastric CAMs and identify stromal biomarkers with 
potential clinical relevance. However, more comprehensive studies on larger 
sample sets are needed to confirm the true utility of identified trends indicating a 
correlation between stromal DNA methylation signatures and clinicopathological 
features of gastric tumours. Also, further studies are needed to characterize the 
role of the genes that were shown to be regulated by aberrant DNA methylation in 
gastric CAMs. These studies may provide novel insights into the different pathways 
involved in gastric CAM programming, thereby improving our understanding of the 
complex interactions between tumour and microenvironment and potentially 
contribute to new diagnostic and treatment strategies. 
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Chapter II  
Materials and Methods 
 
 
 
 
Figure S2.1 Quality of DNA samples used for Illumina Infinium HumanMethylation450k 
array; 1% agarose gel electrophoresis, lambda DNA/HindIII was used as molecular size 
marker (kb). 
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Table S2.1 Quality control information for RNA and DNA samples used for Ilumina 
HumanHT-12 v4 Expression and Illumina Infinium HumanMethylation450k arrays;   
RIN - RNA Integrity Number 
 
 RNA samples DNA samples 
Sample RIN 
RNA 260/280 
Ratio 
DNA 260/280 
Ratio 
C1N 10 2.09 2 
C1H 10 2.1 2 
A1N 9.9 2.08 1.99 
A1H 9.7 2.06 1.98 
C2N 8.1 2.06 2.01 
C2H 7.8 2.11 2 
A2N 10 2.07 2 
A2H 10 2.12 1.95 
C3N 9.9 2.08 1.98 
C3H 9.8 2.07 1.95 
A3N 9.7 2.12 1.96 
A3H 9.8 2.08 1.98 
N1N 10 2.05 2 
N1H 9.2 2.06 1.99 
N2N 9.9 2.08 2.02 
N2H 9.7 2.06 2.01 
N3N 9.8 2.07 2.01 
N3H 9.8 2.05 1.98 
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Table S2.2 Patient information relating to the scoring details. Row displaying the Total represents the prognosis score and is calculated based on the 
sum of all the variables.  
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Table S2.3 Patient information relating to age, gender, tumour location and tumour clinical assessment for oesophageal cancer patients who 
provided CAM and ATM cells used in this study. Tumour staging is defined in terms of pathology of tumour (pT) where 0 defines no sign of tumour        
and 3 maximum size and/or extensions. Similarly, the involvement of local and metastasis to proximal lymph nodes is stated as N0-N3 and metastasis 
severity by M0, no metastasis and M, distal metastasis. 
 
 
 
 
 
Patient 
ID 
Age Gender Location of Tumour Classification 
Tumour 
Staging 
Survival 
(months) 
Adjacent Tissue 
1. 72 M esophagus adenocarcinoma pT3N1M0 18 Barrett’s eosophagus 
2. 70 F esophagus cardia junction adenocarcinoma pT3N1M0 >25 Intestinal metaplasia  
3. 64 M esophagus cardia junction adenocarcinoma pT2N3M0 19 Intestinal metaplasia 
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Chapter III  
Identification of Genome-Wide DNA Methylation Signatures in 
Gastric and Oesophageal Cancer-Associated Myofibroblasts 
 
 
Figure S3.1 Increased migration of gastric cancer cells in response to CAM 
conditioned media (CM) compared to ATM-CM and NTM-CM. A. Representative Boyden 
chamber migration assays of AGS cells treated with CAM, ATM or NTM conditioned media. 
B. Individual patient-paired Boyden chamber migration assays of AGS cells treated with 
CAM-CM or ATM-CM. All data points were corrected for basal migration by subtracting 
respective serum-free media controls. C. Group mean data of AGS cell migration in 
response to CAM-CM (n=4), ATM-CM (n=4) or NTM-CM (n=2). Mean, SEM ** ANOVA       
p-value < 0.01 (p=0.0093). 
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Figure S3.2 Increased proliferation of gastric cancer cells in response to CAM 
conditioned media (CM) compared to ATM-CM and NTM-CM. A. Individual patient-paired 
EdU proliferation assays of AGS cells treated with CAM-CM or ATM-CM. All data points 
were corrected for basal proliferation by subtracting respective serum-free media controls. 
B. Group mean data of AGS cell proliferation in response to CAM-CM (n=3), ATM-CM (n=3) 
or NTM-CM (n=2). Mean, SEM *paired t-test p-value<0.05 (p=0.0143). 
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Figure S3.3 Heatmap representation of differentially methylated regions (DMRs) 
identified in gastric CAMs compared to their patient-matched ATMs. A. Promoters      
B. Genes C. CpG Islands D. Tiling regions as defined in RnBeads* (version 0.99.17);      
|Δβ| > 0.2, p-value <0.05. 
 
*RnBeads uses: (i) Ensembl gene definitions to define genes and promoters. A promoter is 
defined as the region spanning 1,500 bases upstream and 500 bases downstream of the 
transcription start site of the corresponding gene; (ii) UCSC Genome Browser CpG island 
track to define CpG islands; (iii) tiling regions are defined over the whole genome as regions 
with a window size of 5 kilobases.  
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Figure S3.4 Heatmap representation of differentially methylated regions (DMRs) 
identified in oesophageal CAMs compared to their patient-matched ATMs.                  
A. Promoters B. Genes C. CpG Islands D. Tiling regions as defined in RnBeads* (version 
0.99.17); |Δβ| > 0.2, p-value <0.05. 
 
*RnBeads uses: (i) Ensembl gene definitions to define genes and promoters. A promoter is 
defined as the region spanning 1,500 bases upstream and 500 bases downstream of the 
transcription start site of the corresponding gene; (ii) UCSC Genome Browser CpG island 
track to define CpG islands; (iii) tiling regions are defined over the whole genome as regions 
with a window size of 5 kilobases. 
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Chapter IV  
Identification of Gens that Exhibit Correlated Changes in Gene 
Expression and DNA Methylation in Gastric Myofibroblasts 
 
 
 
H
S
P
A
5
C
H
A
C
1
A
T
F
3
S
P
O
N
2
S
E
M
A
5
A
S
L
C
3
A
2
E
C
H
1
G
O
T
1
T
G
F
B
R
2
C
A
S
C
3
S
U
L
F
2
S
T
O
M
S
Y
N
M
R
S
P
O
3
S
E
P
P
1
T
W
IS
T
2
-1 .5
-1 .0
-0 .5
0 .0
0 .5
1 .0
1 .5
C A M  v s  A T M
L
o
g
2
F
C
I lu m in a  H T -1 2
 A ffy m e tr ix
 
Figure S4.1 Representative examples of genes showing consistent changes in gene 
expression profiles in two independent studies of gastric CAM vs ATM gene 
expression profiles. These genes were identified independently by Illumina         
HumanHT-12v4 Expression BeadChip array (yellow) in this study on 3 patient-matched 
CAMs and ATMs and by Affymetrix GeneChip Human Genome U133 Plus 2.0 Array (dark 
orange) in previous gene expression study on 12 patient-matched CAMs and ATMs;           
p-value < 0.05.  
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Figure S4.2 PCP pathway identified in CAM vs ATM comparison (p = 1.52 x 10
-2
;               
z-score = 0.333) by Ingenuity Canonical Pathway Analysis; red – upregulated genes in 
CAMs, green – downregulated genes in CAMs. 
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Chapter V  
Validation of DNA Methylation Patterns that Correlate with CAM-specific Gene Expression Profiles 
Table S5.1 Reproducibility of pyrosequencing assays. Correlation R
2
 between methylation levels for biological replicates. 
 
 
Patient CD47 B4GALT6 
NKAIN3 
/ASPH 
SMAD3 
(p1) 
SMAD3 
(p2) 
SPON2 
FOXF1 
/FENDRR 
ZNF536 MUC2 
mir802 
/RUX1 
HOXA5 
FOXC2 
/FOXF2 
VPS28 
42 0.991 0.875 0.926 0.987 0.869 0.994 0.861 0.846 0.915 0.991 0.981 0.709 0.446 
45 0.952 0.853 0.692 0.994 0.928 0.891 0.779 0.950 0.734 0.059 0.884 0.326 0.800 
192 0.991 0.969 0.954 0.997 0.952 0.974 0.997 0.888 0.979 0.987 0.972 0.961 0.937 
268 0.836 0.814 0.315 0.969 0.367 0.641 0.875 0.828 0.869 NA 0.843 0.870 0.882 
271 0.827 0.809 0.896 0.947 0.909 0.467 0.859 0.981 0.671 0.852 0.959 0.843 0.966 
305 0.905 0.949 0.974 0.988 0.989 0.990 0.981 0.986 0.955 0.990 0.974 0.902 0.800 
308 0.953 0.281 0.867 0.902 0.586 0.994 0.981 0.932 0.951 0.969 0.971 0.983 0.919 
279 0.987 0.999 0.955 1.000 0.619 0.966 0.988 1.000 0.913 0.997 0.982 0.959 0.318 
334 NA NA 0.929 NA NA NA 0.978 0.951 0.957 0.908 0.987 NA NA 
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Figure S5.1 SMAD3 expression in gastric and oesophageal CAMs compared to their 
parent-matched ATMs. SMAD3 expression levels were detected by Affymetrix GeneChip 
Human Genome U133 Plus 2.0 Array (purple) in a previous gene expression study 
performed on 12 gastric patient-matched CAMs and ATMs, p-value < 0.05 (Smith et al, 
unpublished data) and by Illumina HumanHT-12v4 Expression BeadChip array (blue) as part 
of this study in 4 oesophageal patient-matched CAMs and ATMs, p-value < 0.05 
(collaborative work with the Varro group, University of Liverpool). 
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Figure S5.2 Negative correlations between gene expression (qPCR data) and 
promoter methylation (pyrosequencing data) in patient-matched CAMs and ATMs. 
Individual sample methylation levels (methylation index for the interrogated region, X-axis) 
are plotted against individual sample gene expression levels (RQ-value relative to calibrator, 
Y-axis). A. SMAD3 (n=6) B. SPON2 (n=6) C. ZNF536 (n=6) D. FOXF1 (n=5); magenta – 
CAMs, purple – ATMs; r - Spearman’s rank correlation rho. 
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Figure S5.3 Differentially methylated SPON2 promoter-region identified by Illumina 
450k array in oesophageal patient-matched CAM and ATM samples. Mean β-values 
(n=3) for probes identified as differentially methylated in oesophageal CAM vs ATM 
comparison are plotted. The X-axis indicates distance of Illumina 450k probes to SPON2 
transcription start site. Error bars represent SEM. 
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Figure S5.4 Simultaneous negative correlation between promoter methylation and SPON2 gene expression and positive correlation between gene-
body methylation and SPON2 gene expression levels in patient-matched CAM and ATM samples detected in genome–wide DNA methylation and 
gene expression studies using Illumina 450k and HT-12 arrays. Individual sample methylation levels (β-value, X-axis) are plotted against individual 
sample gene expression levels (intensity, Y-axis) for 3 representative CpG loci (red dots) associated with SPON2 regulation; magenta – CAMs,              
purple – ATMs; numbers in brackets indicate the distance to transcription start site of SPON2; r - Spearman’s rank correlation rho. 
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Figure S5.5 Negative correlation between SPON2 gene expression and promoter 
methylation in patient-matched CAMs and ATMs and NTMs detected in           
genome–wide DNA methylation and gene expression study using Illumina 450k and 
HT-12 arrays. Individual sample methylation levels (β-value, X-axis) are plotted against 
individual sample gene expression levels (intensity, Y-axis) for CpG loci associated with 
SPON2 regulation; magenta – CAMs, purple – ATMs, navy - NTMs; r - Spearman’s rank 
correlation rho. 
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Figure S5.6 Simultaneous negative correlation between promoter methylation and ZNF536 gene expression and positive correlation between  
gene-body methylation and ZNF536 gene expression levels in patient-matched CAM and ATM samples detected in genome–wide DNA methylation 
and gene expression studies using Illumina 450k and HT-12 arrays. Individual sample methylation levels (β-value, X-axis) are plotted against individual 
sample gene expression levels (intensity, Y-axis) for 3 representative CpG loci (red dots) associated with ZNF536 regulation; magenta – CAMs,             
purple – ATMs; numbers in brackets indicate the distance to transcription start site of ZNF536; r - Spearman’s rank correlation rho. 
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Figure S5.7 Simultaneous negative correlation between promoter methylation and 
ZNF536 gene expression and positive correlation between gene-body methylation and 
ZNF536 gene expression levels in patient-matched CAMs and ATMs in comparison to 
NTMs, as detected in genome–wide DNA methylation and gene expression studies 
performed using Illumina 450k and HT-12 arrays. Individual sample methylation levels  
(β-value, X-axis) are plotted against individual sample gene expression levels (intensity,     
Y-axis) for 4 representative CpG loci associated with ZNF536 regulation; magenta – CAMs, 
purple – ATMs, navy - NTMs; r - Spearman’s rank correlation rho. 
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Figure S5.8 Comparative DNA methylation profiles within a genomic region on  
chromosome 16 spanning 526,340bp identified by Illumina 450k array in gastric 
stromal myofibroblasts. Mean β-values (n=3) for probes identified as differentially 
methylated in CAM vs ATM and CAM vs NTM comparisons are plotted. The X-axis indicates 
distance of Illumina 450k probes to the FOXF1 transcription start site. Error bars represent 
SEM. 
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Figure S5.9 Comparative DNA methylation profiles within a genomic region on  
chromosome 16 spanning 9,673bp identified by Illumina 450k array in oesophageal 
patient-matched CAM and ATM samples. Mean β-values (n=3) for probes identified as 
differentially methylated in oesophageal CAM vs ATM comparison are plotted. The X-axis 
indicates distance of Illumina 450k probes to the FOXF1 transcription start site. 
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Figure S5.10 Pyrosequencing analysis of the FOXF1 promoter region in gastric cancer 
cell lines. Methylation means for 8 individual CpG sites in interrogated promoter region are 
plotted for AGS cells (n=3) and MKN45 cells (n=2). The X-axis indicates chromosomal 
position of examined CpG sites. Error bars represent SEM. 
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Figure S5.11 Differential DNA methylation data for stomach adenocarcinoma from the Cancer Genome Atlas (TCGA). The presented region 
corresponds to the differentially methylated region identified in gastric CAMs compared to either ATMs or NTMs as shown in Figure 5.6A. Mean β values for 
stomach tumour (n=339; red line) and normal tissue (n=2; blue line) are plotted. The X-axis represents the Illumina 450k probes. TCGA data was obtained 
using Wanderer (Diez-Villanueva, Mallona et al. 2015). 
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Chapter VI  
Effects of Hypoxia on Gene Expression and Secretion of             
Pro-tumorigenic Factors in Gastric Stromal Myofibroblasts 
 
Figure S6.1 Universal gene expression changes induced under hypoxia in gastric 
CAMs, ATMs and NTMs. A. Comparison of hypoxia-induced gene expression signatures 
identified in gastric CAMs, ATMs and NTMs; FDR p-value < 0.05. Overlapping intersections 
of 77 genes is shown in B.B. Genes universally changed in the same direction under 
hypoxia in gastric CAMs, ATMs and NTMs.  
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S6.1  Gene Set Enrichment Analysis (GSEA) 
Unique CAM, ATM and NTM hypoxia-induced gene profiles were subjected to gene 
set enrichment analysis (GSEA) using the complete Molecular Signatures Database 
(MSigDBv5.0). The analysis identified: (i) total of 114 gene sets (all for hypoxia 
phenotype) in unique CAM hypoxia-induced gene profile; (ii) total of 102 gene sets 
(including 48 in hypoxia phenotype and 54 in normoxia phenotype) in unique NTM 
hypoxia-induced gene profile; and (iii) total of 104 gene sets (all for hypoxia 
phenotype) in unique ATM hypoxia-induced gene profile with FDR q-value <0.05. 
Overlap of identified CAM, ATM and NTM significantly enriched gene sets is shown 
in Figure S6.2. Although the gene sets were identified based on unique CAMs, ATMs 
and NTMs hypoxia-changed genes there are some overlapping gene sets indicating 
that some of the uniquely changed genes are involved in regulation of the same 
processes.  
 
 
Figure S6.2 Comparison of enriched MSigDB gene sets identified for unique CAM, 
ATM and NTM hypoxia-induced gene expression profiles; FDR q-value <0.05. 
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S6.2  Leading Edge Analysis  
Enriched gene sets with FDR q-value <0.05 identified in respective unique CAM, 
ATM or NTM hypoxia-induced gene expression profiles were subjected to leading 
edge analysis (LEA) in order to examine genes that are in the leading-edge subsets 
of the enriched gene sets. These genes may have a key role in each of the three 
analysed phenotypes. A summary of the respective LEA results for CAMs, ATMs and 
NTMs enriched gene sets is shown in Table S6.1. 
 
 
Table S6.1 Summary of leading edge analysis (LEA) of enriched MSigDB gene sets 
identified for unique CAM, ATM and NTM hypoxia-induced gene expression profiles. 
Top 10 genes identified in respective leading edge analyses and number of leading-edge 
subsets in which the given gene appears is shown; pink – genes upregulated in hypoxia; 
blue- genes downregulated in hypoxia. 
 
CAM ATM NTM 
Gene symbol 
No of 
subsets 
Gene symbol 
No of 
subsets 
Gene symbol 
No of 
subsets 
IDI1 45 AURKA 42 CYB5A 13 
SQLE 40 BIRC5 41 SOX4 13 
HMGCS1 37 CCNA2 39 EGR1 13 
MSMO1 36 TPX2 38 JUN 12 
HMGCR 35 MAD2L1 36 NME1 12 
SCD 32 AURKB 36 ENG 11 
FDFT1 31 CDKN3 35 APOE 11 
LDLR 31 MELK 34 KLHL24 11 
FDPS 31 MYL9 28 MBNL1 10 
DHCR7 29 CDCA3 27 CREB5 9 
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Figure S6.3 Volcano plots of differentially secreted proteins in the following 
comparisons: A. CAM-hypoxic-CM vs CAM-ctrl-CM B. NTM-hypoxic-CM vs NTM-ctrl-CM   
C. CAM-ctrl-CM vs NTM-ctrl-CM D. CAM-hypoxic-CM vs NTM-hypoxic-CM. Proteins 
highlighted in red were annotated as secreted/extracellular or identified in exosomes based 
on MetazSecKB, Matrisome and ExoCarta searches (as described in section 6.3.4.1). 
Proteins above the line are considered to be differentially secreted between the given 
conditions.  
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Figure S6.4 Differential expression and secretion of gelsolin (GSN), vascular endothelial 
growth factor A (VEGFA) and glucose-6-phosphate isomerase (GPI) in hypoxic CAMs (n=3) 
and hypoxic NTMs (n=3) compared to respective control-normoxic myofibroblasts;              
p-value <0.05. 
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Figure S6.5 Differential expression and secretion of angiopoietin-related protein 4 
(ANGPTL4), insulin-like growth factor-binding protein 3 (IGFBP3), insulin-like growth factor-
binding protein 6 (IGFBP6) and thrombospondin-2 (THBS2) in gastric CAMs (n=3) and 
NTMs (n=3) under hypoxia and normoxia; checked – proteins detected in respective 
comparisons but not identified as differentially secreted (p-value>0.05).  
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Figure S6.6 Differential expression and secretion of enzyme lysyl oxidase (LOX) in 
gastric CAMs (n=3) and NTMs (n=3) under hypoxia and normoxia. LOX mRNA transcript 
was not identified as differentially expressed in hypoxic CAMs compared to control-normoxic 
CAMs whereas LOX protein (checked) was detected in CAM-hypoxic-CM and CAM-ctrl-CM 
however it was not identified as significant in differential secretome analysis (p-value>0.05).  
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Figure S6.7 Global DNA methylation after long-term hypoxia treatment assessed by 
LINE-1 pyrosequencing assays. A. AGS gastric cancer cell line (n=3) was cultured under 
hypoxia and normoxia for 8 days B, C. Two normal tissue myofibroblast (NTM) cell lines 
334/22 (n=3) and 279/22 (n=3) were cultured under hypoxia and normoxia for 6 days. 
Boxplots represent methylation distribution and mean for 6 CpG sites examined inside the 
CpG-rich   ’ internal LINE-1 promoter. 
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